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Abstract
Clinical and economic evaluation of laparoscopic 
surgery compared with medical management for 
gastro-oesophageal reflux disease: 5-year follow-up of 
multicentre randomised trial (the REFLUX trial)
AM Grant,1* C Boachie,1 SC Cotton,1 R Faria,2 L Bojke,2 DM Epstein,2 
CR Ramsay,1 B Corbacho,2 M Sculpher,2 ZH Krukowski,3 RC Heading4 
and MK Campbell1 on behalf of the REFLUX trial group
1Health Services Research Unit, Health Sciences Building, University of Aberdeen, Aberdeen, UK
2Centre for Health Economics, University of York, York, UK
3Aberdeen Royal Infirmary, Aberdeen, UK
4School of Medicine and Health, Wolfson Research Institute, Durham University, Stockton-on-Tees, UK
*Corresponding author a.grant@abdn.ac.uk
Background: Despite promising evidence that laparoscopic fundoplication provides better short-term 
relief of gastro-oesophageal reflux disease (GORD) than continued medical management, uncertainty 
remains about whether benefits are sustained and outweigh risks.
Objective: To evaluate the long-term clinical effectiveness, cost-effectiveness and safety of laparoscopic 
surgery among people with GORD requiring long-term medication and suitable for both surgical and 
medical management.
Design: Five-year follow-up of a randomised trial (with parallel non-randomised preference groups) 
comparing a laparoscopic surgery-based policy with a continued medical management policy. Cost-
effectiveness was assessed alongside the trial using a NHS perspective for costs and expressing health 
outcomes in terms of quality-adjusted life-years (QALYs).
Setting: Follow-up was by annual postal questionnaire and selective hospital case notes review; initial 
recruitment in 21 UK hospitals.
Participants: Questionnaire responders among the 810 original participants. At entry, all had 
documented evidence of GORD and symptoms for > 12 months. Questionnaire response rates (years 1–5) 
were from 89.5% to 68.9%.
Interventions: Three hundred and fifty-seven participants were recruited to the randomised comparison 
(178 randomised to surgical management and 179 randomised to continued medical management) and 
453 to the preference groups (261 surgical management and 192 medical management). The surgeon 
chose the type of fundoplication.
Main outcome measures: Primary: disease-specific outcome measure (the REFLUX questionnaire); 
secondary: Short Form questionnaire-36 items (SF-36), European Quality of Life-5 Dimensions (EQ-5D), 
NHS resource use, reflux medication, complications.
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Results: The randomised groups were well balanced. By 5 years, 63% in the randomised surgical group 
and 13% in the randomised medical management group had received a total or partial wrap 
fundoplication (85% and 3% in the preference groups), with few perioperative complications and no 
associated deaths. At 1 year (and 5 years) after surgery, 36% (41%) in the randomised surgical group – 
15% (26%) of those who had surgery – were taking proton pump inhibitor medication compared with 
87% (82%) in the randomised medical group. At each year, differences in the REFLUX score significantly 
favoured the randomised surgical group (a third of a SD; p < 0.01 at 5 years). SF-36 and EQ-5D scores also 
favoured surgery, but differences attenuated over time and were generally not statistically significant at 5 
years. The worse the symptoms at trial entry, the larger the benefit observed after surgery. Those 
randomised to medical management who subsequently had surgery had low baseline scores that markedly 
improved after surgery. Following fundoplication, 3% had surgical treatment for a complication and 4% 
had subsequent reflux-related operations – most often revision of the wrap. Dysphagia, flatulence and 
inability to vomit were similar in the two randomised groups. The economic analysis indicated that surgery 
was the more cost-effective option for this patient group. The incremental cost-effectiveness ratio for 
surgery in the base case was £7028 per additional QALY; these findings were robust to changes in 
approaches and assumptions. The probability of surgery being cost-effective at a threshold of £20,000 per 
additional QALY was > 0.80 for all analyses.
Conclusions: After 5 years, laparoscopic fundoplication continues to provide better relief of GORD 
symptoms with associated improved health-related quality of life. Complications of surgery were 
uncommon. Despite being initially more costly, a surgical policy is highly likely to be cost-effective.
Trial registration: Current Controlled Trials ISRCTN15517081.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be 
published in full in Health Technology Assessment; Vol. 17, No. 22. See the HTA programme website for 
further project information.
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Executive summary
Background
In the Health Technology Assessment (HTA)-commissioned REFLUX trial, laparoscopic fundoplication for 
people with chronic symptoms of gastro-oesophageal reflux disease (GORD) was shown to significantly 
improve reflux-specific and general health-related quality of life (HRQoL) at least up to 12 months after 
surgery. However, cost-effectiveness was uncertain without more reliable information about longer-term 
costs and benefits. Here, we report the findings from longer-term follow-up of the REFLUX trial.
Objective
To evaluate, at 5 years after surgery, the clinical effectiveness, cost-effectiveness and safety of a policy of 
relatively early laparoscopic surgery compared with continued medical management among people with 
GORD symptoms that are reasonably controlled by medication and who are judged suitable for both 
surgical and medical management.
Methods
Design
1. Long-term follow-up of a pragmatic randomised controlled trial (with parallel non-randomised 
preference groups) comparing a laparoscopic surgery-based policy with a continued medical 
management policy to assess relative clinical effectiveness.
2. An economic evaluation of laparoscopic surgery for GORD to compare the cost-effectiveness of the 
two management policies, based on a within-trial (5-year) economic analysis and exploration of the 
need for a longer-term model.
Setting
Participants had originally been recruited in 21 UK hospitals through local partnership between surgeon(s) 
and gastroenterologist(s) who shared the secondary care of patients with GORD. After operation (surgical 
groups) and after optimisation of anti-reflux therapy (medical groups), participants were returned to the 
care of their general practitioners (GPs). Follow-up was by annual postal questionnaire and selective case 
notes review when questionnaires indicated reflux-related health-care events.
Participants
Participants in this study were questionnaire responders among the 810 original participants. At trial 
entry, all had both documented evidence of GORD and symptoms for > 12 months. Annual questionnaire 
response rates (years 1–5) were 89.5%, 77.5%, 76.7%, 69.8% and 68.9%.
Intervention
Of the 810 participants, 357 were recruited to the randomised comparison (178 randomised to surgical 
management and 179 randomised to continued medical management) and 453 to the parallel non-
randomised preference arm (261 surgical management and 192 medical management). The type of 
fundoplication was left to the discretion of the surgeon.
Main outcome measures
The principal outcome measure was a disease-specific instrument (the REFLUX questionnaire developed 
specifically for this study). Secondary measures were the Short Form questionnaire-36 items (SF-36), the 
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European Quality of Life-5 Dimensions (EQ-5D), surgical events including complications, reflux medication 
use, GP visits, hospital outpatient consultations, day and overnight hospital admissions, and their costs.
Results
At entry to the original trial, participants had been taking GORD medication for a median of 32 months 
and had a mean age of 46 years, and 66% were men; the randomised groups had been well balanced. 
Responders at 5 years were older, had been on medication for a shorter time prior to trial entry and 
had higher baseline quality-of-life scores than non-responders; however, the randomised groups of 
responders were similar in baseline characteristics. Primary analyses were based on the ‘intention-to-treat’ 
(ITT) principle, with secondary per-protocol analyses based on those who, at 1 year, had received their 
allocated treatment.
By 5 years, 63% (n = 112) of the 178 randomised surgery participants and 13% (n = 24) of the 179 
randomised medical management participants had actually received fundoplication (equivalent figures in 
the preference groups were 85% and 3%). There had been a mixture of clinical and personal reasons for 
those allocated surgery not receiving it, sometimes related to long waiting times. A total or partial wrap 
procedure had been performed depending on surgeon preference; perioperative complications had been 
uncommon with no deaths associated with surgery.
By the equivalent to 12 months after surgery, 36% in the randomised surgical group (15% among those 
who had surgery) were taking proton pump inhibitor medication compared with 87% in the randomised 
medical group. At 5 years, the equivalent figures were 41% (26%) in those randomised to surgery and 
82% in those randomised to medical management.
At each year, there were significant differences in the REFLUX score (a third of a SD; p < 0.01 at 5 years) 
favouring the randomised surgical group, reflecting differences in general discomfort (particularly), wind 
and frequency, nausea and vomiting, and activity limitation subscores. SF-36 and EQ-5D scores also 
favoured the randomised surgical group, especially SF-36 norm-based general health, but differences 
attenuated over time and were generally not statistically significant at 5 years [EQ-5D difference (ITT) 
0.047, 95% confidence interval (CI) –0.013 to 0.108; p = 0.13]. The lower the REFLUX score and hence 
the worse the symptoms at trial entry, the larger the benefit observed after surgery. Post hoc exploratory 
analyses showed that those randomly allocated to medical management who subsequently had surgery 
had worse symptoms (lower baseline scores) than those who continued on medical management as 
allocated; following surgery, the scores of these patients markedly improved and this explains, at least in 
part, why differences in outcome between the randomised groups became less marked over time.
The preference surgical group also had low REFLUX scores at baseline. These scores improved substantially 
after surgery and at 5 years they were slightly better than those in the preference medical group.
Overall, 4% (n = 16) of the total 364 in the study who had fundoplication had a subsequent reflux-related 
operation, of whom two had a further (i.e. third) operation. Reoperation was most often conversion to 
a different type of wrap or a reconstruction of the same wrap. There were only two cases of reversal of 
the fundoplication and neither was in the randomised comparison. In total, 3% (n = 12) of those who 
had fundoplication required surgical treatment for a complication directly related to the original surgery, 
including oesophageal dilatation (n = 4) and repair of incisional hernia (n = 3). Patterns of ‘difficulty 
swallowing’, flatulence and ‘wanting to vomit but being physically unable to do so’ – all problems that 
have previously been associated with anti-reflux surgery – were similar in the two randomised groups.
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Economic evaluation
Differences in mean costs and mean quality-adjusted life-years (QALYs) at 5 years were used to derive an 
estimate of the cost-effectiveness of laparoscopic fundoplication and continued medical management 
from the perspective of the NHS. Conventional decision rules were used to estimate incremental cost-
effectiveness ratios (ICERs). Sensitivity analysis (including probabilistic sensitivity analysis) was used to 
explore and quantify uncertainty in the cost-effectiveness results.
Health-care resource-use data were collected prospectively as part of the clinical report forms and patient 
questionnaires at each follow-up point. The cost for each individual patient in the trial was calculated 
by multiplying their use of NHS resources by the associated unit costs (from published sources) and 
discounting at an annual rate of 3.5%. For the base-case analysis, total costs constituted the costs of 
surgery, complications due to surgery, reoperations, reflux-related prescribed medication, reflux-related 
visits to and from the GP and reflux-related hospital inpatient, outpatient and day visits. For the sensitivity 
analysis, all GP visits and all hospital admissions were included in the calculation of total costs. Health 
outcomes were expressed in terms of QALYs. HRQoL was assessed at each follow-up point using the 
EQ-5D. Incremental mean QALYs between randomised treatment groups were estimated with and without 
adjustment for baseline utility, using ordinary least squares regression.
The extent of missing data throughout the trial follow-up was significant; for this reason, the base case 
drew on the multiple imputed data set ITT analysis. A separate scenario – the complete-case analysis, in 
which only participants who returned all questionnaires and completed all EQ-5D profiles are included – 
was employed for both ITT and per-protocol analyses. Multiple imputation provides unbiased estimates 
of treatment effect if data are missing at random. Sensitivity analysis was used to test the impact on the 
cost-effectiveness results if data were missing not at random, that is, if patients with worse outcomes or 
greater costs were more likely to have missing data.
The results show that, for the base-case analysis (multiple imputed data set), the participants randomised 
to fundoplication accrued greater costs (incremental mean cost £1518; 95% CI £1006 to £2029) but 
also reported greater overall HRQoL (incremental mean QALYs 0.2160; 95% CI 0.0205 to 0.4115) than 
participants randomised to continued medical management. Laparoscopic fundoplication is a cost-effective 
strategy for GORD patients eligible for the REFLUX trial on the basis of the range of cost-effectiveness 
thresholds used by the National Institute for Health and Care Excellence (NICE) (£20,000–30,000 per 
additional QALY). The results for the complete-case analysis concurred with the multiple imputed data 
set: across analyses adjusted and unadjusted for baseline EQ-5D, ICERs ranged between £5468 and 
£8410, well below the NICE cost-effectiveness thresholds. For both data sets (multiple imputation and 
complete case), the probability of surgery being the more cost-effective intervention was > 0.82 for 
incremental analyses unadjusted for baseline EQ-5D and > 0.93 once incremental QALYs were adjusted for 
baseline EQ-5D.
A sensitivity analysis was carried out comparing the groups according to their ‘per-protocol’ status at 
1 year. A per-protocol analysis compares the efficacy of the treatments received, whereas an ITT analysis 
compares the effectiveness of the strategies as offered to patients. The per-protocol analysis (in complete 
cases) suggested that surgery was more cost-effective than medical management. Other sensitivity analyses 
were carried out using a wider set of resource-use data. The results of the first alternative scenario, using 
the costs of primary care visits for any reason rather than only reflux-related reasons, increased the ICER 
slightly in relation to the base case. Nevertheless, the ICER remains well below conventional thresholds, 
and the probability of surgery being cost-effective was > 0.85 for both adjusted and unadjusted analyses. 
In the second alternative scenario, replacing reflux-related hospital costs by all hospital costs, medical 
management was ‘dominated’ by the surgical policy; the probability of surgery being cost-effective 
was > 0.90.
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The base-case analysis imputes missing data. This assumes that missing data are missing at random, that 
is, their values can be predicted (with uncertainty) from observed data. This assumption is impossible to 
confirm or repute but its effect on the results can be tested in sensitivity analysis. The base-case analysis 
may be biased if the values of a missing variable are different from the observed values (for given values 
of other covariates). Sensitivity analysis using the multiple imputation data set showed that the cost-
effectiveness of surgery was relatively insensitive to any increase in costs: cost-effectiveness changed little 
when costs were increased for patients with missing data in both treatment groups and when costs were 
increased just for patients randomly allocated surgery with missing data. A similar result was observed 
after reducing the total QALYs for all patients with missing data. In contrast, the cost-effectiveness of 
surgery was highly sensitive to the assumption that patients randomly allocated surgery with missing 
data experience lower HRQoL than patients with complete data. A 10% decrease in QALYs for patients 
randomised to surgery with missing data results in the cost-effectiveness increasing above £20,000 per 
QALY gained. This scenario shows that missing data can have an impact on the results. Nevertheless, 
although it is impossible to empirically confirm or refute this scenario from the data in the trial, it would 
seem improbable in practice that surgical patients with poor quality of life are less likely to respond to 
follow-up questionnaires than similar participants undergoing medical management.
Comparison with similar randomised trials
The findings of the REFLUX trial were considered in the context of the three other randomised trials 
that have compared laparoscopic surgery with medical management. In respect of benefits, the trials 
consistently show better relief of GORD symptoms following surgery, with parallel, though less marked, 
improvements in generic HRQoL. The four trials are also consistent in respect of complications of surgery, 
with small numbers having associated visceral injuries, postoperative problems and dilatation of the 
fundoplication wrap. The REFLUX trial suggests that 4.5% have a reoperation and the other trials are 
broadly consistent with this. Difficulty swallowing (dysphagia), flatulence and bloating have been linked 
with fundoplication in the other trials. In contrast, although a small number of REFLUX participants had a 
dilatation of the fundoplication wrap, responses to the questionnaires did not show a difference between 
those randomised to surgery and those randomised to medical management in these respects.
Conclusions
After 5 years’ follow-up, a policy of relatively early laparoscopic fundoplication among patients for whom 
reasonable control of GORD symptoms requires long-term medication and for whom both surgery and 
medical management are suitable continues to provide better relief of GORD symptoms with associated 
better quality of life. Complications of surgery were rare. Despite being initially more costly, a surgical 
policy is likely to be more cost-effective for such patients suffering from GORD who were eligible for the 
REFLUX trial.
Implications for health care
Extending the use of laparoscopic fundoplication to people whose GORD symptoms require long-term 
medication for reasonable control and who would be suitable for surgery would provide health gains 
that extend over a number of years. The longer-term data reported here indicate that this would also be 
a cost-effective use of resources. The more troublesome the symptoms, the greater the potential benefit 
from surgery.
Recommendations for research
Most patients taking anti-reflux medication are managed in general practice. It is uncertain how many 
of these people might be suitable for surgery and hence what the most efficient provision of future 
care might be. Further research to explore the feasibility and resource impact of alternative policies for 
fundoplication within the NHS is therefore recommended.
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Chapter 1 Introduction
This report describes the long-term follow-up of the REFLUX trial assessing the clinical effectiveness and cost-effectiveness of laparoscopic surgery compared with continued medical management for people 
with gastro-oesophageal reflux disease (GORD). This comparison was identified as a priority for research by 
the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme, which 
funded the trial in two stages. The first stage, encompassing preliminary economic modelling, outcome 
development, trial recruitment, initial clinical management, follow-up to a time equivalent to 1 year 
after surgery and modelling of cost-effectiveness based on results available at that time, was reported 
in 2008.1–5 The second stage, reported here, describes analyses based on further follow-up to 5 years 
after surgery.
Gastro-oesophageal reflux disease
The lower oesophagus, at its junction with the stomach, normally acts as a sphincter to prevent the 
contents of the stomach flowing back up the oesophagus. When the sphincter does not work adequately, 
the acid stomach contents leak, or ‘reflux’, into the oesophagus. The commonest symptom that this causes 
is heartburn, a burning sensation in the chest or throat. GORD has been defined through an international 
consensus process as ‘a condition which develops when the reflux of stomach contents causes 
troublesome symptoms and/or complications’; in this consensus, symptoms were considered ‘troublesome’ 
‘if they adversely affected a patient’s well-being’.6
Symptoms caused by gastro-oesophageal reflux are common: between 20% and 30% of a ‘Western’ adult 
population experience heartburn and/or reflux intermittently.7–9
Treatment of GORD includes both medical and surgical management, the options depending on the 
severity of symptoms. The majority of people with reflux have only mild symptoms and require little, if any, 
medication. The simplest is self-administered antacids with advice to alter lifestyle factors such as dietary 
modification, smoking cessation and weight reduction. A minority have severe symptoms and develop 
overt complications, despite full medical therapy, and require surgical intervention. Among the remainder, 
control of symptoms requires regular or continuous acid-suppression therapy using either histamine 
receptor antagonists (H2RAs) or proton pump inhibitors (PPIs); initial high-dose therapy may be followed by 
maintenance treatment using these drugs either intermittently or continuously at a reduced dose sufficient 
to suppress symptoms. It is from this intermediate group of patients with significant disease requiring 
maintenance medical treatment that most of the treatment costs for the health service arise.
Laparoscopic fundoplication
Interest in surgery as an alternative to long-term medical therapy for GORD has been considerable since 
the introduction of the minimal access laparoscopic approach in the early 1990s.10 Randomised trials 
conducted comparing laparoscopic with open surgery showed similar improvement in symptoms but with 
clear benefits of the laparoscopic approach in terms of recovery and fewer postsurgical complications.11 As 
a consequence, surgery was suggested as an alternative to long-term maintenance medical treatment with 
anti-reflux drugs.
The operative method, whether using an open or a laparoscopic approach, involves performing a 
fundoplication by wrapping the fundus of the stomach around the lower oesophagus to create a high-
pressure zone, thus reducing gastro-oesophageal reflux. The wrap created can be either complete (360°) 
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or partial. Many operative variants have been described. The commonest operation is a 1-cm complete 
wrap fashioned over a large bougie, the so-called ‘short-floppy Nissen’.12,13 There has been debate about 
the use of a partial rather than a total fundoplication. The partial approach has a number of potential 
advantages (such as fewer postoperative complications) but several controlled studies have shown broad 
equivalence between the two approaches;14 for the purpose of this study they were therefore regarded as 
equivalent. Although fundoplication is reported to produce resolution of reflux symptoms in upwards of 
90% of patients, like all surgery it carries risks and can have side effects. There is also uncertainty about 
the durability of benefit and frequency and severity of side effects following surgical therapy. Long-term 
follow-up to 12 years after open reflux surgery suggested attenuated but continuing better control of 
reflux symptoms; however, other symptoms such as difficulties swallowing (dysphagia), rectal flatulence 
and inability to belch or vomit were more common in surgical patients.15 An important objective of this 
study was to determine if the long-term pattern of symptoms following laparoscopic surgery was similar.
Medical management
Proton pump inhibitors, sometimes supplemented with prokinetics or alginates, are the most effective 
medical treatment for moderate to severe GORD. Once started on PPIs, the majority of patients with 
significant GORD remain on long-term treatment.16 It is estimated that around 1% or more of the UK 
adult population are prescribed PPI maintenance therapy.17–19 The cost to the NHS of medical management 
of GORD is considerable. In England alone, the cost of PPIs is estimated to be £220M per year.20 Of this 
budget, most of this prescribing occurs within the primary care setting.21,22
Although PPIs are generally considered safe, there is increasing acknowledgement of their possible adverse 
effects.23,24 Gastric acid suppression predisposes to enteric infections and the sustained hypergastrinaemia 
resulting from PPI use causes rebound acid hypersecretion and the development of acid-related symptoms 
if the drug is stopped. Acute severe hypomagnesaemia has been recognised relatively recently as a rare 
adverse reaction to PPIs; the mechanism underlying it is not known. The clinical significance of impaired 
vitamin B12 and iron absorption due to PPIs is uncertain; there is also controversy about the risk of 
fractures and pneumonia and about the occurrence and significance of gastric mucosal atrophy and 
intestinal metaplasia, which have been seen in Helicobacter pylori-positive patients taking PPIs. Drug–drug 
interactions have also been a cause for concern,25 although unequivocal evidence of their occurrence does 
not in itself establish clinical significance.
For the purpose of this study, medical therapy was taken to mean long-term therapy with PPIs (or H2RAs if 
intolerant to PPIs).
Rationale for the study design
The original study design was based on the belief that decisions about the management of GORD should 
be made using unbiased, statistically precise comparisons of alternative policies. At study entry all patients 
fulfilled three criteria: they were on long-term acid suppression with PPIs; they had symptoms that were 
thought to be adequately controlled; and they were suitable in terms of fitness and comorbidity for either 
surgical or continuing medical treatment for their GORD. At the time that the study was planned, the 
consensus opinion of clinicians was that these three criteria identified GORD patients for whom surgical 
and continuing medical treatment could be considered equally acceptable treatment options and that, 
consequently, the comparison should be undertaken in patients meeting these criteria.
The most likely sources of bias were in the ways in which the groups being compared were selected; how 
their outcomes were assessed; and how the management was actually delivered. This is the basis for using 
a pragmatic randomised controlled trial (RCT) design. Random allocation protected against selection bias. 
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Confining the trial to those with no clear treatment preference limits biased patient-centred assessment of 
outcome, and pragmatic comparison of alternative policies [with intention-to-treat (ITT) analysis] avoids 
bias introduced by individual cases of non-compliance. This approach had limitations, however, and for 
this reason we chose to incorporate two parallel, non-randomised preference groups.
Including those with a clear preference for one policy or the other allows broader extrapolation and 
generalisability. Study of this group may give insights into the reasons for preference and hence give 
pointers to patient choices after the study.26 Furthermore, preference may influence outcome and, if so, 
this may also help when making treatment decisions.26,27 A third reason for the parallel, non-randomised 
preference groups28 was that the addition of data from the preference groups may reduce imprecision 
around the estimates from the randomised comparison and this may be particularly useful for rare events, 
such as complications that can be confidently ascribed to one or other treatment. (The limitation is that 
the preference groups are not derived by random allocation, and hence the comparisons are exposed to 
the biases of non-randomised studies.)
Reliable comparisons within and between randomised and preference groups require valid measurement 
of treatment outcome. Although there were a number of quality-of-life (QoL) tools available, none was 
sufficiently specific to assess the spectrum of gastrointestinal symptoms associated with the treatment 
of GORD, particularly those due to surgery. For this reason we developed and validated a new outcome 
measure (the REFLUX questionnaire). We have continued to use this as the primary outcome measure in 
the longer-term follow-up reported here. Details of the REFLUX questionnaire and its derivation have been 
described elsewhere.1,4
Gastro-oesophageal reflux disease and its management represent a very significant call on NHS resources. 
Although clinical effectiveness, acceptability and safety will be important determinants of future policy, 
the issues of cost and resource use may be over-riding. This is the reason for the economic evaluation 
component of this study. Policy should be guided by both assessment of the relative cost-effectiveness of 
alternative policies and assessment of the impact that possible policy changes would have for the NHS and 
for patients with GORD.
The cost of laparoscopic fundoplication appears to be equivalent to the cost of 2–3 years of maintenance 
treatment with PPIs, although it is acknowledged that the costs of PPIs are falling.29 The costs of surgery 
are related largely to two factors: the incidence of complications/length of hospital stay and the number of 
patients requiring long-term medical interventions after surgery.
We addressed cost-effectiveness in our report of the first phase of the REFLUX trial.1 We reported both a 
within-trial cost-effectiveness analysis based on the results up to 12 months after surgery and an extended 
cost-effectiveness model that explored a number of scenarios beyond 12 months. The within-trial analysis 
related the extra mean costs associated with the surgical policy to the estimated increase in mean quality-
adjusted life-years (QALYs) associated with surgery up to that time. The incremental cost-effectiveness ratio 
(ICER) was around £19,000 when the ITT analysis was used. Taking into account the uncertainties around 
the estimates of both costs and utilities, it was calculated that the chance that the surgical policy would 
be cost-effective at a threshold of £20,000 per QALY was 46%. This indicated considerable uncertainty 
at thresholds that are currently commonly applied to costs per QALY. The limitations of the within-trial 
analysis were discussed in detail in the earlier report, in particular that it ignored costs and benefits that 
accrued after 1 year.
The economic model was designed to address the limitations of the within-trial analysis. It explored a 
range of scenarios of varying lifetime benefits and costs, and analyses gave a wide range of incremental 
costs per QALY of £1000–44,000, again indicative of wide uncertainty. The factors contributing most to 
this uncertainty were the projected health-related quality-of-life (HRQoL) parameters and the long-term 
uptake of medication following surgery.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
INTrODuCTION
4
Thus, although data available up to a time equivalent to 1 year after surgery provided promising evidence 
that surgical management might well be cost-effective, there was too much uncertainty, especially about 
longer-term costs and benefits, to provide clear guidance for decision-makers. This was the justification for 
the longer-term follow-up to 5 years reported here.
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Chapter 2 Methods
Original study design
The study had two complementary components:
1. a multicentre, pragmatic30 RCT (with parallel non-randomised preference groups) comparing a 
laparoscopic surgery-based policy with a continued medical management policy to assess their relative 
clinical effectiveness
2. an economic evaluation of laparoscopic surgery for GORD to compare the cost-effectiveness of 
the two management policies, identify the most efficient provision of future care and describe the 
resource impact that various policies for fundoplication would have on the NHS.
Eligible patients who consented to participate in the RCT were randomly allocated to either laparoscopic 
surgery or continued medical management. Those patients who had a strong preference for one or other 
of the two treatment options could be recruited to the preference study. Clinical history was recorded at 
study entry. Participants completed health status questionnaires at the time of recruitment to the study 
and then at specified times equivalent to 3 and 12 months and then 2, 3, 4 and 5 years after surgery.
Approval for this study was obtained from the Scottish Multicentre Research Ethics Committee and the 
appropriate Local Research Ethics Committees.
Clinical centres
Clinical centres were based on local partnerships between surgeons with experience of laparoscopic 
fundoplication and gastroenterologists, with whom they shared the secondary care of patients with GORD. 
Centres were eligible if they included:
 z a surgeon who had performed at least 50 laparoscopic fundoplication operations
 z one or more gastroenterologists who agreed to collaborate with the surgeon(s) in the trial.
Study population
Eligible patients were those for whom care had been provided by a participating clinician who was 
uncertain which management policy (surgical or medical) was better. In addition, patients had to have 
documented evidence of GORD (based on endoscopy and/or manometry/24-hour pH monitoring) as 
well as symptoms for >12 months requiring maintenance PPI therapy for reasonable symptom control. 
Patients who were intolerant to PPIs and therefore required H2RA therapy to control their symptoms were 
also eligible. Patients who were morbidly obese [body mass index (BMI) > 40 kg/m2] or who had Barrett’s 
oesophagus of > 3 cm or evidence of dysplasia, a paraoesophageal hernia or an oesophageal stricture were 
all excluded.
Eligible patients who did not want to take part in the randomised trial because of a strong preference 
for one type of management or the other were invited to take part in the preference arm of the study. 
For logistical reasons and to maintain a balance between the sizes of the randomised and the preference 
groups, we aimed to cap the numbers of participants recruited to the preference arms to 20 per arm in 
each centre.
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All participants gave their informed consent.
Health technology policies being compared
Laparoscopic surgery policy
For those participants allocated to the randomised surgical group or recruited to the preference surgical 
group of the trial, subsequent deferring or declining of surgery, by either the participant or the surgeon, 
was always an option (i.e. even after trial entry), particularly among those recruited by a gastroenterologist 
and referred to a surgeon for consideration of surgery within the trial. Participants who had not had 
manometry/pH studies underwent these tests before surgery to exclude achalasia.
The surgery was performed either by an experienced surgeon who had undertaken > 50 laparoscopic 
fundoplications or by a less experienced surgeon working under the supervision of an experienced 
surgeon. It was recommended that crural repair be routine and that non-absorbable synthetic sutures (not 
silk) be used for the repair. The type of fundoplication used was left to the discretion of the experienced 
surgeon. For the purposes of the main comparisons, the different surgical techniques for laparoscopic 
fundoplication were considered as part of a single policy. The study design, however, allowed for indirect 
comparisons between techniques.
Medical management policy
Those allocated to the medical management policy had their therapy reviewed and adjusted as necessary 
by the local gastroenterologist to be ‘best medical management’. It was recommended that management 
conformed to the principles of the Genval Workshop Report.31 These include stepping down antisecretory 
medication in most patients to the lowest dose that maintained acceptable symptom control. Following 
the therapy review by the gastroenterologist, trial participants had their medication managed by their 
general practitioner (GP). Although, in general, trial participants allocated to medical management 
were managed in this way, the protocol did include the option of surgery if a clear indication for it 
subsequently developed.
Study registration (and treatment allocation when randomised)
The treatment allocation for participants in the randomised component of the trial was computer 
generated; it was stratified by centre, with balance in respect of other key prognostic variables – age 
(18–49 years or 50+ years), sex (male or female) and BMI (≤ 28 or >29 kg/m2) – by a process of 
minimisation. Randomisation was organised centrally at the Health Services Research Unit, University of 
Aberdeen, and was independent of all clinical collaborators.
Clinical management
Participants who were allocated to surgical management were invited to a consultation with the 
collaborating surgeon. During this consultation, the surgeon confirmed that there was no contraindication 
to surgery and discussed the operation in more detail, before arranging an operation date. The surgeon 
recorded intraoperative details on specially designed study forms. All other in-hospital data collection 
was the responsibility of the local study nurse. In all respects, other than the trial interventions, clinical 
management was left to the discretion of the clinician responsible for care. This continued to be the case 
in the extended follow-up phase, which is the focus of this report, with GPs monitoring subsequent care 
needs throughout the follow-up period.
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Data collection
Follow-up by postal questionnaire was first performed at 3 months after surgery, or at an equivalent time 
among those who did not have surgery, and then annually. The questionnaire used for the follow-up 
at 2–5 years was similar to the questionnaire that had been used in the earlier phase of the trial up 
to 12 months after surgery. Non-responders received up to two reminder telephone calls or letters to 
encourage return of their postal questionnaires. On occasion, and at the participants’ convenience, a 
shortened version of the questionnaire was completed over the telephone.
From around half-way through the 5-year follow-up, participants were sent a £5 gift voucher with their 
final postal reminder to compensate for their time in completing the questionnaire. This decision was 
taken based on the findings of a systematic review of the effects of incentives on postal questionnaire 
return32 and specific randomised trials that evaluated the use of vouchers.33–35
All data were sent to the trial office in Aberdeen for processing. A random 10% sample of all data 
was double-entered to check accuracy and no significant errors were identified. Extensive range and 
consistency checks further enhanced the quality of the data.
The principal study outcome measure
The primary outcomes for measuring the differences in effects between medical and surgical 
management were:
 z a ‘disease-specific’ measure incorporating assessment of reflux and other gastrointestinal symptoms 
and the side effects and complications of both therapies (the REFLUX questionnaire was developed 
specifically for this study4)
 z NHS costs including treatments, investigations, consultations and other contacts with the 
health service.
The secondary outcome measures were:
 z HRQoL – measured using the European Quality of Life-5 Dimensions (EQ-5D)36 and Short Form 
questionnaire-36 items (SF-36)37
 z patient costs, including loss of earnings, reduction in activities and the costs of prescriptions and travel 
to health care
 z other serious morbidity, such as operative complications
 z (further) anti-reflux surgery
 z mortality.
An example of the annual questionnaire used for collecting this information is provided in Appendix 1.
Sample size
The original aim was to recruit 600 participants to the randomised trial to give 80% power to identify a 
difference between the two groups of 0.25 of a standard deviation (SD) in respect of the disease-specific 
instrument and other continuous variables such as EQ-5D and SF-36, using a significance level of 5%. 
Based on the same arguments, it was planned that 300 people would be recruited to each arm of the 
preference study. The cost savings of a surgical policy largely depend on the number of patients managed 
surgically who no longer require PPI treatment, and a trial with 300 surgically managed patients would 
have estimated this proportion to within about 5% with 95% statistical confidence.
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However, prompted by a lower rate of recruitment than expected, this target was revised in January 2003 
in consultation with the Data Monitoring Committee (DMC) and representatives of the HTA programme. 
It was agreed that a larger benefit (0.3 of a SD) was clinically plausible based on improvements seen after 
surgery in the accruing literature among more severely affected people (who were not eligible for the trial). 
This was calculated to require 196 in each group to give 80% power (2p = 0.05).
Statistical considerations
This report describes analyses of annual questionnaire data up to 5 years after surgery (or an equivalent 
time if managed medically). As a general rule, in the tables and analyses presented in this report, the 
participants in the randomised groups are separate from those in the preference groups. A sizeable group 
of patients allocated to surgery did not receive surgery. Therefore, to investigate the potential influence 
of this non-compliance with allocation, summary statistics in the results tables are given for four main 
analysis populations (comprising eight groups of participants):
1. Randomised ITT population (groups that were randomised to either surgery or medical management).
2. Per-protocol (PP) population (groups that were either randomised to surgery and received surgery in 
the first year or randomised to medical management and did not receive surgery in the first year).
3. Preference ITT population (groups that preferred either surgery or medical management 
at recruitment).
4. Preference PP population (groups that either preferred surgery at recruitment and received surgery in 
the first year or preferred medical management and did not receive surgery in the first year).
The primary outcome measure (REFLUX QoL score) and secondary outcome measures (SF-36, EQ-5D, 
REFLUX symptom scores, anti-reflux surgery and use of reflux-related drugs) were analysed using general 
linear models. The analyses adjusted for the minimisation covariates (age, BMI and sex) and where 
appropriate (defined by significant at the 5% significance level) also adjusted for baseline measures and 
baseline measures by treatment interaction. A secondary, pre-stated subgroup analysis explored the 
differential effects of surgeon’s preferred operative procedure on the primary outcome measure. All 
analyses were reported with 95% confidence intervals (CIs).
The primary analysis of the randomised groups was by ITT. The ITT approach sustains the integrity of the 
randomisation and gives the least biased estimate of effectiveness of the two forms of management. 
Given that a sizeable minority of the randomised surgical participants did not receive surgery, we were 
also interested in estimating the efficacy of the initial treatment received as a secondary comparison (i.e. 
commonly known as a PP analysis). In an open trial design a PP analysis can have substantial selection bias. 
To minimise the effects of selection bias we used the method of ‘adjusted treatment received’ as described 
by Nagelkerke et al.38 and others.39,40 The method used a two-stage least-squares approach whereby 
treatment randomised was regressed onto treatment received and the residuals from that model were 
used as an independent variable in a second model, together with the treatment received, to estimate the 
effects on the various primary and secondary outcome measures.
For the preference study, only the primary outcome was analysed statistically. The analysis compared the 
preference surgical group with the preference medical group and adjusted for the minimisation factors. As 
described above, for logistical reasons and to maintain balance between the randomised and preference 
groups, we capped the number of preference participants at 20 per group per centre. The study design 
was not therefore a true comprehensive cohort. We did consider modelling differences between the 
randomised and preference groups; however, it is not universally accepted that formal modelling is 
appropriate in this context. In this case we knew from the randomised arms that there was a strong 
interaction between treatment effects and baseline REFLUX QoL, and in addition we knew that there was 
a large difference in QoL between preference arms at baseline (and patient demographics such as age and 
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sex). We therefore decided that formal modelling of the arms would add little to the comparison given the 
large confounding between preference groups.
Sensitivity analyses
The sensitivity of the primary outcome analysis result was investigated using two approaches – the effect 
of excluding a large centre and the effects of missing data. In the first approach the largest recruiting 
centre, Aberdeen, was excluded and the analysis as described above was rerun. Second, previous work 
demonstrated that the primary outcome was likely missing at random (MAR) or missing completely at 
random (MCAR) and that a repeated measures analysis (using all available data) was an appropriate 
statistical method for analysing data up to 12 months.41 We therefore used a repeated measures analysis 
on the primary outcome across all of the follow-up data (12 months to 5 years) to investigate the effect 
of incorporating a profile of measures for each participant. No further imputation for missing values 
was necessary.
Data monitoring
During recruitment, an independent DMC met on three occasions and each time saw no reason to 
recommend any fundamental changes to the protocol. The committee did not meet after recruitment 
was completed.
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Chapter 3 Trial results and clinical effectiveness
Recruitment to the trial
Participants were recruited in 21 clinical centres, all within the UK (their locations are listed on the left-
hand side of Table 1). Recruitment to the trial was open from March 2001 until the end of June 2004, 
although not all centres enrolled over the total period because of the staggered introduction of centres 
and early closure for logistical reasons in a few places.1
A total of 357 participants were recruited to the randomised component: 178 allocated to surgery and 
179 allocated medical management. 453 participants agreed to join the preference component: 261 
choosing surgery and 192 choosing medical management. Table 1 shows recruitment by centre. Around 
one-fifth of the randomised participants were enrolled in Aberdeen; no centre contributed > 10% of 
participants in the preference component.
Analysis populations
Throughout the analyses presented later in this chapter, the participants in the randomised component are 
kept separate from those in the preference component (other than for rare surgical events). The numbers 
of participants in each of the four main analysis populations are shown in Table 2. All 357 who joined the 
randomised component are in the randomised ITT population; only the 280 within this group who actually 
received their allocated management over the first year are in the randomised PP population. All 453 
participants who joined the preference component are in the preference ITT population; the 407 of these 
who, by the end of the first year, were managed as originally chosen were in the preference PP population.
Trial conduct
The derivation of the main study groups and their progress through the stages of follow-up in the trial 
are shown in Figure 1. This is in the form of a CONSORT (Consolidated Standards of Reporting Trials) flow 
diagram. In total, 1078 patients were considered for trial entry and 200 of these were found not to meet 
one or more of the eligibility criteria. Of the 68 patients eligible for the study but not recruited, 51 declined 
to participate, six were subsequently deemed inappropriate for the study by the surgeon responsible for 
care and the remaining 11 were missed.
Details of the clinical management actually received are described later in this chapter.
The mean (SD) time intervals in months between the receipt by the trial office of each subsequent annual 
postal questionnaire are shown in Table 3; all were near 12 months, as would be expected. There was, 
however, a difference between the randomised groups in the time interval between the 1-year and the 
2-year questionnaires (mean 12.2 months surgical group vs 13.9 months medical group). In part, this was 
due to more late returns in the medical management group – the median intervals were closer: 12.00 
and 13.00 months respectively. As described previously,1 early follow-up was adjusted to be at a time 
equivalent to 3 and 12 months after surgery. The adjustments in the medical group to match this could 
be only approximate and this is the explanation for the difference that remained between the randomised 
groups. An advantage of long-term follow-up to 5 years is that any difference in the timing of follow-up 
becomes proportionately smaller over time.
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TABLE 1 Number of participants by centre
Randomised participants, n (%) Preference participants, n (%)
Surgical 
(n = 178)
Medical 
(n = 179)
Surgical 
(n = 261)
Medical 
(n = 192)
Aberdeen: Aberdeen Royal Infirmary 38 (21.3) 40 (22.3) 20 (7.7) 21 (10.9)
Belfast: Royal Victoria Hospital 15 (8.4) 14 (7.8) 4 (1.5) 20 (10.4)
Bournemouth: Royal Bournemouth Hospital 4 (2.2) 3 (1.7) 20 (7.7) 3 (1.6)
Bristol: Bristol Royal Infirmary 12 (6.7) 11 (6.1) 18 (6.9) 20 (10.4)
Bromley: Princess Royal Infirmary 3 (1.7) 3 (1.7) 20 (7.7) 17 (8.9)
Edinburgh: Royal Infirmary of Edinburgh 11 (6.2) 11 (6.1) 1 (0.4) 15 (7.8)
Guildford: Royal Surrey County Hospital 10 (5.6) 10 (5.6) 17 (6.5) 10 (5.2)
Hull: Hull Royal Infirmary 7 (3.9) 7 (3.9) 1 (0.4) 2 (1.0)
Inverness: Raigmore Hospital 7 (3.9) 8 (4.5) 2 (0.8) 8 (4.2)
Leeds: Leeds General Infirmary 1 (0.6) 2 (1.1) 10 (3.8) 3 (1.6)
Leicester: Leicester Royal Infirmary 0 (0.0) 0 (0.0) 3 (1.1) 1 (0.5)
London: St Mary’s Hospital 8 (4.5) 7 (3.9) 4 (1.5) 10 (5.2)
London: Whipps Cross Hospital 4 (2.2) 3 (1.7) 16 (6.1) 5 (2.6)
Poole: Poole Hospital 10 (5.6) 10 (5.6) 25 (9.6) 13 (6.8)
Portsmouth: Queen Alexandra Hospital 10 (5.6) 10 (5.6) 15 (5.7) 1 (0.5)
Salford: Hope Hospital 0 (0.0) 1 (0.6) 6 (2.3) 3 (1.6)
Stoke-on-Trent: North Staffordshire Hospital 5 (2.8) 6 (3.4) 20 (7.7) 9 (4.7)
Swansea: Morriston Hospital 8 (4.5) 8 (4.5) 14 (5.4) 9 (4.7)
Telford: Princess Royal Hospital 11 (6.2) 12 (6.7) 24 (9.2) 8 (4.2)
Yeovil: Yeovil District Hospital 9 (5.1) 8 (4.5) 18 (6.9) 8 (4.2)
York: York District Hospital 5 (2.8) 5 (2.8) 3 (1.1) 6 (3.1)
Total 178 (100) 179 (100) 261 (100) 192 (100)
TABLE 2 Number of participants in each analysis population
Surgical, n (%) Medical, n (%) Total, n
Randomised ITT 178 (49.9) 179 (50.1) 357
Randomised PP 111 (39.6) 169 (60.4) 280
Preference ITT 261 (57.6) 192 (42.4) 453
Preference PP 218 (53.6) 189 (46.4) 407
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Assessed for eligibility
(N = 1078)
Patients randomised
Participants (n = 357)
Preferred surgery Preferred medicationRandomisation
Preference surgery (n = 261)
Withdrawn before surgery (n = 16)
Received surgery (n = 218)
Declined surgery (n = 25)
Death (n = 2)
Allocated to surgery (n = 178)
Withdrawn before surgery (n = 20)
Received surgery (n = 111)
Declined surgery (n = 47)
Allocated to medicine (n = 179)
Received surgery (n = 10)
Preference medicine (n = 192)
Received surgery (n = 3)
Baseline questionnaire returned
(n = 258) 
Baseline questionnaire returned
(n = 175)
Baseline questionnaire returned
(n = 174)
Baseline questionnaire returned
(n = 189)
Follow-up at time equivalent to 1 year
after surgery (n = 230)
Address unknown/prior lost to follow-up
(n = 12)
Declined further follow-up (n = 9)
Death (n = 2)
Response (n = 230)
Non-response (n = 8)
Number analysed using REFLUX QoL
score (n = 121) 
Follow-up at time equivalent to1 year
after surgery (n = 154)
Address unknown/prior lost to follow-up
(n = 10)
Declined further follow-up (n = 10)
Death (n = 0)
Response (n = 154)
Non-response (n = 4)
Number analysed using REFLUX QoL
score (n = 145)  
Follow-up at time equivalent to 1 year
after surgery (n = 164)
Address unknown/prior lost to follow-up
(n = 5)
Declined further follow-up (n = 6)
Death (n = 1)
Response (n = 164)
Non-response (n = 3)
Number analysed using REFLUX QoL
score (n = 154)
Follow-up at time equivalent to 1 year
after surgery (n = 177)
Address unknown/prior lost to follow-up
(n = 3)
Declined further follow-up (n = 8)
Death (n = 0)
Response (n = 177)
Non-response (n = 4)
Number analysed using REFLUX QoL
score (n = 163) 
Ineligible (n = 200)
Eligible but not recruited (n = 68)
Follow-up at time equivalent to 2 years
after surgery (n = 203)
Address unknown/prior lost to follow-up
(n = 26)
Declined further follow-up (n = 15)
Death (n = 2)
Response (n = 203)
Non-response (n = 15)
Number analysed using REFLUX QoL
score (n = 187)  
Follow-up at time equivalent to 2 years
after surgery (n = 128)
Address unknown/prior lost to follow-up
(n = 17)
Declined further follow-up (n = 13)
Death (n = 0)
Response (n = 128)
Non-response (n = 20)
Number analysed using REFLUX QoL
score (n = 118) 
Follow-up at time equivalent to 2 years
after surgery (n = 142)
Address unknown/prior lost to follow-up
(n = 11)
Declined further follow-up (n = 11)
Death (n = 1)
Response (n = 142)
Non-response (n = 14)
Number analysed using REFLUX QoL
score (n = 137) 
Follow-up at time equivalent to 2 years
after surgery (n = 156)
Address unknown/prior lost to follow-up
(n = 5)
Declined further follow-up (n = 15)
Death (n = 0)
Response (n = 156)
Non-response (n = 16)
Number analysed using REFLUX QoL
score (n = 140)
Follow-up at time equivalent to 3 years
after surgery (n = 196)
Address unknown/prior lost to follow-up
(n = 30)
Declined further follow-up (n = 21)
Death (n = 2)
Response (n = 196)
Non-response (n = 12)
Number analysed using REFLUX QoL
score (n = 176) 
Follow-up at time equivalent to 3 years
after surgery (n = 132)
Address unknown/prior lost to follow-up
(n = 21)
Declined further follow-up (n = 14)
Death (n = 0)
Response (n = 132)
Non-response (n = 11)
Number analysed using REFLUX QoL
score (n = 124) 
Follow-up at time equivalent to 3 years
after surgery (n = 134)
Address unknown/prior lost to follow-up
(n = 14)
Declined further follow-up (n = 21)
Death (n = 1)
Response (n = 134)
Non-response (n = 9)
Number analysed using REFLUX QoL
score (n = 126)
Follow-up at time equivalent to 3 years
after surgery (n = 159)
Address unknown/prior lost to follow-up
(n = 7)
Declined further follow-up (n = 18)
Death (n = 1)
Response (n = 159)
Non-response (n = 7)
Number analysed using REFLUX QoL
score (n = 141) 
Follow-up at time equivalent to 4 years
after surgery (n = 168)
Address unknown/prior lost to follow-up
(n = 33)
Declined further follow-up (n = 26)
Death (n = 2)
Response (n = 168)
Non-response (n = 32)
Number analysed using REFLUX QoL
score (n = 152) 
Follow-up at time equivalent to 4 years
after surgery (n = 126)
Address unknown/prior lost to follow-up
(n = 22)
Declined further follow-up (n = 14)
Death (n = 0)
Response (n = 126)
Non-response (n = 16)
Number analysed using REFLUX QoL
score (n = 111) 
Follow-up at time equivalent to 4 years
after surgery (n = 129)
Address unknown/prior lost to follow-up
(n = 14)
Declined further follow-up (n = 21)
Death (n = 2)
Response (n = 129)
Non-response (n = 13)
Number analysed using REFLUX QoL
score (n = 105)
Follow-up at time equivalent to 4 years
after surgery (n = 142)
Address unknown/prior lost to follow-up
(n = 11)
Declined further follow-up (n = 24)
Death (n = 1)
Response (n = 142)
Non-response (n = 14)
Number analysed using REFLUX QoL
score (n = 129) 
Follow-up at time equivalent to 5 years
after surgery (n = 176)
Address unknown/prior lost to follow-up
(n = 35)
Declined further follow-up (n = 26)
Death (n = 2)
Response (n = 176)
Non-response (n = 22)
Number analysed using REFLUX QoL
score (n = 144) 
Follow-up at time equivalent to 5 years
after surgery (n = 127)
Address unknown/prior lost to follow-up
(n = 23)
Declined further follow-up (n = 14)
Death (n = 2)
Response (n = 127)
Non-response (n = 12)
Number analysed using REFLUX QoL
score (n = 109) 
Follow-up at time equivalent to 5 years
after surgery (n = 119)
Address unknown/prior lost to follow-up
(n = 16)
Declined further follow-up (n = 23)
Death (n = 2)
Response (n = 119)
Non-response (n = 19)
Number analysed using REFLUX QoL
score (n = 97)
Follow-up at time equivalent to 5 years
after surgery (n = 136)
Address unknown/prior lost to follow-up
(n = 11)
Declined further follow-up (n = 26)
Death (n = 1)
Response (n = 136)
Non-response (n = 18)
Number analysed using REFLUX QoL
score (n = 116) 
FIGURE 1 The CONSORT diagram.
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TrIAL rESuLTS AND CLINICAL EffECTIVENESS
14
More details of the response rates to the annual questionnaires are provided in Table 4. The overall rates of 
return of annual follow-up questionnaires (years 1–5) were 89.5%, 77.7%, 76.7%, 69.8% and 68.9% of 
the study participants. Seven participants are known to have died up to the end of the 5-year follow-up; 
equivalent response rates among those not known to have died are 89.8%, 77.9%, 77.0%, 70.2% and 
69.5%. There were no substantive differences in response rates between the groups.
Three participants died before the 1-year follow-up was reached: two in the preference surgery group 
and one in the randomised medical group. None of these participants actually had surgery. Four died 
subsequently; there is no evidence linking these deaths to trial participation.
Description of the groups at trial entry
Sociodemographic and clinical factors
Table 5 provides a description of the groups at trial entry. The main division within the table is between 
participants in the randomised component and those in the preference component. These two halves of 
the table are further divided according to the allocation of participants and then subdivided according to 
ITT or PP.
Randomised arms
Within the randomised groups there were no apparent imbalances between the medical and surgical 
intervention arms. The patients were, on average, 46 years old, 66% were men, around two-thirds were in 
full employment and participants had been on GORD medication for a median of 32 months. The baseline 
characteristics in the randomised PP groups were similar.
Preference arms
The sociodemographic characteristics of the preference participants were broadly similar to those of the 
randomised participants. However, preference medical participants tended to be older (mean age 50 years) 
and were more likely to be female, fewer were in full-time employment and participants had been on 
GORD medication for a shorter period (approximately 6 months less than randomised participants).
Prescribed medications
The prescribed medications at the time of trial entry are shown in Table 6. There was a similar profile of 
prescribed medications across the randomised and preference groups. As would be expected, nearly all 
participants reported taking a reflux-related drug in the previous 2 weeks. Over 90% had taken a PPI, of 
which lansoprazole was the most common.
TABLE 3 Interval between randomisation and follow-up (months), mean (SD)
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT (n = 178) ITT (n = 179) ITT (n = 261) ITT (n = 192)
1 year to 2 years 12.2 (1.9) 13.9 (3.1) 12.4 (1.8) 12.9 (4.6)
2 years to 3 years 11.8 (1.2) 11.6 (1.2) 11.6 (1.5) 11.8 (1.2)
3 years to 4 years 12.0 (1.5) 12.0 (1.4) 12.1 (1.2) 12.0 (1.1)
4 years to 5 years 11.8 (1.3) 12.0 (1.3) 12.1 (1.5) 12.0 (1.3)
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TABLE 4 CONSORT table
Year Category
Randomised participants, n (%) Preference participants, n (%)
Surgical 
(n = 178)
Medical 
(n = 179)
Surgical 
(n = 261)
Medical 
(n = 192)
1 Responded 154 (87) 164 (92) 230 (88) 177 (92)
Declined further follow-up 10 (6) 6 (3) 9 (3) 8 (4)
Deceased 0 (0) 1 (1) 2 (1) 0 (0)
Address unknown/lost to follow-up 10 (6) 5 (3) 12 (5) 3 (2)
Non-responder 4 (2) 3 (2) 8 (3) 4 (2)
2 Responded 128 (72) 142 (79) 203 (78) 156 (81)
Declined further follow-up 13 (7) 11 (6) 15 (6) 15 (8)
Deceased 0 (0) 1 (1) 2 (1) 0 (0)
Address unknown/lost to follow-up 17 (10) 11 (6) 26 (10) 5 (3)
Non-responder 20 (11) 14 (8) 15 (6) 16 (8)
3 Responded 132 (74) 134 (75) 196 (75) 159 (83)
Declined further follow-up 14 (8) 21 (12) 21 (8) 18 (9)
Deceased 0 (0) 1 (1) 2 (1) 1 (1)
Address unknown/lost to follow-up 21 (12) 14 (8) 30 (11) 7 (4)
Non-responder 11 (6) 9 (5) 12 (5) 7 (4)
4 Responded 126 (71) 129 (72) 168 (64) 142 (74)
Declined further follow-up 14 (8) 21 (12) 26 (10) 24 (13)
Deceased 0 (0) 2 (1) 2 (1) 1 (1)
Address unknown/lost to follow-up 22 (12) 14 (8) 33 (13) 11 (6)
Non-responder 16 (9) 13 (7) 32 (12) 14 (7)
5 Responded 127 (71) 119 (66) 176 (67) 136 (71)
Declined further follow-up 14 (8) 23 (13) 26 (10) 26 (14)
Deceased 2 (1) 2 (1) 2 (1) 1 (1)
Address unknown/lost to follow-up 23 (13) 16 (9) 35 (13) 11 (6)
Non-responder 12 (7) 19 (11) 22 (8) 18 (9)
Health status
Randomised arms
The HRQoL scores at study entry are displayed in Table 7. The scores were broadly similar in the 
randomised surgical and randomised medical groups, although they were slightly higher (better health) 
in the randomised medical group. When the DMC first met after the initial 143 participants had been 
recruited to the randomised component, the committee did ask us to change the enrolment procedure 
to ensure that baseline questionnaires were completed before formal entry and randomisation. We 
understand that this was because they were concerned about an apparent imbalance between the 
randomised groups in baseline health status at that time. After satisfying themselves that this was not 
due to a breakdown in the randomisation procedure, the DMC surmised that this might be due to prior 
knowledge of the treatment allocation affecting questionnaire responses (with those allocated surgery 
tending to project worse health status than those allocated medical management). Certainly, the groups 
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based on the first 143 participants were well balanced in other respects, and there was subsequently good 
balance in health status as well. The apparent small imbalance between the randomised groups in health 
status measures is therefore likely to be a reflection of the imbalance in the first 143 participants.
The most prevalent reflux symptoms (those with lowest scores) were general discomfort and wind. The 
participants had lower SF-36 and EQ-5D scores than a normal UK population with the same average age 
and sex characteristics (SF-36 population norm approximately 50 for all domains; EQ-5D norm 0.88).
Preference arms
The preference for surgery participants reported worse REFLUX QoL scores and worse health in general 
than the preference for medicine participants. It can be seen from Table 7 that the randomised participants 
reported QoL measures in between these two extremes.
Baseline characteristics of groups compared at 5 years
There were differences in baseline characteristics between those who had completed a questionnaire at 
5 years and those who had not (Table 8). For example, responders had a higher mean age (47.9 years vs 
43.6 years), had been on prescribed medication for a shorter period at recruitment to the REFLUX trial 
(50.5 months vs 60.2 months) and had higher QoL scores at baseline (measured on the disease-specific 
REFLUX instrument, EQ-5D and SF-36).
However, the baseline characteristics of those in the randomised surgical and randomised medical groups 
who completed a questionnaire at 5 years were very similar, with the only notable difference being in 
BMI (Table 9). The mean baseline BMI among responders in the randomised surgical group was higher 
(29.0 kg/m2) than that for responders in the randomised medical management group (27.7 kg/m2). As 
described in Chapter 2, these results confirmed that a repeated measures analysis assuming no differential 
loss to follow-up could be considered.
Surgical management
Table 10 summarises the use of surgery in the four study groups over the full 5-year follow-up period. 
At the end of the first year, 111 participants (62.4%) randomised to surgery had actually undergone 
fundoplication. Over the next 4 years, one more member of this group had fundoplication, bringing the 
total to 112 (62.9%). In the randomised medical group, 10 participants (5.6%) had fundoplication in 
the first year, with a further 14 participants having fundoplication in subsequent years, bringing the total 
at 5 years to 24 (13.4%). In the preference surgical group, 218 participants (83.5%) had fundoplication 
in the first year, with four more in the period up to 5 years, taking the percentage to 85.1%. Surgical 
management applied to only three participants (1.6%) in the preference medical group in the first year, 
with a further three being operated on in the subsequent 4 years (total 3.1%).
Information about the reasons why participants allocated surgery did not receive it in the first year is 
available for 47. For 25 of these 47, this was a clinical decision, most commonly the surgeon deciding 
that surgery was not appropriate; most of the other 22 changed their minds about surgery for a variety of 
work- or home-related reasons. A further 20 withdrew for unknown reasons. There is no doubt, however, 
that a number of these participants suffered long delays before being formally offered surgery, and this 
was an important factor in their eventual decision to choose not to have surgery after all. The trial was 
conducted at a time when there was great pressure on surgical services in the NHS, with long delays 
for elective surgery for non-life-threatening benign conditions being common. Indeed, the average time 
between trial entry and surgery in the trial was 8–9 months.1
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TABLE 8 Baseline characteristics of responders and non-responders at 5 years
Characteristic
Responder 
(max. n = 558)
Non-responder 
(max. n = 252)
p-value 
(two- sided)
BMI (kg/m2), mean (SD), n 27.9 (4.0), 557 28.2 (4.3), 252 0.37
Age (years), mean (SD), n 47.9 (11.2), 558 43.6 (12.2), 252 < 0.01
Sex, n/N (%)
Male 343/558 (61) 174/252 (69) 0.04
Female 215/558 (39) 78/252 (31) –
Duration of prescribed medication (months), mean (SD), n 50.5 (62.9), 544 60.2 (65.2), 250 0.05
Erosive oesophagitis, n/N (%)
Yes 262/493 (53) 111/213 (52) 0.78
No 231/493 (47) 102/213 (48)
Helicobacter pylori status, n/N (%)
Positive (subsequently treated) 39/440 (9) 20/186 (11) 0.81
Positive (subsequently untreated) 9/440 (2) 5/186 (3) –
Negative 238/440 (54) 102/186 (55) –
Uncertain 154/440 (35) 59/186 (32) –
Hiatus hernia, n/N (%)
Yes 330/524 (63) 135/222 (61) 0.58
No 194/524 (37) 87/222 (39) –
Age (years) left full-time education, n/N (%)
≤ 16 304/552 (55) 170/250 (68) < 0.01
17–19 143/552 (26) 43/250 (17) –
20+ 105/552 (19) 37/250 (15) –
Employment status, n/N (%)
Full-time 348/551 (63) 146/251 (58) 0.01
Part-time 65/551 (12) 19/251 (8) –
Student 6/551 (1) 7/251 (3) –
Retired 62/551 (11) 25/251 (10) –
Housework 32/551 (6) 21/251 (8) –
Seeking work 10/551 (2) 6/251 (2) –
Other 28/551 (5) 27/251 (11) –
REFLUX QoL, mean (SD), n 66.6 (24.2), 533 61.3 (24.1), 226 < 0.01
REFLUX symptom score, mean (SD), n
General discomfort symptom score 61.1 (25.5), 544 55.4 (25.4), 231 < 0.01
Wind and frequency symptom score 51.5 (21.7), 546 48.9 (23.0), 235 0.13
Nausea and vomiting symptom score 83.8 (18.3), 549 77.1 (21.5), 239 < 0.01
Activity limitation symptom score 79.9 (16.1), 547 77.5 (17.4), 232 0.06
Constipation and swallowing symptom score 78.8 (20.0), 550 75.2 (21.7), 236 0.03
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Characteristic
Responder 
(max. n = 558)
Non-responder 
(max. n = 252)
p-value 
(two- sided)
EQ-5D, mean (SD), n 0.735 (0.234), 544 0.662 (0.279), 239 < 0.01
SF-36 score, mean (SD), n
SF-36 physical 45.2 (9.5), 530 44.0 (9.7), 232 0.10
SF-36 mental 46.3 (11.2), 530 42.7 (12.9), 232 < 0.01
Norm-based physical functioning 47.2 (9.9), 545 46.1 (10.7), 239 0.15
Norm-based role physical 46.6 (10.7), 546 45.0 (11.0), 238 0.06
Norm-based bodily pain 45.1 (10.1), 546 42.3 (9.9), 236 < 0.01
Norm-based general health 42.0 (9.8), 544 39.3 (10.7), 236 < 0.01
Norm-based vitality 44.3 (10.8), 549 42.8 (11.4), 237 0.07
Norm-based social functioning 45.5 (10.8), 542 41.8 (12.0), 237 < 0.01
Norm-based role emotional 47.0 (11.5), 543 44.5 (13.2), 239 0.01
Norm-based mental health 47.0 (10.6), 549 42.9 (12.4), 237 < 0.01
Any PPI, n/N (%) 508/552 (92) 213/242 (88) 0.07
Any reflux drug, n/N (%) 530/552 (96) 225/242 (93) 0.07
max., maximum.
TABLE 9 Baseline characteristics of responders at 5 years by randomised allocation
Characteristic
Surgical 
(max. n = 127)
Medical 
(max. n = 119)
p-value 
(two-sided)
BMI (kg/m2), mean (SD), n 29.0 (4.3), 127 27.7 (3.8), 119 0.01
Age (years), mean (SD), n 48.5 (9.3), 127 46.4 (11.6), 119 0.12
Sex, n/N (%)
Male 79/127 (62) 76/119 (64) 0.79
Female 48/127 (38) 43/119 (36) –
Duration of prescribed medication (months), mean (SD), n 57.2 (63.4), 124 46.3 (60.1), 117 0.17
Erosive oesophagitis, n/N (%)
Yes 63/111 (57) 68/107 (64) 0.35
No 48/111 (43) 39/107 (36) –
Helicobacter pylori status, n/N (%)
Positive (subsequently treated) 6/96 (6) 10/91 (11) 0.52
Positive (subsequently untreated) 1/96 (1) 2/91 (2) –
Negative 55/96 (57) 45/91 (49) –
Uncertain 34/96 (35) 34/91 (37) –
Hiatus hernia, n/N (%)
Yes 73/117 (62) 71/114 (62) 0.99
No 44/117 (38) 43/114 (38) –
continued
TABLE 8 Baseline characteristics of responders and non-responders at 5 years (continued)
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Characteristic
Surgical 
(max. n = 127)
Medical 
(max. n = 119)
p-value 
(two-sided)
Age (years) left full-time education, n/N (%)
≤ 16 77/125 (62) 70/119 (59) 0.46
17–19 27/125 (22) 31/119 (26) –
20+ 21/125 (17) 18/119 (15) –
Employment status, n/N (%)
Full-time 86/124 (69) 76/118 (64) 0.77
Part time 13/124 (10) 10/118 (8) –
Student 2/124 (2) 1/118 (1) –
Retired 9/124 (7) 13/118 (11) –
Housework 4/124 (3) 7/118 (6) –
Seeking work 4/124 (3) 3/118 (3) –
Other 6/124 (5) 8/118 (7) –
REFLUX QoL, mean (SD), n 65.9 (23.7), 121 68.6 (24.0), 110 0.38
REFLUX symptom score, mean (SD), n
General discomfort symptom score 60.1 (24.1), 123 63.9 (25.2), 115 0.23
Wind and frequency symptom score 48.0 (19.7), 125 48.7 (20.9), 117 0.78
Nausea and vomiting symptom score 82.9 (18.9), 125 84.7 (18.9), 117 0.46
Activity limitation symptom score 79.9 (15.2), 124 79.9 (16.8), 117 0.99
Constipation and swallowing symptom score 78.2 (19.2), 124 75.9 (20.0), 118 0.35
EQ-5D, mean (SD), n 0.736 (0.223), 122 0.755 (0.228), 118 0.51
SF-36 score, mean (SD), n
SF-36 physical 44.8 (10.0), 121 46.1 (9.1), 114 0.30
SF-36 mental 46.6 (11.0), 121 46.5 (11.1), 114 0.98
Norm-based physical functioning 46.8 (10.0), 123 48.4 (10.2), 117 0.22
Norm-based role physical 46.9 (10.8), 124 47.0 (10.8), 116 0.96
Norm-based bodily pain 44.6 (10.1), 123 45.7 (10.1), 117 0.39
Norm-based general health 41.4 (9.4), 124 42.4 (10.2), 116 0.41
Norm-based vitality 43.9 (10.4), 125 44.9 (11.2), 117 0.47
Norm-based social functioning 45.4 (10.5), 124 46.4 (10.8), 115 0.45
Norm-based role emotional 47.2 (11.4), 124 46.7 (12.1), 116 0.74
Norm-based mental health 47.3 (10.9), 125 48.0 (10.6), 117 0.60
Any PPI, n/N (%) 120/125 (96) 109/118 (92) 0.23
Any reflux drug, n/N (%) 124/125 (99) 113/118 (96) 0.08
max., maximum.
TABLE 9 Baseline characteristics of responders at 5 years by randomised allocation (continued)
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Details of the surgery received by the 111 participants (62.4%) randomised to surgery and the 218 
preference participants (83.5%) who actually received surgery in the first year, the perioperative 
complications that they experienced and their hospital stay have been reported previously but are 
summarised in Appendix 2 for completeness. There were no perioperative deaths.
Table 11 shows the numbers of those who had fundoplication who subsequently had a second reflux-
related operation during the 5 years of follow-up. Overall, this applied to 16 participants (4.4%) among 
the 364 who had a first operation: five (4.5%) in the randomised surgery group; one (4.2%) in the 
randomised medical group; eight (3.6%) in the preference surgery group; and two (33.3%) in the 
preference medical group. In total, five of the 16 operations were reconstructions of the same wrap, three 
were repairs of hiatus hernia only, six were conversions to a different type of wrap and two were reversals 
of the fundoplication. Two of these 16 participants had a third reflux-related operation; both were in the 
preference surgery group – one a reconstruction of the same wrap and one a repair of hiatus hernia only.
Late postoperative complications
Table 12 describes late postoperative complications among those participants who had surgery, in each of 
the study groups and overall. Of the total 364 who had fundoplication, 12 (3.3%) had a late complication: 
four (1.1%) were oesophageal dilatations/stricture dilatations; three (0.8%) were repairs of incisional 
hernias; and five (1.4%) were a heterogeneous group of other complications as detailed in the table.
Medication
Figure 2 summarises reported use of any PPI medication in the previous 2 weeks across the follow-up 
time points of the trial. Full details are provided in the tables in Appendix 3. From the time of the first 
annual follow-up onwards, rates in both medical groups were consistently around 80%. The rates in 
the randomised surgical ITT group at the first, second and third annual follow-ups were approximately 
36–38%, rising to 43% in the fifth year. The extent to which these rates reflected medication taking among 
those allocated to surgery and who had fundoplication (rather than those who did not have surgery) can 
be gauged from the randomised surgery PP group: 7.3% (3 months), 12.5% (1 year), 15.1% (2 years), 
19.6% (3 years), 23.9% (4 years) and 25.6% (5 years).
Table 13 allows further exploration of the reasons for the rise in medication use in the randomised surgery 
group. It distinguishes those reporting taking medication at the end of the first year of follow-up from 
TABLE 10 Initial fundoplication operations
Surgery
Randomised participants Preference participants
Surgical 
(n = 178)
Medical 
(n = 179)
Surgical 
(n = 261)
Medical 
(n = 192)
First fundoplication in first year, n (%) 111 (62.4) 10 (5.6) 218 (83.5) 3 (1.6)
First fundoplication after first year, n 1 14 4 3
In second year 0 1 2 0
In third year 0 7 1 2
In fourth year 1 4 1 1
In fifth year 0 2 0 0
Fundoplication at any time during 
5-year follow-up, n (%)
112 (62.9) 24 (13.4) 222 (85.1) 6 (3.1)
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TABLE 11 Subsequent reflux-related operations among participants who had fundoplication
Surgery
Randomised 
participants Preference participants
Total 
cohort
Surgical 
(n = 178)
Medical 
(n = 179)
Surgical 
(n = 261)
Medical 
(n = 192)
First fundoplication operation at any time, n 112 24 222 6 364
Second reflux-related reoperation, n (%) 5 (4.5) 1 (4.2) 8 (3.6) 2 (33.3) 16 (4.4)
Reconstruction of same wrap 2 1 1 1 5
Repair of hiatus hernia only 1 0 2 0 3
Conversion of type of wrap 2 0 4 0 6
Reversal of fundoplication 0 0 1 1 2
Third reflux-related reoperation, n
Reconstruction of same wrap 0 0 1 0 1
Repair of hiatus hernia only 0 0 1 0 1
Conversion of type of wrap 0 0 0 0 0
Reversal of fundoplication 0 0 0 0 0
TABLE 12 Late postoperative complications (> 1 month after surgery)
Complication
Randomised 
participants Preference participants
Total 
cohort
Surgical 
(n = 178)
Medical 
(n = 179)
Surgical 
(n = 261)
Medical 
(n = 192)
First fundoplication operation at any time 112 24 222 6 364
Late postoperative complications (within first year of original operation), n
Oesophageal dilatation/stricture dilatation 0 0 3 0 3
Repair of incisional hernia 0 0 1 0 1
Other (admission for deep-vein thrombosis/
pulmonary embolism) 
0 0 1 0 1
Late postoperative complications (within second year following operation), n
Oesophageal dilatation/stricture dilatation 1 0 0 0 1
Repair of incisional hernia 0 0 0 0 0
Other (pain from operation; hole between 
stomach and liver)
0 0 1 1 2
Late postoperative complications (beyond second year), n
Oesophageal dilatation/stricture dilatation 0 0 0 0 0
Repair of incisional hernia 0 0 2 0 2
Other (pain due to original wrap shifting; 
bleed in stomach/bowel)
1 0 0 1 2
Total late postoperative complications, n (%) 2 (1.8) 0 (0.0) 8 (3.6) 2 (33.3) 12 (3.3)
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those who indicated that they were not taking medication at that time. It shows that around 10–20% of 
those taking medication at the end of the first year did not report medication use at subsequent annual 
follow-up. Among those not taking medication at the first annual follow-up in the surgical groups, around 
10% rising to around 20% reported medication use at subsequent annual follow-up. This contrasts with 
the rates in the medical groups, with around 50–60% of those not taking medication at the end of the 
first year reporting anti-reflux drug use in subsequent annual follow-up. The pattern of type of PPI used 
changed over the course of the study. Although lansoprazole had been the most commonly used PPI at 
trial entry, omeprazole use increased over time to become the predominant PPI.
Outcome
Health status
Full details of the health status and QoL measures at each time point of follow-up are in the tables in 
Appendix 4. Details of the statistical testing of the health status and QoL scores can be found in the next 
section of this chapter.
REFLUX score
Figure 3 summarises changes in the disease-specific REFLUX score over the follow-up period. From this it 
can be seen that the scores at all time points are highest (indicating fewest symptoms) in the randomised 
surgical and preference surgical groups. However, the differences between the surgical and medical groups 
narrow over time. This is due principally to the scores in the randomised medical group improving over the 
first 3 years and, to a lesser extent, those in the preference medical group improving over the latter end 
of the follow-up period. The scores for the five components of the measure are summarised graphically in 
Figures 4–8. These show that the overall difference between the groups is principally due to the ‘general 
discomfort’ component and, to a lesser extent, the ‘nausea and vomiting’ and ‘activity limitations’ 
components.
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FIGURE 2 Use of PPI medication at baseline and at follow-up points up to 5 years.
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FIGURE 3 Mean REFLUX QoL score at baseline and at follow-up points up to 5 years (score range 0–100; the higher 
the score, the better the patient felt).
FIGURE 4 Mean REFLUX QoL general discomfort symptom score at baseline and follow-up points to 5 years (score 
range 0–100; the higher the score, the better the patient felt).
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FIGURE 5 Mean REFLUX QoL wind and frequency symptom score at baseline and follow-up points to 5 years (score 
range 0–100; the higher the score, the better the patient felt).
FIGURE 6 Mean REFLUX QoL nausea and vomiting symptom score at baseline and follow-up points to 5 years (score 
range 0–100; the higher the score, the better the patient felt).
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FIGURE 7 Mean REFLUX QoL activity limitation symptom score at baseline and follow-up points to 5 years (score range 
0–100; the higher the score, the better the patient felt).
FIGURE 8 Mean REFLUX QoL constipation and swallowing symptom score at baseline and follow-up points to 5 years 
(score range 0–100; the higher the score, the better the patient felt).
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Short Form questionnaire-36 items
The pattern of SF-36 scores, both for the composite physical and mental scores and for the individual 
dimensions (Figures 9–16), was similar to that seen for the REFLUX score, although more compact. 
Differences narrowed over the 5 years of follow-up, with the ‘general health’ dimension showing the 
clearest differences between the surgery and the medical management groups.
European Quality of Life-5 Dimensions
Figure 17 graphically displays the EQ-5D scores over the course of the follow-up period. The pattern is 
similar to that seen for the REFLUX score although differences are less marked and only clearly seen over 
the first 3 years.
Use of health services
Table 14 shows use of health services for the randomised groups. The larger number of overnight 
hospital admissions in the medical group largely reflected admissions for surgery; as described above, 
14 participants allocated to medical management had fundoplication after the first year. However, seven 
participants in the medical group compared with one in the surgical group had admissions for a non-
surgery-related reason (data not shown).
Numbers of day-case hospital admissions were similar in the two groups. The larger number of visits to 
or from a GP for a reflux-related reason in the randomised medical group reflected both more individuals 
attending their GPs and a higher frequency of visits for those who sought GP care.
Individual symptoms of gastro-oesophageal reflux disease or its treatment
Table 15 shows the frequency with which participants reported symptoms of GORD or its treatment at 3 
and 5 years of follow-up for the randomised groups.  At both 3 and 5 years, heartburn was reported by a 
higher proportion of participants in the randomised medical group than in the randomised surgical group.  
In addition, a higher proportion of participants in the randomised medical group reported more frequent 
heartburn than in the randomised surgical group.  At both time points, a higher proportion of participants 
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FIGURE 9 Mean SF-36 norm-based physical functioning score at baseline and follow-up points to 5 years (score range 
0–100; the higher the score, the better the patient felt).
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FIGURE 10 Mean SF-36 norm-based role physical score at baseline and follow-up points to 5 years (score range 0–100; 
the higher the score, the better the patient felt).
FIGURE 11 Mean SF-36 norm-based bodily pain score at baseline and follow-up points to 5 years (score range 0–100; 
the higher the score, the better the patient felt).
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FIGURE 12 Mean SF-36 norm-based general health score at baseline and follow-up points to 5 years (score range 
0–100; the higher the score, the better the patient felt).
FIGURE 13 Mean SF-36 norm-based vitality score at baseline and follow-up points to 5 years (score range 0–100; the 
higher the score, the better the patient felt).
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FIGURE 14 Mean SF-36 norm-based social functioning score at baseline and follow-up points to 5 years (score range 
0–100; the higher the score, the better the patient felt).
FIGURE 15 Mean SF-36 norm-based role emotional score at baseline and follow-up points to 5 years (score range 
0–100; the higher the score, the better the patient felt).
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FIGURE 16 SF-36 norm-based mental score at baseline and follow-up points to 5 years (score range 0–100; the higher 
the score, the better the patient felt).
FIGURE 17 EQ-5D at baseline and follow-up points to 5 years.
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in the randomised medical management group also reported regurgitation symptoms and burping/
belching than in the randomised surgical group. At both 3 and 5 years, the proportions who reported no 
difficulty swallowing and no wind from the lower bowel were similar between the randomised surgical 
and the randomised medical groups. There was also little difference between the groups at each time 
point in the proportion of participants who reported a feeling of wanting to be sick but being physically 
unable to do so.
Statistical analyses
Primary outcome
The pre-chosen primary outcome was the REFLUX QoL score after 5 years of follow-up. The differences 
between groups with corresponding 95% CIs are shown in Table 16. Two types of analysis are presented 
for the randomised participants – ITT and adjusted treatment received. Table 16 also displays the impact of 
including adjustment for baseline score and randomised group*baseline score interaction terms.
Intention to treat
For the ITT analysis there was a mean difference of 6.4 between the groups in favour of surgery when only 
the minimisation variables were adjusted for (95% CI 1.6 to 11.2; p = 0.009). A repeated measures analysis 
across the 5 years gave a difference of 8.1 (95% CI 4.4 to 11.7). This was not the most parsimonious 
model – there was strong evidence of an interaction effect between randomised group and baseline 
REFLUX QoL score (interaction term was –0.23, 95% CI –0.43 to –0.03; p = 0.023). This implied that as 
baseline REFLUX QoL score increased the treatment effect decreased. Estimating the treatment difference 
at the trial baseline mean REFLUX QoL score of 65.2 resulted in a trial effect size of 8.5 (95% CI 3.9 to 
13.1; p < 0.001). If the average patient had a lower mean REFLUX QoL score at baseline of 56.0, the 
effect size increased to 10.6 (95% CI 5.3 to 15.8). If the patient had a higher baseline score of 78.0, the 
treatment effect size decreased to 5.5 (95% CI 0.6 to 10.4). All results, however, showed strong evidence 
of increases in REFLUX QoL scores favouring surgery.
TABLE 14 Use of health services
Use of health service Year Randomised surgical Randomised medical
Overnight hospital admissions: reflux-
related (and all reasons), n
1 4 (8) 2 (8)
2 1 (8) 2 (10)
3 2 (6) 9 (10)
4 2 (2) 9 (10)
5 0 (1) 8 (11)
Day hospital admissions: reflux related 
(and all reasons), n
1 22 (40) 24 (53)
2 5 (23) 4 (24)
3 4 (4) 6 (10)
4 12 (13) 9 (11)
5 4 (7) 11 (14)
Visits to and from the GP: reflux related 
(and all reasons), n
1 110 (394) 103 (376)
2 34 (269) 115 (373)
3 38 (381) 99 (386)
4 55 (422) 126 (469)
5 36 (404) 119 (370)
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TABLE 15 Frequency of GORD symptoms at 3 and 5 years
GORD symptom
3 years 5 years
Randomised 
surgery
Randomised 
medical
Randomised 
surgery
Randomised 
medical
Frequency of heartburn, n (%)
None at all 77 (58.8) 46 (34.8) 65 (58.6) 28 (26.4)
One to three times per week 44 (33.6) 64 (48.5) 38 (34.2) 64 (60.4)
More than three times per week 10 (7.6) 22 (16.7) 8 (7.2) 14 (13.2)
Frequency of regurgitation, n (%)
None at all 102 (77.3) 83 (61.9) 89 (75.4) 71 (63.4)
One to three times per week 27 (20.5) 47 (35.1) 26 (22.0) 37 (33.0)
More than three times per week 3 (2.3) 4 (3.0) 3 (2.5) 4 (3.6)
Frequency of difficulty swallowing, n (%)
None at all 100 (75.8) 102 (76.1) 91 (77.1) 82 (74.5)
One to three times per week 30 (22.7) 27 (20.1) 25 (21.2) 25 (22.7)
More than three times per week 2 (1.5) 5 (3.7) 2 (1.7) 3 (2.7)
Frequency of wind from the bowel, n (%)
None at all 19 (14.4) 20 (15.0) 14 (11.9) 14 (12.7)
One to three times per week 37 (28.0) 35 (26.3) 27 (22.9) 30 (27.3)
More than three times per week 76 (57.6) 78 (58.6) 77 (65.3) 66 (60.0)
Frequency of burping/belching, n (%)
None at all 53 (40.2) 33 (24.8) 46 (39.3) 27 (24.5)
One to three times per week 39 (29.5) 48 (36.1) 40 (34.2) 37 (33.6)
More than three times per week 40 (30.3) 52 (39.1) 31 (26.5) 46 (41.8)
Frequency of wanting to be sick but being physically unable to, n (%)
None at all 116 (87.9) 110 (83.3) 101 (85.6) 92 (82.9)
One to three times per week 15 (11.4) 17 (12.9) 15 (12.7) 16 (14.4)
More than three times per week 1 (0.8) 5 (3.8) 2 (1.7) 3 (2.7)
TABLE 16 Primary outcome: REFLUX QoL scores after 5 years of follow-up
REFLUX QoL score
Randomised participants
ITT Adjusted treatment received
Mean 
differencea
95% CI p-value Mean 
differencea
95% CI p-value
Adjusted for minimisation variables 6.4 1.6 to 11.2 0.009 9.4 1.7 to 17.0 0.017
Adjusted for minimisation variables 
and baseline REFLUX QoL score
7.6 3.0 to 12.2 0.001 10.6 3.3 to 17.9 0.004
Adjusted for minimisation variables, 
baseline score and treatment*baseline 
REFLUX QoL score interaction
8.5 3.9 to 13.1 < 0.001 11.5 4.2 to 18.7 0.002
a Difference is surgery group minus medical group.
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Adjusted treatment received
The adjusted treatment received analyses attempted to mitigate the effect of non-compliance with the 
allocated treatment and hence provide an estimate of ‘efficacy’.40 As expected, this approach gave a larger 
difference, but with wider CIs (9.4, 95% CI 1.7 to 17.0; p = 0.017).
Preference groups
The preference for surgery participants reported considerably worse mean REFLUX QoL scores at baseline 
than the preference for medicine participants (55.8 vs 77.5) (see Table 7). Despite starting from a much 
lower baseline score, at follow-up, the REFLUX QoL score slightly favoured the surgical group using an 
ITT analysis (difference = 0.61; 95% CI –3.44 to 4.66; p = 0.767) and an adjusted treatment received 
analysis (difference = 0.10; 95% CI –4.77 to 4.97; p = 0.967). The differences were not, however, 
statistically significant.
Secondary outcomes
The secondary outcomes were the health status measures (EQ-5D, SF-36) and REFLUX symptom score 
at times equivalent to 3 months and then annual follow-up after surgery, and REFLUX QoL (at time 
points other than 5 years, when it was the primary end point). Analyses of these outcomes are shown in 
Tables 17–22.
REFLUX symptom score
There were statistically significantly higher REFLUX QoL scores at all time points, albeit with some 
diminution over time in the surgical group (see Figure 3). Although symptom category scores favoured 
surgery across all domains at all time points, the most marked and sustained difference was in 
‘general discomfort’.
Short Form questionnaire-36 items
The SF-36 scores in all domains also favoured the surgical group at all time points. Differences decreased 
over time and this was reflected in most p-values being < 0.05 up to 3 years, whereas at year 5 this applied 
to only ‘norm-based general health’ and ‘norm-based role emotional’.
European Quality of Life-5 Dimensions
Differences in EQ-5D had a similar pattern to differences in REFLUX QoL and SF-36 scores – differences 
all favoured the surgical group but tended to narrow such that scores at years 2 and 3 were statistically 
significantly different, but at later time points they were not. Variability tended to increase over time. 
Despite the general narrowing of the EQ-5D difference over time, at year 5 it was actually the same as that 
at 12 months after surgery but with wider CIs.
Adjusted treatment received
As would be expected, all (with a small number of exceptions) the adjusted treatment received analyses 
had larger differences than the corresponding ITT analyses (around 25–50% higher), but with wider CIs.
Subgroup analyses
Removal of data from the single largest clinical centre (Aberdeen)
No formal exploration of centre effects was undertaken because of the small numbers of participants 
recruited in many of the clinical centres. However, a sensitivity analysis removing the data from the 
Aberdeen centre, the centre where the largest number of participants were recruited, did not significantly 
change the conclusions (adjusted difference in REFLUX score at 60 months = 5.43, 95% CI 0.96 to 9.90).
Partial compared with total wrap procedure
In an observational analysis, there was no evidence of a difference between a total wrap procedure and 
a partial wrap procedure. The difference in the REFLUX QoL score between these procedures at time 
equivalent to 5 years post surgery was –1.0 (95% CI –5.4 to 3.7; p = 0.649).
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Discussion
Follow-up to 5 years after laparoscopic surgery described here provides clear evidence of sustained 
improvement in GORD symptoms, as judged by the REFLUX QoL scores. Differences between the groups 
as randomised did tend to diminish over the course of the study; nevertheless, the analyses at 5 years 
(the primary end point) showed highly statistically significant results with effect sizes of the order of 0.6 
of a SD.
This report concentrates on the data collected annually at a time equivalent to between 2 and 5 years 
post surgery. Data were collected through self-complete postal questionnaires, backed up by postal and 
telephone reminders and occasional completion of the questionnaire over the telephone. The response rate 
did drop over time, from 90% at 1 year to around 70% at 5 years. The principal reason for not obtaining a 
follow-up questionnaire was a loss of contact, such as following a home move; the second most common 
reason was a decision by a participant to decline further follow-up. The category of ‘non-responder’ 
accounted for only around 8% of those without a follow-up questionnaire. Response analysis showed 
that responders at 5-year follow-up had a higher mean age, had been prescribed anti-reflux medication 
for a shorter period of time at recruitment and had higher QoL at baseline. However, the characteristics of 
responders and non-responders at 5 years were similar across the two randomised groups.
Randomised trials, such as the REFLUX trial, that compare surgery with medical management are 
challenging to mount because of the stark contrast between the treatments compared. As described in 
the previous report of this study, recruitment was not easy and it is to the credit of the many staff in the 
21 centres involved in the trial that this was accomplished successfully. A second challenge was that, after 
randomisation, a sizable proportion of participants did not receive the treatment to which they had been 
allocated – again, reflecting the contrasts in the treatments. We explored the impact of this in a number 
of ways.
Figure 18 shows the results of a supplementary analysis of the group randomly allocated surgery stratified 
by whether or not they actually had surgery. It shows that those who had surgery started from a lower 
REFLUX QoL baseline score (had worse symptoms) than those who did not undergo surgery, and then had 
a sharp rise in score following the operation such that their scores were consistently higher than those 
who did not actually have fundoplication. To put this another way, the improvement seen among those 
who had surgery was greater than that in the randomised group overall.
Figure 19 shows a similar supplementary analysis of the group allocated medical management stratified 
by whether or not they in fact had surgery in the first year. This shows that those who had fundoplication 
(the lowest line) had more severe symptoms of GORD (low REFLUX QoL scores) at the time of trial entry, 
worse even than the preference surgical group. In contrast, those solely managed medically had relatively 
high baseline scores. Scores among those randomised to medical management who had surgery improved 
markedly over the course of the follow-up, such that by years 4 and 5 the scores in the two strata were 
similar. This indicates that much of the narrowing of the scores in the ITT groups over the 5 years can be 
explained by surgery in the randomised medical group.
We assessed more formally the extent to which surgery in the randomised medical management group 
might have affected the results by undertaking adjusted treatment received analyses. We decided to base 
these on treatment status at the first year follow-up point. We chose this partly to be consistent with our 
previous report of the results up to 1 year and partly because we considered that those who had surgery 
after that time point were likely to be highly selected. To put this another way, we were concerned that 
a PP analysis up to 5 years would be particularly prone to bias. The adjusted treatment received analyses, 
as expected, indicated larger effects of surgery – with differences in score around 25–50% higher. As 
illustrated by the preference groups in this study, the proportion of those recommended surgery and 
willing to have it who subsequently go on to have fundoplication is likely to be higher in everyday 
practice. Hence, we would argue that the results of the adjusted treatment received analyses are likely to 
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provide a better estimate of the benefits of a policy of laparoscopic fundoplication as would apply in the 
health service.
The principal concern about laparoscopic fundoplication is possible risks associated with the surgery. We 
described intra- and postoperative surgical outcomes in our previous report.1 Among the 329 patients 
in the randomised surgical and preference surgical groups who had fundoplication in the first year, 
100
90
80
70
60
R
EF
LU
X
 Q
o
L 
sc
o
re
Baseline 3 months Year 1 Year 2 Year 3 Year 4 Year 5
50
40
30
20
10
0
Allocation
Total randomised
to surgery
Randomised surgery
and got surgery
Randomised surgery,
but did not get
surgery
100
90
80
70
60
R
EF
LU
X
 Q
o
L 
sc
o
re
Baseline 3 months Year 1 Year 2 Year 3 Year 4 Year 5
50
40
30
20
10
0
Allocation
Randomised to
medicine and got
medicine
Total randomised to
medicine
Randomised
medicine, but got
surgery
FIGURE 18 Mean REFLUX QoL scores for (a) all randomised to surgery, (b) those randomised to surgery who had 
fundoplication and (c) those randomised to surgery who did not have surgery.
FIGURE 19 Mean REFLUX QoL scores for (a) all randomised to medical management, (b) those randomised to medical 
management who did not have surgery and (c) those randomised to medical management who had fundoplication.
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there were no major surgical complications. Two patients (0.6%; 95% CI 0.1% to 2.2%) required 
conversion to an open procedure; eight (2.4%; 95% CI 1.2% to 4.7%) had a visceral injury; and one 
(0.3%; 95% CI < 0.1% to 1.7%) had a blood transfusion. Three were admitted to a high-dependency 
unit, but none to an intensive care unit. The 5-year follow-up provides information about longer-term 
risks. We are aware of seven deaths among trial participants; however, none has an apparent link to the 
trial. Twelve (3.3%) of the total of 364 participants who had a fundoplication had a late complication: 
four were oesophageal dilatations/stricture dilatations, three had repairs of incisional hernias and five 
were a heterogeneous group of other complications (see Table 12). Sixteen (4.4%) of those who had 
fundoplication required further surgery (see Table 11): five reconstruction of the same wrap, six conversion 
to another type of wrap, three repair of hiatus hernia only and two reversal of fundoplication. These, albeit 
uncommon, complications need to be taken into account when surgery is being considered.
Proton pump inhibitor use in the randomised medical group was consistently around 80%, although these 
participants were not always the same people at each follow-up. In our questionnaire, we chose to ask 
about anti-reflux drug use over the preceding 2 weeks as we thought that a recollection over a longer 
period would be unreliable. Nevertheless, taking of PPIs seems to be dynamic (patients stopping and 
restarting) and rates of use at any time over a longer period would likely have been higher. We did observe 
more visits to GPs in the medical groups for reflux-related reasons during the 5 years of follow-up but are 
not able to say whether this was due to routine reassessments or because symptom control was less stable 
or inadequately controlled in the medical group.
The pattern of PPIs used did change over the course of the study. At baseline, the commonest PPI was 
lansoprazole, but omeprazole superseded this over the course of the trial. Much of this change occurred 
in the first year and hence could be a consequence of the review of medical management that was part of 
the trial management for those randomised to medical management.
The larger number of overnight hospital admissions in the randomised medical management group was 
largely, but not totally, explained by the minority who went on to have surgery; as discussed in Chapter 5 
describing the economic evaluation, this was the principal driver of extra resource use by the medical 
group during the longer-term follow-up.
Despite the methodological challenges alluded to above, the study, through the data presented here, 
has successfully addressed the first of the objectives of this longer-term follow-up: to assess whether or 
not short-term clinical benefits, principally in terms of symptom control, are sustained – they are, albeit 
attenuated. In the next chapter we consider the REFLUX trial in the context of the three other randomised 
trials that have been conducted worldwide comparing laparoscopic fundoplication with medical 
management, and assess whether or not the results of the REFLUX trial are consistent with those of the 
other trials.
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Chapter 4 Comparison of the REFLUX trial with 
other randomised trials of laparoscopic surgery 
compared with medical management for gastro-
oesophageal reflux disease
Introduction
The REFLUX trial is one of four randomised trials that have compared laparoscopic surgery with medical 
management of GORD. Although the REFLUX trial has similarities to the other trials, its design is the 
most pragmatic42 and this is reflected in significant differences in comparison with the other trials. 
The characteristics of the four trials are summarised in some detail in Appendix 5; key similarities and 
differences in characteristics between the REFLUX trial and the other trials will be highlighted here. This 
overview draws heavily on the relevant Cochrane review,43 two of whose authors are authors of this report, 
but incorporates reports published since the Cochrane review, identified primarily through an updated 
search using a similar strategy to the one described in the Cochrane review.
The three comparable trials
The Anvari et al. trial44–46 is a publicly funded single-centre trial conducted in Canada, led by upper 
gastrointestinal surgeons. It is the smallest of the four trials (104 randomised). The two intervention 
policies were standardised and the surgery was undertaken by only four surgeons (Table 23). Reflecting 
this, nearly all participants – unlike in the REFLUX trial – were managed in the way allocated. Like the 
REFLUX trial, its primary outcome was a GORD-related QoL instrument (the GERSS or Gastro-Esophageal 
Reflux Symptom Score), and HRQoL was measured with the same instruments as in REFLUX (SF-36 and 
EQ-5D). The first report described the trial up to 12 months after surgery,44 and recent papers have 
reported 3-year results45 and an economic evaluation.46 At 3 years, participants in the medical group were 
offered surgery and a large proportion (42%) accepted; hence, although further follow-up is reported to 
be ongoing, it will be of limited usefulness in comparing laparoscopic surgery with medical management.
The LOng-Term Usage of esomeprazole versus Surgery for treatment of chronic GERD (LOTUS) trial47–50 
is the largest of the four trials (554 randomised). The study was funded by a pharmaceutical company, 
AstraZeneca, and the reports all include authors based in the company. The trial involved 39 centres in 
11 European countries and was led by an upper gastrointestinal surgeon. The trial is described as ‘not 
designed as a superiority or equivalence trial but, rather, was an exploratory study to estimate the efficacy 
of laparoscopic anti-reflux surgery and PPI treatment in PPI responders’. Unlike in the REFLUX trial, all 
participants had shown response to PPI treatment in a run-in phase, and both clinical management 
policies were strictly standardised (see Table 23).
The method by which the total fundoplication approach was standardised has been described in detail.50 
In the medically managed group, the only PPI used was esomeprazole, initially at the standard dose 
of 20 mg. Both the surgical and medically treated patients were followed up by the investigators at 
6-monthly intervals and symptoms were assessed using the Gastrointestinal Symptoms Rating Scale (GSRS) 
questionnaire. In the medically treated group, esomeprazole could be increased to 40 mg once a day and 
then to 20 mg twice a day if symptom control was insufficient. Another key difference from the REFLUX 
trial was that the primary outcome measure was ‘treatment failure’. A single definition of treatment failure 
could not be used for both trial groups; rather, this was specifically defined for each group (including 
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in the medical group need for escalation of medication and in the surgical group, need for regular 
medication). The concern is that the thresholds for these may not reflect similar levels of GORD. A GORD-
specific QoL instrument (Quality of Life in Reflux and Dyspepsia or QOLRAD54) was among the secondary 
outcomes but was given relatively little emphasis in the reporting of the trial. No HRQoL instruments were 
used and there was no economic evaluation. Although the main analysis was said to be carried out on an 
ITT basis, it seems that the 40 people allocated surgery who did not receive it were excluded from analyses. 
Results were first reported after 3 years’ follow-up47 and recently 5-year data have been published.48
The Mahon et al. trial51–53 was a two-centre UK trial led by and involving two upper gastrointestinal 
surgeons. It is not clear how the main trial was funded but supplementary funds were provided by Jansen 
Pharmaceuticals ‘for physiological studies’ and by Ethicon Endo-Surgery for the economic analysis.52 In 
total, 217 people were randomised; the sequence was ‘computerised’ but the randomisation process and 
extent of concealment were not described. The two surgeons used a similar Nissen fundoplication method 
(see Table 23) and there was the option of four different PPI regimens depending on what PPI a participant 
had been taking prior to the trial. A range of outcome measures were reported and these included a 
gastrointestinal symptom score (GSRS) and a HRQoL measure [Psychological General Well-Being Index 
(PGWI)].55 All those allocated to medical management were offered surgery after 1 year (and apparently 
this was made clear to potential participants before trial entry) and the majority [54/94 (57%)] then had 
surgery. The 1-year follow-up was thus essentially the end of this randomised trial, even though a further 
follow-up has been reported.53
Gastro-oesophageal reflux disease-related quality-of-life and 
symptom scores
Data available for each of the trials that describe GORD QoL or symptom scores at 1, 3 and 5 years’ 
follow-up are summarised in Tables 24–26. Although it is not possible to combine data because different 
instruments (or subscales of instruments) were used in the trials, the results are consistent.
At 1 year there are eligible data from all four trials (see Table 24). In each case there are highly statistically 
significant differences all favouring the surgically managed groups. As mentioned above, the randomised 
element of the Mahon et al. trial51–53 ended at 1 year but data at 3 years are available for the other three 
trials (see Table 25). Again, all favour the surgical group and this was statistically significant in both the 
LOTUS47–50 and the REFLUX1–3 trials.
Only the LOTUS and (now) the REFLUX trial have reported 5-year follow-up. GORD-related QoL scores 
significantly favour the surgical groups in both trials (see Table 26).
TABLE 23 Surgical procedure/experience in the four trialsa
Trial Surgeon experience Crural repair Gastric division
No. of surgeons 
participating
Anvari44–46 > 50 procedures 
performed
Not reported Short vessels divided 4
LOTUS47–50 > 40 procedures 
performed and 
current workload ≥ 20 
per annum
Protocol specified 
posterior repair
Protocol specified 
division
40 trained
Mahon51–53 ‘Experienced’ Yes, all patients Short vessels divided 2
REFLUX1–3 > 50 procedures 
performed 
Surgeon discretion Surgeon discretion Not reported
a Adapted from Wileman et al.43
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TABLE 24 Gastro-oesophageal reflux disease-related QoL and symptom scores at 1 year
Trial
Surgical Medical
Mean difference 
(95% CI) p-valuen Mean (SD) n Mean (SD)
Anvari44–46
GERSS 52 8.3 (8.4) 52 13.6 (9.5) –5.3 (–8.7 to –2.0) 0.002
LOTUS47–50
QOLRAD
Vitality 203 6.84 (0.52) 220 6.42 (0.92) 0.42 (0.28 to 0.56) < 0.001
Food and drink 203 6.78 (0.60) 220 6.34 (0.98) 0.44 (0.28 to 0.60) < 0.001
Sleep 203 6.87 (0.49) 220 6.53 (0.76) 0.34 (0.22 to 0.46) < 0.001
Physical/social 203 6.93 (0.36) 220 6.72 (0.52) 0.21 (0.12 to 0.30) < 0.001
GSRS
REFLUX dimension 248 1.18 (0.44) 266 1.66 (0.88) –0.48 (–0.60 to –0.36) < 0.001
Mahon51–53
GSRS 80 37.0 (5.4) 86 35.0 (7.3) 2.00 (0.003 to 3.94) 0.003
REFLUX1–3
REFLUX QoL 178 84.6 (17.9) 179 73.4 (23.3) 14.0 (9.6 to 18.4) < 0.001
TABLE 25 Gastro-oesophageal reflux disease-related QoL and symptom scores at 3 years
Trial
Surgical Medical
Mean difference 
(95% CI) p-valuen Mean (SD) n Mean (SD)
Anvari44–46
GERSS 49 6.21 (8.66) 44 9.05 (10.40) –2.84 (–6.77 to 1.09) 0.166
LOTUS47–50
QOLRAD
Vitality 181 6.90 (0.31) 189 6.53 (0.85) 0.37 (0.24 to 0.50) < 0.001
Food and drink 181 6.85 (0.40) 189 6.38 (0.91) 0.47 (0.33 to 0.61) < 0.001
Sleep 181 6.92 (0.33) 189 6.53 (0.82) 0.39 (0.26 to 0.52) < 0.001
Physical/social 181 6.94 (0.25) 189 6.74 (0.58) 0.20 (0.11 to 0.29) < 0.001
Mahon51–53 – trial terminated at 1 year
REFLUX1–3
REFLUX QoL 132 87.0 (15.0) 134 79.7 (20.1) 9.0 (4.9 to 13.1) < 0.001
Health-related quality of life
No general HRQoL measure has been reported for the LOTUS trial.47–50 Data for the other three trials are 
shown in Tables 27–29. The SF-36 was used in the Anvari et al. trial44–46 as it was in the REFLUX trial.1–3 
Unfortunately, it is reported only as the two summary component scores, physical (PCS) and mental (MCS), 
plus the ‘general health’ domain score. For comparability, in Tables 27 and 28 the same score formats 
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TABLE 26 Gastro-oesophageal reflux disease-related QoL and symptom scores at 5 years
Trial
Surgical Medical
Difference (95% CI) p-valuen Mean (SD) n Mean (SD)
Anvari44–46 – no data available
LOTUS47–50
QOLRAD
Vitality 160 6.86 (0.44) 179 6.49 (0.99) 0.37 (0.20 to 0.54) < 0.001
Food and drink 160 6.80 (0.51) 179 6.47 (0.80) 0.33 (0.18 to 0.48) < 0.001
Sleep 160 6.89 (0.47) 179 6.61 (0.72) 0.28 (0.15 to 0.41) < 0.001
Physical/social 160 6.94 (0.23) 179 6.75 (0.51) 0.19 (0.10 to 0.28) < 0.001
Mahon51–53 – trial terminated at 1 year
REFLUX1–3
REFLUX QoL 127 86.7 (13.8) 119 80.7 (20.3) 6.42 (1.61 to 11.23) 0.009
are shown for the REFLUX trial but it should be borne in mind that the eight domain scores shown in 
Chapter 3 for the REFLUX trial are more informative.
At 1 year, in both trials, the PCS and MCS favour the surgical group, although only the difference in the 
PCS in the REFLUX trial1–3 is statistically significant. Both trials showed marked differences in the ‘general 
health’ domain score. There was also a statistically significant difference favouring surgery in the Mahon et 
al. trial51–53 (based on the PGWI).
Although EQ-5D data were collected in the Anvari et al. trial,44–46 they were not reported in a way that 
allows interpretation. At baseline, scores were markedly lower in the surgery group [mean 0.68 (SD 0.28) 
vs 0.76 (SD 0.21)] and the reason for this imbalance is not clear. At 1 year the equivalent results were 0.79 
(SD 0.23) compared with 0.81 (SD 0.19), that is, still lower in the surgery group. As shown in Table 27, in 
the REFLUX trial,1–3 the mean 1-year EQ-5D score was higher in the surgery group (p = 0.07).
At 3 years, the report of the Anvari et al. trial mentions collection of the SF-36 ‘every 3 months’ but the 
only data reported are for the ‘general health’ domain score. This, as in the REFLUX trial, significantly 
favours the surgical group (see Table 28). There is no mention of collection of EQ-5D data in the 3-year 
follow-up of the Anvari et al. trial. At 5 years, the only data describing generic HRQoL are from the REFLUX 
trial (as the LOTUS trial has not included a measure) (see Table 29).
Individual symptoms of gastro-oesophageal reflux disease or 
its management
Data describing individual symptoms are available for all trials, although only dysphagia was reported in 
the Mahon et al. trial.51–53
Heartburn
As would be expected from the overall GORD-related QoL and symptom scores, all three trials providing 
data reported less heartburn in their surgical groups. At 1 year in the Anvari et al. trial,44–46 the GERSS 
heartburn subscore is lower in the surgical group (p <0.001); in the LOTUS trial47–50 there is clearly 
less heartburn in the surgical group but data are presented only graphically; and in the REFLUX trial1–3 
heartburn rates in the surgical group are around half those in the medical group. At 3 years, Anvari 
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TABLE 27 Health-related quality of life at 1 year
Trial
Surgery Medical
Difference  
(95% CI) p-valuen Mean (SD) n Mean (SD)
Anvari44–46
SF-36
PCS 52 46.4 (10.9) 52 43.9 (10.3) 3.15 (–0.94 to 7.23) 0.13
MCS 52 52.7 (10.9) 52 51.5 (9.1) 0.98 (–2.8 to 4.76) 0.61
General health 
domain score
52 75.4 (23.2) 52 66.4 (23.6) 12.3 (3.7 to 20.8) 0.005
LOTUS47–50 – not reported
Mahon51–53
PGWB 79 106.2 (16.3) 86 100.4 (18.9) 5.8 (0.43 to 11.17), 
adjusted 7.1 (2.5 to 11.7)
REFLUX1–3
SF-36
PCS 150 48.0 (10.2) 161 45.1 (9.7) 3.51 (1.77 to 5.25) < 0.001
MCS 150 46.6 (12.8) 161 45.1 (13.1) 1.63 (–0.79 to 3.85) 0.195
General health 
domain score
178 45.2 (11.1) 179 40.7 (11.2) 4.8 (2.7 to 6.8) < 0.001
EQ-5D 178 0.75 (0.25) 179 0.71 (0.27) 0.047 (–0.004 to 0.097) 0.07
TABLE 28 Health-related quality of life at 3 years
Trial
Surgery Medical
Difference  
(95% CI) p-valuen Mean (SD) n Mean (SD)
Anvari44–46
SF-36
PCS – not reported
MCS – not reported
General health 
domain score
49 78.50 (19.76) 44 71.41 (21.73) 12.19a (2.65 to 21.72) 0.0124
LOTUS47–50 – not reported
Mahon51–53 – trial terminated at 1 year
REFLUX1–3
SF-36
PCS 128 47.2 (9.9) 127 46.6 (10.0) 1.43 (–0.45 to 3.32) 0.136
MCS 128 48.9 (10.6) 127 45.6 (12.6) 4.05 (1.57 to 6.52) 0.001
General health score 132 45.3 (10.0) 134 42.4 (11.8) 3.69 (1.50 to 5.87) 0.001
EQ-5D 132 0.803 (0.231) 134 0.747 (0.262) 0.070 (0.0015 to 0.126) 0.013
a Presumably adjusted.
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TABLE 29 Health-related quality of life at 5 years
Trial
Surgery Medical
Difference (95% CI) p-valuen Mean (SD) n Mean (SD)
Anvari44–46 – no data available
LOTUS47–50 – not reported
Mahon51–53 – trial terminated at 1 year
REFLUX1–3
SF-36
PCS 113 46.1 (9.9) 109 46.1 (10.5) 1.47 (–0.84 to 3.79) 0.211
MCS 113 47.8 (11.7) 109 47.9 (11.7) 1.27 (–1.36 to 3.90) 0.343
General health 
domain score
117 44.1 (10.3) 111 43.2 (11.5) 2.76 (0.21 to 5.31) 0.034
EQ-5D 127 0.774 (0.259) 119 0.761 (0.282) 0.047 (–0.013 to 0.108) 0.126
et al.44–46 report significantly more heartburn-free days in the surgical group (p = 0.008); in the LOTUS 
trial,47–50 less heartburn in the surgical group is shown graphically and the p-value is reported as < 0.001; 
and in the REFLUX trial1–3 51% of the randomised surgical group compared with 75% of the randomised 
medical management group report any heartburn (see Table 15). At 5 years, data are available only from 
the LOTUS and REFLUX trials. In LOTUS,47–50 8% in the surgery group compared with 16% in the medical 
group are reported to have heartburn, ‘although there was no significant difference in the severity of 
heartburn (p = 0.14)’. In the REFLUX trial,1–3 41% in the surgery group compared with 74% in the medical 
group reported any heartburn (see Table 15).
Regurgitation
Again, as would be expected from the overall GORD-related QoL and symptom scores, all three trials 
providing data reported less regurgitation in the surgical groups. At 1 year in the Anvari et al.44–46 trial, the 
GERSS regurgitation subscore is significantly lower in the surgical group (p = 0.002); in the LOTUS trial,47–50 
graphical presentation clearly indicates less regurgitation in the surgical group, although no figures are 
reported; and in the REFLUX trial,1–3 regurgitation rates in the surgical group are half those in the medical 
group. At 3 years, information is available only for the LOTUS and REFLUX trials and both report lower 
rates in the surgical groups. At 5 years in the LOTUS trial, 2% in the surgical group compared with 13%  
in the medical group (p < 0.001) have regurgitation, and in the REFLUX trial 25% in the surgical group 
compared with 37% in the medical group report any regurgitation.
Dysphagia
As mentioned in Chapter 1, dysphagia following both open fundoplication and laparoscopic 
fundoplication has been reported. At 1 year, Anvari et al.44–46 report a higher GERSS dysphagia subscore 
in the surgical group but this was not statistically significant (p = 0.8); in the LOTUS trial47–50 there were 
more reports of dysphagia in the surgical group but data were presented only graphically; in the Mahon 
et al. trial,51–53 dysphagia persisting beyond 3 months was reported in 5 out of 104 (4.8%) having surgery; 
and in the REFLUX trial,1–3 rates of ‘difficulty swallowing’ were the same in the two randomised groups. At 
3 and 5 years, information is available only from the LOTUS and REFLUX trials. In the LOTUS trial there is 
more dysphagia in the surgical group (p < 0.001) at both time points: at 5 years 11% in the surgical group 
report dysphagia compared with 5% in the medical group. In the REFLUX trial, one further participant had 
undergone oesophageal dilatation (see Table 12), but the numbers reporting difficulty swallowing were 
the same in the two randomised groups (see Table 15, e.g. any difficulty swallowing 24.2% vs 23.9%).
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Grant et al. under the terms of a commissioning contract issued by the Secretary of State for Health. 
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided 
that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed 
to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, 
Southampton SO16 7NS, UK.
DOI: 10.3310/hta17220 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 22
55
Flatulence
Flatulence has also been reported as more common after both open and laparoscopic fundoplication. 
Information is available only from the LOTUS47–50 and REFLUX1–3 trials. In the LOTUS trial, flatulence was 
more common in the surgery group than in the medical management group at 1, 3 and 5 years. At 
5 years, the rates are 57% in the surgical group and 40% in the medical group (p < 0.001). In the REFLUX 
trial, rates of ‘wind from the lower bowel’ are not statistically significantly different between the groups 
[more than three times per week: 65.0% in the randomised surgical group vs 59.4% in the randomised 
medical group at 1 year; 57.6% vs 58.5% at 3 years; and 65.3% vs 60.0% at 5 years (see Table 15 for 
more detail)].
Other symptoms
In the LOTUS trial,47–50 ‘bloating’ was reported more commonly in the surgical group (40% vs 28% at 
5 years). In contrast, ‘bloating/trapped wind’ was reported less commonly in the surgical group in the 
REFLUX trial1–3 (at 1 year: 72.1% vs 82.4%). A particular concern following fundoplication is an inability 
to vomit despite wanting to. In the REFLUX trial we attempted to address this through a question on 
‘frequency of wanting to be sick but being physically unable to’ and found no difference between the 
groups (see Table 15).
Surgical complications
Like all procedures involving surgery under general anaesthesia, laparoscopic fundoplication carries risks. 
Table 30 summarises intra and early postoperative complications reported in the four trials.
Conversion to an open procedure
The decision to convert from a laparoscopic to an open approach is usually indicative of difficulties 
experienced during the procedure. Rates varied from 0% in the Anvari et al. trial44–46 to 2.4% in the LOTUS 
trial47–50 (see Table 30).
Intraoperative complications
In the Mahon et al.51–53 and REFLUX1–3 trials combined, the 10 intraoperative complications reported 
(overall rate 2.3%) were injuries to the spleen (n = 3), liver (n = 3), pleura (n = 3) and oesophagus (n = 1). 
In the LOTUS trial47–50 it was unclear whether intraoperative complications occurred or whether they 
were incorporated within all postoperative complications; however, the report noted that 29 participants 
encountered a variety of operative difficulties that were described as ‘trivial’.
TABLE 30 Intra- and early postoperative events in the four trialsa
Trial n having operation Conversion, n (%) 
Intraoperative 
complications,  
n (%) 
Postoperative 
complications,  
n (%) 
Anvari44–46 51 0 (0.0) 0 (0.0) 7 (13.7)
LOTUS47–50 248 6 (2.4) Unclear 7 (2.8)
Mahon51–53 109 1 (0.9) 4 (3.7) 6 (5.5)
REFLUX1–3
Randomised 111 2 (1.8) 2 (1.8) 1 (0.9)
Preference 218 0 (0.0) 4 (1.8) 2 (0.9)
a Adapted from Wileman et al.43
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Early postoperative complications
In the Anvari et al. trial,44–46 seven (14%) participants had postprandial bloating, two of whom were 
treated with a single dilatation of the wrap. No details are given of the postoperative complications in the 
LOTUS trial. In the Mahon et al. trial51–53 there were three wrap migrations, two respiratory tract infections 
and one case of a sutured nasogastric tube. In the REFLUX trial,1–3 one participant in the randomised 
group and two in the preference group were admitted to a high-dependency unit immediately after the 
surgical procedure.
Reoperations
By the time of the 3-year follow-up in the Anvari et al. trial,44–46 4 of 51 (7.8%) participants had undergone 
a second fundoplication operation. Four (3.7%) in the Mahon et al. trial51–53 required reoperation within 
3 months of their first fundoplication, one of whom had a gastric resection because of necrosis. It is not 
clear if anyone in the LOTUS trial47–50 had a reoperation. As shown in Table 11, in the REFLUX trial,1–3 
5 of the 112 (4.5%) randomised to surgery who actually had a fundoplication had a second reflux-
related operation, and this applied to 16 (4.4%) of the total 364 participants in the study who had a 
laparoscopic fundoplication.
Other late postoperative complications
Dilatation of the wrap was reported for two (3.9%) people in the Anvari et al. trial44–46 and four (3.7%) 
in the Mahon et al. trial.51–53 It is not stated whether or not dilatation occurred in the LOTUS trial.47–50 In 
the REFLUX trial,1–3 two (1.8%) participants in the randomised surgical group (plus two in the preference 
surgical group – giving an overall rate of 1.1%) had stricture dilatation or food disimpaction (see Table 12). 
There were three cases (0.8%) of repair of incisional hernia in the REFLUX trial – all in the preference group 
– but this complication was not mentioned in the other trials’ reports. There were no deaths in any of the 
trials associated with surgical or medical management.
Surgery-related mortality
No perioperative deaths were reported among the 771 people in the four trials who had 
fundoplication surgery.
Discussion
Of the four trials, the REFLUX trial is the most pragmatic in design. It involved a large proportion of UK 
centres where laparoscopic anti-reflux surgery is undertaken and the surgery was undertaken by NHS 
upper gastrointestinal surgeons within these centres, all of whom had experience of carrying out the 
procedure. The exact method of fundoplication was left to the discretion of the surgeon, so he or she was 
comfortable with the approach. After surgery and, in the medically treated patients, after optimisation 
of their PPI medication, care of the participants was the responsibility of GPs. The principal measure of 
outcome was a patient-reported disease-specific QoL measure. Unlike the other trials, the REFLUX trial was 
coordinated from an accredited trials unit, local recruitment was led by gastroenterologist/gastrointestinal 
surgeon partnerships rather than by gastrointestinal surgeons alone, and the trial was publicly funded 
through the HTA programme rather than by industry.
In respect of potential benefits of surgery, the four trials appear to be consistent. All show significantly 
better relief of GORD symptoms for as long as the length of their current follow-up. (Surprisingly, 
the LOTUS trial report48 does not draw attention to this but, judged on data describing the QOLRAD 
reported in an e-table, there are significant differences between the groups in all dimensions of this 
instrument, favouring surgery.) Data available describing the principal symptoms of GORD (heartburn and 
regurgitation) show large differences, again favouring surgery. Only limited data are available from generic 
QoL measures, and much of this is from the REFLUX trial; although differences are less marked than for the 
GORD-related QoL instruments, they are consistent with benefit from surgery.
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The four trials are broadly consistent in respect of intraoperative and early postoperative complications: 
a small number of operations are converted to an open procedure, a small number of laparoscopic 
procedures have associated visceral injuries, a small number of people have problems postoperatively and 
a small number require dilatation of the wrap. The REFLUX trial suggests that 4.5% have reoperations and 
the other trials are broadly consistent with this. None of the trials had a reported perioperative death. Data 
from the Finnish Registry56 suggest a mortality of 0.1%, but this is based on a single case among 1162 
people who had laparoscopic fundoplication; furthermore, the registry included all cases of fundoplication 
and hence went beyond the sorts of patients recruited to the REFLUX trial.
The other trials, particularly the LOTUS trial, show higher rates of dysphagia and flatulence following 
laparoscopic fundoplication than in the medically managed group. As mentioned above, a small number 
of participants in the REFLUX trial did have a dilatation procedure, presumably because of difficulty 
swallowing, but this was not reflected in responses to the REFLUX questionnaire, suggesting that there 
were only a few isolated cases of dysphagia following surgery in this trial. Similarly, there were no 
significant differences in flatulence in the REFLUX trial.
Hence, taking all four trials together, it is now possible to give a clear picture of most of the potential 
benefits and risks of laparoscopic fundoplication, at least up to 5 years. There are, however, differing 
resource implications of surgery and medical management. In the next chapter we explore whether or not 
the benefits of surgery in patients with established GORD requiring long-term PPI therapy for reasonable 
control and suitable for either clinical policy (average age around 45 years) are sufficient to outweigh any 
differences in costs.
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Chapter 5 Economic analysis
The economic evaluation aimed to determine the cost-effectiveness of laparoscopic fundoplication compared with continued medical management in patients with GORD symptoms that are reasonably 
controlled by medication and who are judged suitable for both surgical and medical management. The 
analysis entailed three components:
1. systematic review of existing cost-effectiveness evidence
2. within-trial (5-year) economic analysis
3. validation of within-trial analysis and exploration of the need for a longer-term model.
Systematic review of existing cost-effectiveness evidence
The aim of this systematic review is to identify any existing cost-effectiveness studies that compare 
laparoscopic fundoplication with medical management for GORD. A previous HTA report included a review 
of the evidence available from 1995 to December 2005 and identified three relevant studies (described 
below).1 The updated search focuses on the period from December 2005 to April 2011. The methods used 
to identify studies and the results of the systematic search are discussed in the sections below.
Methods
The following data sets were searched to identify published evidence: MEDLINE and MEDLINE In-Process 
& Other Non-Indexed Citations (1948 to present), EMBASE (1996 to week 15, 2011), Cochrane Database 
of Systematic Reviews (CDSR) and the NHS Centre for Reviews and Dissemination databases [Database of 
Abstracts of Reviews of Effects (DARE), NHS Economic Evaluation Database (NHS EED), HTA]. The search 
strategy incorporated broad reflux-related search terms as used in a recent Cochrane Review.57 The search 
also focused on identifying health-related and GORD-specific QoL evidence.
Studies were considered relevant for inclusion in the review if they were published in English and were 
full health economic evaluations (cost-effectiveness, cost-utility or cost–benefit analysis) comparing costs 
and outcomes associated with laparoscopic fundoplication and medical management. For the purpose of 
this study laparoscopic fundoplication includes both complete and partial wrap procedures. Publications 
outside the above criteria were excluded from this review. Details of the updated search strategy are 
presented in Appendix 6.
Results
A total of 3662 references were identified from the searches (MEDLINE: 1640, EMBASE: 1825, CDSR: 
44, DARE: 56, NHS EED: 85, HTA: 12). Titles and/or abstracts were reviewed and studies that satisfied 
all inclusion criteria were included in the review. Papers describing five additional studies were obtained 
for inclusion. These were published between 2007 and 2011 and were related to the UK and Canadian 
settings. Of the total of eight studies, five are linked to three of the randomised trials described in 
Chapter 4: Anvari et al.,44–46 Mahon et al.51–53 and the REFLUX trial,1 the long-term follow-up of which is 
the topic of this report. There is no economic evaluation in the LOTUS trial.48 Three of the studies were 
based on the REFLUX trial. These were published as part of the earlier HTA report1 and in two journal 
articles.3,5 Summaries of the two within-trial economic evaluations are presented in Appendix 7. Below is 
a brief description of the eight reports – the five linked to the three randomised trials are considered first, 
followed by the three studies based on observational data.
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Economic analyses based on clinical trials
Economic evaluation based on the Anvari et al. trial46
This was an economic evaluation conducted alongside the Anvari et al. trial described in Chapter 4. 
Laparoscopic fundoplication was compared with PPI for patients with chronic GORD. The follow-up period 
was 3 years and the analysis was conducted from a societal perspective. Cost-effectiveness was reported in 
terms of cost per QALY gained.
Three generic preference-based questionnaires were administered during the trial: Health Utilities Index 
Mark 3 (HUI3), EQ-5D and Short Form questionnaire-6 dimensions (SF-6D). Although these instruments 
have been valued by large general public samples, they differ in the attributes used for their descriptive 
system and the method of valuation applied. The EQ-5D has been valued using time trade-off whereas 
the SF-6D and HUI3 use the standard gamble. Utility scores showed an improvement in patients’ HRQoL 
in both groups across the three utility instruments; however, the degree of improvement varied according 
to the utility instrument used. The base-case analysis (using the HUI3 instrument), after adjustment for 
baseline differences, indicated that, over the 3 years, laparoscopic fundoplication patients experienced a 
0.109 gain in QALYs compared with PPI patients. The ICER for laparoscopic fundoplication patients was 
around C$29,400 (£19,000) per QALY gained. An increased ICER of C$76,300 (£49,300) was obtained 
using the EQ-5D as the HRQoL measure.
Economic evaluation based on the Mahon et al. trial52
This study looked at the cost-effectiveness of laparoscopic fundoplication compared with maintenance PPI 
medication for severe GORD based on the Mahon et al. randomised trial described in Chapter 4. Results 
based on the 12-month follow-up were extrapolated using other published data sets. Costs and outcomes 
for up to 12 months were obtained from a sample of patients in the trial (the first 100) and resource use 
was quantified using data from hospital records and GPs’ notes. The incremental cost of laparoscopic 
fundoplication compared with PPI therapy per additional patient returned to a physiologically normal acid 
score (< 13.9) at 3 months was £5515 (95% CI £3655 to £13,400) and the incremental cost per point 
improvement in combined gastrointestinal and psychological well-being score at 12 months was £293 
(90% CI £149 to £5250). The authors concluded that laparoscopic surgery would break even compared 
with medical management after 8 years and would be cost saving thereafter.
Economic evaluation based on the REFLUX trial1,3,5
Bojke et al.5 present a preliminary cost-effectiveness analysis conducted before the availability of the 1-year 
REFLUX trial results. The analysis compared the cost-effectiveness of surgery (laparoscopic fundoplication) 
with long-term medical management (PPIs) for GORD disease in an average 45-year-old man. A lifetime 
(30 years) Markov model that adopted the perspective of the NHS was developed. Effectiveness data 
were obtained from a fixed-effect meta-analysis that synthesised data from multiple sources. QALYs were 
estimated using utility scores (measured by the EQ-5D instrument) derived from a subset of UK patients 
included in the REFLUX trial. Over a lifetime, expected costs associated with surgery (£5014) were higher 
than expected costs associated with PPI (£4890). Expected QALYs associated with surgery (13.04) were 
greater than QALYs associated with PPIs (12.36). The incremental cost per QALY gained (ICER) for surgery 
compared with medical care was £180. The estimated probability that surgery was cost-effective at the 
threshold of £30,000 per QALY was 0.639. The authors highlighted important areas for further research, 
such as the HRQoL of patients on PPIs or post surgery.
The within-trial cost-effectiveness analysis, comparing laparoscopic fundoplication with medical 
management 1 year post surgery, was described in full in the 2008 report of the REFLUX trial.1 The analysis 
was conducted on an ITT basis from a NHS perspective. HRQoL was assessed at baseline and at 3 and 
12 months’ follow-up using the EQ-5D. Cost-effectiveness was reported in terms of the difference in mean 
QALYs between the treatment groups. This difference was estimated using ordinary least squares (OLS) 
regression, adjusting for baseline differences in EQ-5D between individuals. The estimated difference in 
mean costs between the groups was £1280 (95% CI £1054 to £1468). The HRQoL of patients randomised 
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to surgery tended to improve on average by 0.066 more QALYs (95% CI 0.023 to 0.107) than in the 
medical management group. The estimated mean ICER was around £19,000. At a threshold of £30,000 
per QALY, the probability of surgery being cost-effective was 0.86.
Epstein et al.3 developed a Markov model using 12-month data from the REFLUX trial and other sources 
in order to extrapolate the cost-effectiveness of laparoscopic fundoplication compared with medical 
management over the longer term (lifetime). Cost-effectiveness was reported in terms of the cost per QALY 
gained from surgery. The analysis was conducted from a NHS perspective. Under base-case assumptions, 
surgery had an additional mean cost of £847 and additional mean QALYs of 0.37 over the lifetime of the 
patients. The incremental cost per additional QALY gained was around £3000. At a threshold of £20,000 
per QALY, the probability that surgery was cost-effective was around 0.74.
Economic analyses based on observational data
Economic evaluation based on Romagnuolo et al.58
This study is based on observational data and compares the cost-effectiveness of maintenance regimens 
of omeprazole and laparoscopic fundoplication within the Canadian medical system. The effectiveness, 
HRQoL and resource-use data were derived from studies published between 1985 and 2000. Outcomes 
were expressed as QALYs and costs were estimated from the perspective of a provincial health ministry. A 
two-stage Markov model (healing and maintenance phases) was used to estimate costs and utilities using 
a time horizon of 5 years. Laparoscopic fundoplication was the most cost-effective option at 3.3 years of 
follow-up and was cost saving at 5 years. These results were sensitive to the price of omeprazole. QALYs 
did not differ significantly between treatment groups.
Economic evaluation based on Arguedas et al.59
This study, also based on observational data, compared the cost-effectiveness of laparoscopic 
fundoplication and medical management in patients with severe reflux oesophagitis. Outcomes were 
quantified using QALYs with model inputs derived from the published literature. A Markov simulation 
model was used to extend a previous analysis to a 10-year time horizon. Procedure and hospitalisation 
costs were estimated using Medicare reimbursement rates from the authors’ institution. Medical therapy 
was associated with a total cost of $8798 and 4.59 QALYs, whereas the surgery was more expensive 
($10,475) and less effective (4.55 QALYs). The authors concluded that medical therapy dominated surgery.
Economic evaluation based on Comay et al.60
This is a cost-effectiveness analysis, based on observational data, principally concerned with assessing 
an endoscopic therapy (Stretta procedure) compared with PPIs and laparoscopic fundoplication in the 
management of GORD. The Strettra procedure is out of the scope of our analysis; however, the data on 
costs and QALYs provided by the authors allow us to better understand QoL related to these technologies 
and make comparisons with other authors’ estimates. The authors constructed a Markov model that 
tracked patients over a period of 5 years. Analysis was undertaken from the Canadian Ministry of Health 
perspective. A literature review for published studies before 2004 was carried out to derive effectiveness 
and utility data. Symptom-free months and QALYs were used to measure benefit. PPI was the dominant 
strategy, producing more symptom-free months at lower costs than the other strategies. Laparoscopic 
fundoplication was associated with higher costs and generated more QALYs. The discounted mean QALYs 
over 5 years were 4.6487 for laparoscopic fundoplication and 4.6357 for PPI. The ICER for laparoscopic 
fundoplication compared with PPI was C$384,692 (£240,470). This is unlikely to be considered 
cost-effective.
Conclusions
The different outcomes used make it difficult to compare the results of the various studies analysed here. 
For those studies quantifying the benefits associated with the two treatments using QALYs, the results 
differ depending on the type of analysis conducted. Although the trial-based results suggest that there 
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is good short- and medium-term evidence indicating that surgery may well represent a cost-effective 
alternative intervention, the model-based studies are not so optimistic.
The ICER for surgery ranged from £180 to £49,000 per QALY gained. However, the limitations of the 
studies included in this review suggest that we should be cautious when interpreting these results. The 
decision model developed as part of the REFLUX trial extrapolated from data at 12 months and was 
based on the assumption that the treatment effect of surgery (in terms of impact on HRQoL) remains 
constant over the lifetime of patients. However, as would be expected, the results of the sensitivity analysis 
suggested that surgery was less cost-effective when the beneficial effect of surgery was limited to 5 years 
(increasing the ICER to £11,300) and when HRQoL was worse in those for whom surgery failed (increasing 
the ICER to £11,310 when considering very high rates of surgical failure).
The value of conducting additional research to reduce any uncertainty in the REFLUX model was 
demonstrated. The expected value of perfect information (EVPI) is the maximum amount that a decision-
maker should be willing to pay to eliminate all uncertainty that arises because of imprecision in the 
parameters of the model. The value of information analysis suggested that further research could be 
worthwhile. At a threshold of £30,000, the per-patient EVPI was £15,106.
Within-trial economic evaluation
Follow-up data from the REFLUX trial up to 5 years after surgery are now available. These economic data 
represent the longest follow-up of randomised patients currently available. These data can help to inform 
the question regarding the sustainability of initial improvement in HRQoL following surgery. This section 
describes the updating of the cost-effectiveness analysis using these data to reduce the level of uncertainty 
about the cost-effectiveness of surgery and thus its role in the NHS.
Overview
Differences in mean costs and QALYs at 5 years (based on data collected within the REFLUX trial) were 
used to derive an estimate of the cost-effectiveness of laparoscopic surgery (laparoscopic fundoplication) 
and continued medical management. The extent of missing data throughout the trial follow-up is 
significant; therefore, the base case consists of the multiple imputed data set following ITT analysis. A 
separate scenario – complete-case analysis, in which patients with any missing data are excluded – was 
employed for ITT and PP for 1-year analyses. Costs and QALYs were evaluated on the basis of costs falling 
on the NHS and Personal Social Services expressed in UK pounds sterling at a 2010 price base. All analysis 
and modelling were undertaken in Stata/SE 11.1 (StataCorp LP, College Station, TX, USA).
Methods
Patient population
As described in earlier chapters, the patient population in the REFLUX trial was patients with GORD 
whose symptoms required medication for reasonable control and for whom either surgery or continued 
medical management appeared to be an acceptable treatment option. A policy of offering relatively early 
laparoscopic fundoplication was compared with the alternative policy of continued medical management. 
The analysis used data only from the randomised trial component of the REFLUX trial (i.e. not from the 
preference groups). As described in Chapter 3, 357 patients were randomised to either surgical treatment 
(n = 178) or medical management (n = 179) and patients were followed for up to 5 years.
Health-care resource use
Health-care resource-use data were collected prospectively as part of the clinical report forms and patient 
questionnaires at 3 and 12 months and 2, 3, 4 and 5 years. Patient questionnaires at 3 and 12 months 
collected information for the previous 3 and 9 months respectively. In addition, a questionnaire at 
12 months recorded resource use for the whole of the first year (see following section on costs). Patient 
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questionnaires from the second year onwards collected information for the previous 12 months on 
hospital admissions (day and overnight admissions) and GP visits, and data on medication for the previous 
2 weeks. Clinical report forms collected data on surgery and perioperative complications of surgery.
Costs
The cost for each individual patient in the trial was calculated by multiplying his or her use of health-care 
resources by the associated unit costs (Table 31). Discount was applied from year 2. Unit costs were all 
sourced from published data (see Table 31). Total costs include the costs of surgery, GP visits, hospital 
admissions and medication. Incremental costs (laparoscopic fundoplication vs medical management) 
for each year and per category of resource use, according to ITT allocation, were calculated using 
OLS regression.
The questionnaires asked for details of anti-reflux medication taken in the previous 2 weeks: name, dose 
and number of tablets/capsules. The cost of anti-reflux medication during these 2 weeks was calculated by 
multiplying the prices published in the Drug Tariff for December 201061 for each medicine by the number 
of tablets taken. Yearly medication costs are calculated using the area under the curve method,62 which 
assumes linear interpolation between follow-up points. The costs of reflux-related inpatient, outpatient 
and day-case visits were derived from the NHS Reference Costs 2009–10,63 in which the relevant codes 
were weighted by activity level.
For the base-case analysis, total costs included the costs of surgery, complications due to surgery, 
reoperations, reflux-related prescribed medication, reflux-related visits to and from the GP and reflux-
related hospital inpatient, outpatient and day visits. For the sensitivity analysis, all GP visits and all hospital 
admissions are included in the calculation of total costs (see Incremental analysis for more details on 
sensitivity analysis). Costs of hospital admissions and GP visits were obtained by multiplying the relevant 
unit costs by the numbers of admissions and visits reported by the patients respectively. Patients themselves 
classified how many visits and admissions were reflux related in relation to the total number of visits. There 
is a possibility that patients may not have fully understood the clinical consequences of GORD; hence, they 
may misclassify the reason for a consultation. If such misclassification is different across treatment groups, 
estimates of incremental costs may be biased.
For the first year of the trial, data on resource use were collected at 3 months and 12 months, and for 
the whole year using an additional questionnaire. To make the most efficient use of the data available for 
the first year of the trial, resource use at 1 year was estimated as the greater of the area under the curve 
between the first and second questionnaire and the 12-month health-care survey. This is in line with the 
procedure employed for the earlier publication evaluating the REFLUX trial.1
The cost of surgery included the costs of (1) presurgical procedures (endoscopy, pH monitoring and 
manometry), (2) the surgery team, (3) operative complications, (4) hospital stay, (5) capital costs and 
overheads and (6) consumables. The cost of reoperations was assumed to be equivalent to the mean cost 
of the first surgery. The cost of reflux-related visits to and from the GP was assumed to be equivalent to 
the average cost of visits to and from the GP.64
Quality-adjusted life-years
Health outcomes were expressed in terms of QALYs. HRQoL was assessed in the REFLUX trial at baseline 
and 3 months and then yearly until 5 years using the EQ-5D.65,66 The EQ-5D is a standardised and validated 
generic instrument for the measurement of HRQoL. It has five dimensions: mobility, ability to self-care, 
ability to undertake usual activities, pain and discomfort, and anxiety and depression. Each dimension has 
three possible responses (no problems, moderate problems or severe problems), creating 245 mutually 
exclusive health states. Each of these health states has been valued in a large UK population study using 
the time trade-off method, in which 1 corresponds to perfect health (thus the maximum value possible) 
and 0 corresponds to death.65,66
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QALYs for each patient were calculated as the area under the curve following the trapezium rule,67 which 
assumes linear interpolation between follow-up points. Incremental mean QALYs between treatment 
groups were estimated with and without adjustment for baseline utility, using OLS regression.
Discounting
Costs and outcomes from year 2 were discounted using a 3.5% annual discount rate, in line with current 
guidelines.65,68
Missing data and multiple imputation
Given the extent of missing data, the multiple imputed data set is presented as the base case. This was 
created using all available data and multiple imputation with chained equations.69 Mean imputation was 
used to predict missing data at baseline,70 as randomisation should ensure equal distribution of potentially 
confounding variables. Complete-case analysis refers to only those patients who returned all questionnaires 
and completed all EQ-5D profiles.
Missing or inconsistent answers to questions on resource use were dealt with as follows. For medication 
use, patients were asked at each follow-up questionnaire whether or not they were using prescribed 
medication for reflux and, if so, to indicate the name, strength and the number of tablets taken in 
the past 2 weeks. It was evident from preliminary analyses that the answers to the first question were 
not necessarily consistent with the answers to the second question. Therefore, the following rule was 
applied for the costing of drugs: (1) if the patient provided the name, strength and number of tablets 
taken, he/she was assumed to be taking medication; (2) if the patient did not specify either a drug or the 
number of tablets taken, he/she was considered not to be taking medication; (3) if the patient specified a 
particular drug but no dosage, the missing data were imputed as the median of all other patients on that 
medication. Similarly, missing answers to the questions regarding GP visits and hospital admissions were 
assumed to indicate that no visits or admissions occurred. Because of the nature of the questionnaire, it is 
reasonable to assume that absence of an answer indicates no use of services.
Multiple imputation71 was the statistical technique chosen to deal with missing cost and HRQoL 
data because of non-returned questionnaires and incomplete EQ-5D profiles, using the user-defined 
programme ‘ice’ in Stata 11.1. Multiple imputation presents three major advantages over standard ad 
hoc methods for dealing with missing data (such as mean imputation and last value carried forward): (1) 
it makes full use of all of the available data, (2) it incorporates uncertainty associated with the missing 
data and (3) it ensures unbiased estimates and standard errors as long as data are MAR.69 [Little and 
Rubin72 defined three missing data mechanisms: (1) MCAR if the probability of data being unobserved is 
independent of both observed and unobserved values; (2) MAR if the probability of data being unobserved 
is dependent on the observed values but independent of unobserved ones and (3) missing not at random 
(MNAR) if the probability of data being unobserved is dependent on unobserved values.]
Multiple imputation follows three steps. First, regression models are used to predict plausible values 
for the missing observations from the observed values. A random component is included to reflect the 
uncertainty around the predictions. These values are then used to fill in the gaps in the data set. This 
process is repeated m number of times (m being the number of imputations), creating m number of 
imputed data sets. Second, each data set is analysed independently using complete-case methods. Third, 
the estimates obtained from each imputed data set are combined to generate mean estimates of costs and 
QALYs, variances and CIs using Rubin’s rules,73 in such a way that the uncertainty around the predicted 
values is fully taken into account.69,74 Because the REFLUX trial has missing data for both costs and EQ-5D 
scores, multiple imputation using chained equations (MICE) was employed. For MICE, each variable is 
predicted with its own regression model. Each imputed data set is created by running the regression 
models over several cycles, in which each variable informs the prediction of the other variables.69,74 To 
obtain overall estimates of mean and incremental costs and QALYs across all of the imputed data sets, the 
‘mim’ command was used.75 Semi-parametric bootstrapping in Stata 11.1 was employed to estimate the 
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probability that surgery is cost-effective, while maintaining the correlation between costs and QALYs (see 
Incremental analysis for more details).76
Plausible prediction of the missing data depends on the appropriate specification of the regression 
models used in MICE.74 If a model is misspecified, the distribution of imputed values may not resemble 
that of the observed values, and thus the estimates of treatment effect may be biased.69 The regression 
model specified will depend on the type and distribution of the variable to be predicted.70 The variables 
required for the economic evaluation are costs for each year and EQ-5D scores at each time point. 
Both are continuous variables and neither is normally distributed; EQ-5D scores in the REFLUX trial 
are bounded between –0.594 and 1,66 and costs are bounded at zero and tend to present a positive 
skew. Two approaches to deal with non-normality with MICE have been suggested in the literature:69 
(1) transformation towards normality and (2) predictive mean matching. [In predictive mean matching 
the missing observation is imputed with an observed value from an individual with a similar linear 
predictor.70 Consequently, the distribution of imputed values tends to closely match the distribution of the 
observed values.69] Using the REFLUX data set none of the transformation approaches (Box–Cox,77 log-
transformation and log-transformation of non-zero values with generation of an indicator variable78) were 
successful in transforming the data distribution to normality. As a result, predictive mean matching was 
the strategy employed to ensure that the distribution of imputed values closely resembled the distribution 
of observed values. All known covariates thought to be associated with the missingness mechanism, 
costs and EQ-5D scores were included in the prediction equations: EQ-5D scores at each follow-up point, 
costs at each year, allocation, BMI, age and sex. A total of 100 imputations (m = 100) was used to ensure 
efficient and reproducible estimates.69
Multiple imputation provides unbiased estimates of treatment effect if data are MAR. Whether or not data 
are MAR is an untestable assumption by definition, as unobserved values are unknown. Departure from 
the MAR assumption may have implications for decision-making if the results from the cost-effectiveness 
analysis differ from those of the base case. Sensitivity analysis was used to test the impact on the cost-
effectiveness results if data were MNAR, that is, if patients with worst outcomes or greater costs were 
more likely to have missing data.70,79 Four scenarios were tested. In scenario (1), all patients with missing 
data had their total QALYs reduced by 10%, 20%, 30%, 40% and 50%. Conversely, in scenario (2), for 
all patients with missing data costs were increased by the same proportions (10%, 20%, 30%, 40% and 
50%). In scenario (3), only surgery patients with missing data had their QALYs reduced. In scenario (4), 
costs were increased only for patients undergoing surgery.
Incremental analysis
The cost-effectiveness of surgery was evaluated by comparing the costs and QALYs incurred in the 
surgery arm with the costs and QALYs in the medical management arm at 5 years of follow-up, using 
conventional decision rules and estimating ICERs as appropriate.80 If one intervention is associated with 
greater mean QALYs and lower mean costs it is deemed cost-effective by dominance. The ICER is calculated 
if either treatment arm does not dominate. The ICER summarises the additional costs associated with 
one intervention over another and relates this to the additional benefits. This ICER is then compared 
with a threshold for the cost per QALY. The National Institute for Health and Care Excellence (NICE) uses 
a threshold cost per QALY of around £20,000–30,000 to determine whether or not an intervention 
represents good value for money in the NHS.65 Consequently, if the ICER is < £20,000, laparoscopic 
fundoplication could be considered potentially cost-effective. ICERs between £20,000 and £30,000 per 
QALY are considered borderline and an ICER > £30,000 is not typically considered cost-effective.
The ICER can be re-expressed using the net monetary benefit (NMB). The NMB of an intervention is 
the value of the health benefits gained from a particular intervention compared with standard care in 
monetary terms, minus the incremental costs of the intervention. The translation of health benefits into the 
monetary scale was made using a cost-effectiveness threshold of £20,000. This is the threshold commonly 
use by NICE (this corresponds to 1 QALY being valued at £20,000). Therefore, the NMB provides a measure 
of the gain (or loss) in resources of investing in a particular intervention when those resources could have 
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been used elsewhere.81 The NMB of laparoscopic fundoplication and medical management were calculated 
and used to demonstrate the influence of trial duration on the estimates of cost-effectiveness of surgery.
As discussed previously, the multiple imputed data set was used as the base case for the cost-effectiveness 
analysis because of the large proportion of data lost for the complete-case analysis. Because total costs 
and total QALYs are cumulative quantities, any missing data at any of the follow-up points will result 
in that patient being dropped from a complete-case analysis. The cost-effectiveness results using the 
complete case are presented for comparison. Complete-case analysis will provide unbiased estimates only if 
the data are MCAR, that is, the probability of data being unobserved is independent of both observed and 
unobserved values. Multiple imputation ensures unbiased estimates if the data are MAR (the probability 
of data being unobserved is dependent on the observed values but independent of unobserved ones). 
Because unobserved values are unknown, the missing data mechanism and hence the validity of either 
assumption is untestable. Nevertheless, multiple imputation presents two advantages. First, it requires a 
less stringent assumption for ensuring unbiased estimates. Second, if data are MCAR, both complete-case 
and multiple imputation estimates will be unbiased whereas, if data are MAR, complete-case analysis will 
be biased.
Analysis of uncertainty for incremental analysis
Sensitivity analysis is used to explore and quantify any uncertainty in the cost-effectiveness results. Three 
types of sensitivity analysis were undertaken: structural, scenario and probabilistic sensitivity analysis. 
Structural and scenario sensitivity analyses were carried out on the complete-case data set. Probabilistic 
sensitivity analysis was carried out in both the complete case and the multiple imputation data set.
Structural sensitivity analysis consisted of a PP analysis that classified patients according to treatment 
compliance at 1 year of follow-up, that is, whose management at 1 year was consistent with their original 
random allocation. Consequently, the PP data set consisted of the patients randomised to surgery who 
actually had surgery, and of the patients randomised to medical management who did not undergo 
surgery at 1 year. Patients randomised to medical management who had surgery might differ from 
those randomised to medical management who were managed medically without surgery, for several 
reasons. A patient’s condition might have worsened, prompting surgery, or patients might have changed 
their preferences and wish to be taken off medication. The latter implies that, had they been screened 
for the study at the point in time when they had surgery, they would not have been eligible for the 
study. These patients would have had a preference and would not have accepted randomisation. The 
condition itself is complex because of its recurrent and cyclical nature (patients suffering from reflux have 
punctual exacerbations, which can lead them to change their preferences and request surgery). Therefore, 
the reasons for not complying with randomisation are likely to be a combination of the two motives 
(worsening of condition and change in preference). PP was chosen because it was thought to be more 
similar to clinical practice, where patients can experience a wait for surgery and change their preferences 
during this period. Any switching of treatment after 1 year is assumed to be because of a change in clinical 
status, which would preclude inclusion in the clinical trial.
The base-case analysis included only the costs of reflux-related GP visits and hospitalisations. Two 
alternative costing scenarios were tested in sensitivity analysis: including either all GP visits or all hospital 
use, regardless of whether they had been classified as reflux or non-reflux related.
Probabilistic sensitivity analysis attempts to quantify the joint effect of uncertainty around the costs and 
QALYs. Semiparametric bootstrapping was used to estimate the probability that each intervention is cost-
effective for a range of cost-effectiveness threshold values. In bootstrapping, the original data are sampled 
with replacement to create a new data set, in order to calculate estimates of treatment effect. Repeating 
this process a large number of times results in a vector of replicated statistics, which ultimately provide an 
empirical estimate of the CIs around mean incremental costs and QALYs. The probability of an intervention 
being the most cost-effective is the conventional method of presenting the uncertainty around the cost-
effectiveness results. The CIs around the ICER are not presented because they are difficult to interpret and 
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are not easy to use: a negative ICER can indicate that an intervention dominates (because it is associated 
with more benefits and lower costs than its comparator) or it is dominated (because it is associated with 
fewer benefits and higher costs).76
Validation
Several procedures were used to ensure the validity of the analysis. First, two statistical analysis codes 
(written in Stata) were developed in parallel and their results compared. Second, the code was developed 
by one analyst and checked independently by another. Third, the results were cross-checked in Microsoft 
Excel (Microsoft Corporation, Redmond, WA, USA) for a sample of the data set. Lastly, selected results 
were represented graphically and examined for face validity. The validity of the imputation strategy was 
explored by (1) analysing the data for predictors of missingness,70 (2) comparing the distributions of 
the observed and imputed values graphically70 and (3) estimation of Monte Carlo errors.69 Appendix 8 
describes the validation process in more detail.
Results
Patient population
Complete-case analysis consisted of the patients who returned all questionnaires and completed all 
EQ-5D profiles. Overall, there are 172 patients in the complete-case analysis (88 randomised to medical 
management and 84 randomised to surgery). Table 32 shows the numbers of questionnaires returned 
(includes those with some missing data) and the numbers of completed questionnaires returned for 
each year. As expected, the number of questionnaires returned in each year of follow-up decreases with 
time. The return of questionnaires does not follow a monotonic pattern, that is, patients who did not 
return the questionnaire for one particular year may have returned a questionnaire in subsequent years. 
Therefore, the number of patients in the complete-case analysis is lower than the number of completed 
questionnaires in year 5. The large number of patients not included in the complete-case analysis because 
of missing data strengthens the rationale for using the multiple imputation data sets in the base case.
Health-care resource use
Table 33 summarises yearly health-care resource use in the two trial arms according to ITT analysis. During 
the first year of the trial, 111 patients randomised to surgery and 10 patients randomised to medical 
management underwent laparoscopic fundoplication. The 111 patients who were randomised to and 
received surgery constituted the surgery group in the PP analysis. The 169 patients who were randomised 
to medical management and did not undergo surgery during the first year of follow-up constituted 
the medical management group in the PP analysis. In the subsequent years of follow-up there were 
15 patients who underwent surgery (one patient who had been randomised to surgery and 14 patients 
TABLE 32 Numbers of questionnaires returned and completed questionnaires returned and corresponding proportions 
per trial arm, according to ITT analysis
Year
Questionnaires returned, n (%) Completed questionnaires,a n (%)
Surgery Medical management Surgery Medical management
1 154 (87) 164 (92) 134 (75) 147 (82)
2 128 (72) 142 (79) 121 (68) 134 (75)
3 132 (74) 134 (75) 112 (63) 119 (66)
4 126 (71) 129 (72) 114 (64) 118 (66)
5 127 (71) 119 (66) 115 (65) 113 (63)
Number of patients in complete-case analysis 88 (49) 84 (47)
a Completed questionnaires means that all of the questions on health-care resource use and EQ-5D were filled in.
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who had been randomised to medical management). These patients are included in the overnight hospital 
admissions category. Patients randomised to medical management reported more hospital and GP visits 
than the surgery patients over the 5 years of follow-up.
Table 34 shows the costs associated with health-care use according to ITT analysis for all available cases 
(see Appendix 9 for corresponding table for PP). All available cases uses data from all questionnaires 
returned at each time point. Per annum costs and costs per category refer to all available data, that is, 
to all participants who returned the questionnaire for that particular year or for that particular category. 
Therefore, the sum of the costs per category is different from the sum of the costs per annum. Similarly, 
total costs for complete-case analysis do not correspond to the sum of the costs per category or to 
the sum of the costs per annum because complete case is a subset of all available data because of 
TABLE 33 Health-care resource use per year per trial arm, according to ITT analysis
Health-care resource Year
Reflux-related reasons, n All reasons, n
Surgery 
(n = 178)
Medical 
management 
(n = 179)
Surgery 
(n = 178)
Medical 
management 
(n = 179)
Laparoscopic fundoplication 
(first year)
1 111 10 N/A N/A
Hospital overnight admissions 
(excluding surgery in the first 
year)
1 4 2 8 8
2 1 2 8 10
3 2 9 6 10
4 2 9 2 10
5 0 8 1 11
Total 9 30 25 49
Hospital day admissions 1 22 24 40 53
2 5 4 23 24
3 4 6 4 10
4 12 9 13 11
5 4 11 7 14
Total 47 54 87 112
Visits to and from GP 1 110 103 394 376
2 34 115 269 373
3 38 99 381 386
4 55 126 422 469
5 36 119 404 370
Total 273 562 1870 1974
Number of patients on reflux-
related medication
1 58 148 N/A N/A
2 48 124 N/A N/A
3 51 113 N/A N/A
4 51 106 N/A N/A
5 56 98 N/A N/A
N/A, not applicable.
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the non-monotone missing data pattern. Total costs for complete-case analysis refer to the patients 
who returned all questionnaires and completed all EQ-5D profiles (84 surgery patients and 88 medical 
management patients).
Patients randomised to medical management accumulate lower costs than patients randomised to surgery. 
Table 34 indicates that surgery patients accrued a large proportion of the total costs in the first year, and 
accumulated lower costs during the remaining 4-year follow-up than the medical management group. In 
contrast, the costs accrued by medical management patients are evenly distributed across the duration 
of the trial. These results suggest that the cost trend in medical management patients is steeper than 
in surgery patients; hence, that cumulative costs in medical management patients tend to increase at 
a greater rate than in surgery patients. Costs associated with surgery were the major cost driver for the 
surgery group. Costs associated with reflux-related medication were significantly greater for the medical 
management group than for the surgery group. Costs associated with admissions to hospital and GP visits 
were not statistically significantly different between the two groups. Surgery during years 2–5 is accounted 
for in the overnight hospital admissions. There were a few crossovers from medical management to 
surgery from year 2; hence, the difference in costs associated with overnight hospital admissions between 
the two treatment groups is small. These results suggest that patients undergoing surgery in subsequent 
years are not a major cost driver in determining the cost-effectiveness of surgery.
Quality-adjusted life-years
Table 35 summarises the EQ-5D scores reported at each follow-up point for all available cases (see 
Appendix 9 for the corresponding table for PP). All available cases uses data from all questionnaires 
returned at each time point. The surgery group appears to have better HRQoL than the medical 
TABLE 34 Costs associated with resource use for all available cases, discounted from year 2 at 3.5%, according to 
ITT analysis
Returned questionnaires  
in each year Mean (SD) resource-use cost (£)
Incremental mean cost 
(cost surgery – cost medical 
management) (95% CIa) (£) Surgery
Medical 
management Year Surgery
Medical 
management
154 164 1 2500.75 (1697.99) 559.62 (1006.81) 1941.13 (1621.43 to 2260.83)
128 142 2 94.15 (317.63) 150.96 (356.57) –56.81 (–138.08 to 24.46)
132 134 3 94.35 (340.33) 276.41 (894.16) –182.05 (–345.87 to –18.24)
126 129 4 111.41 (394.00) 303.50 (1337.26) –192.09 (–436.56 to 52.28)
127 119 5 58.38 (178.58) 234.03 (629.33) –175.65 (–290.26 to –61.03)
Cost category
Surgery in year 1b 1734.05 (1407.58) 164.31 (644.63) 1569.74 (1342.05 to 1797.42)
Reflux-related hospital night 
admissions
343.82 (1176.05) 302.34 (818.41) 41.47 (–247.48 to 330.42)
Reflux-related hospital day 
admissions
221.67 (633.61) 250.35 (631.37) –28.68 (–209.24 to 151.87)
Reflux-related GP visits 127.18 (178.96) 200.13 (462.53) –72.95 (–173.26 to 27.35)
Medication 121.34 (265.05) 365.70 (517.05) –244.35 (–361.82 to –126.89)
a CIs estimated using OLS regression.
b Only surgery occurring during the first year of the trial was included here. Laparoscopic fundoplication occurring 
in the subsequent years of the trial has been included in reflux-related hospital admissions. For the 10 medical 
management patients who had surgery in the first year of the trial, the average (SD) cost was £2679 (£126). For the 
111 surgery patients who had surgery in the first year of the trial, the average (SD) cost was £2798 (£501).
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management group, despite starting from a lower baseline EQ-5D on average (0.7201 in the medical 
management group and 0.7107 in the surgery group). The difference in HRQoL between the two 
treatment groups decreased with time. This may be due to patients randomised to medical management 
undergoing surgery throughout the follow-up period and/or to diminishing treatment effect over time.
Comparison of costs and quality-adjusted life-years between multiple 
imputation and complete case
Table 36 shows the comparison of the total costs per year between the complete-case data set and the 
multiple imputation results. Complete case includes only those participants who returned all questionnaires 
and fully completed the EQ-5D questionnaires. The similarity of both the means and the CIs provides some 
reassurance of the validity of the multiple imputation model. The distribution of costs and EQ-5D scores 
in the imputed data sets matches reasonably well the distribution of the original data (see Appendix 8 for 
details). Furthermore, the Monte Carlo errors are < 15% of the coefficient and CI estimates, suggesting that 
100 imputations are sufficient to ensure reproducibility and statistical efficiency.69
For both the complete-case and multiple imputation data sets, the participants randomised to laparoscopic 
fundoplication accrued greater costs but also reported greater HRQoL than participants randomised to 
continued medical management. The 95% CI for mean incremental QALYs crosses zero for the unadjusted 
for baseline estimates, whereas it remains above zero for the adjusted values. This result reflects the 
baseline imbalance in mean utility between treatment groups. Therefore, these results strongly indicated 
that surgery is associated with a greater QALY improvement than medical management. The sum of the 
differences in EQ-5D for the ITT groups does not correspond to the incremental mean QALYs because of 
the effect of discounting.
Cost-effectiveness
The results of the incremental analysis suggest that laparoscopic fundoplication is a cost-effective strategy 
for GORD patients eligible for the REFLUX trial (Table 37). The results for the complete-case analysis 
concur with those for the multiple imputation data set; across adjusted and unadjusted ICER for baseline 
EQ-5D, ICERs range between £5468 and £8410, well below conventional cost-effectiveness thresholds of 
£20,000 and £30,000 per additional QALY. For both data sets (complete case and multiple imputation), 
the probability of surgery being the more cost-effective intervention is > 0.82 for incremental analysis 
TABLE 35 Health-related quality of life (EQ-5D) for all available cases according to ITT analysis
Completed questionnaires 
returned at each time point
Follow-up
Mean (SD) EQ-5D
Difference in EQ-5D 
(surgery – medical 
management) (95% CI)b,c
Surgery 
(n = 178a)
Medical 
management 
(n = 179a) Surgery
Medical 
management
171 173 Baseline 0.7107 (0.2581) 0.7201 (0.2545) –0.0094 (–0.0638 to 0.0445)
149 153 3 months 0.7881 (0.2328) 0.6894 (0.3012) 0.0987 (0.0376 to 0.1597)
152 164 Year 1 0.7537 (0.2468) 0.7097 (0.2715) 0.0440 (–0.0136 to 0.1016)
122 138 Year 2 0.7619 (0.2718) 0.7172 (0.3127) 0.0447 (–0.0273 to 0.1167)
129 132 Year 3 0.8034 (0.2312) 0.7474 (0.2621) 0.0560 (–0.0043 to 0.1163)
125 127 Year 4 0.7713 (0.2438) 0.7544 (0.2719) 0.0169 (–0.0472 to 0.0810)
124 117 Year 5 0.7743 (0.2590) 0.7612 (0.2815) 0.0131 (–0.0555 to 0.0817)
a n refers to the number of patients originally randomised to each trial arm.
b CIs estimated using OLS regression.
c Unadjusted for baseline EQ-5D.
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TABLE 37 Incremental analysis for the ITT analysis at 5 years of follow-up for the complete-case and multiple 
imputation data sets
Data set
Adjustment 
for baseline 
EQ-5D?
Incremental 
mean costs 
(£) (95% CI)
Incremental 
mean QALYs 
(95% CI) ICER (£)
Probability 
cost-effective 
at £20,000 
per QALYa
Probability 
cost-effective 
at £30,000 
per QALYa
Complete case No – 
unadjusted 
QALYs
1661.78 
(1130.00 to 
2193.55)
0.1976 
(–0.0857 to 
0.4810)
8409.82 0.828 0.866
Yes – adjusted 
QALYs
1661.78 
(1130.00 to 
2193.55)
0.3039 
(0.0928 to 
0.5150)
5468.36 0.989 0.996
Multiple 
Imputation
No – 
unadjusted 
QALYs
1517.95 
(1006.49 to 
2029.41)
0.1948 
(–0.0356 to 
0.4251)
7792.35 0.861 0.906
Yes – adjusted 
QALYs
1517.95 
(1006.49 to 
2029.41)
0.2160 
(0.0205 to 
0.4115)
7027.55 0.932 0.962
a Probability of intervention being cost-effective calculated with semiparametric bootstrapping.
unadjusted for baseline EQ-5D and > 0.93 once incremental QALYs are adjusted for baseline EQ-5D. In 
the ITT analysis the ICER is higher for the multiple imputed data than for the complete case if QALYs are 
adjusted for baseline EQ-5D, but lower if QALYs are unadjusted. This might reflect the effect of having 
baseline EQ-5D in the prediction model, which would preclude the need for adjustment.
Figure 20 shows how the NMB associated with laparoscopic fundoplication increases with the duration 
of the trial. This reflects the increase in costs associated with the medical group, which offsets the initial 
investment made in laparoscopic fundoplication in the surgery group.
Structural sensitivity analysis: per-protocol status for the complete case
Structural sensitivity analysis consisted of PP status at 1 year for the complete case. In the PP analysis 
patients are classified according to the treatment actually received at 1 year of follow-up. The PP group 
consists of 111 patients who were randomised to surgery and who actually had surgery during the 
first year of the trial and 169 patients who were randomised to medical management and who did 
not undergo surgery during this time period. However, complete-case data exist only for 84 medical 
management patients and 66 laparoscopic fundoplication patients. Appendix 9 presents detailed results 
for costs and HRQoL according to PP analysis. As expected, patients who actually had surgery have higher 
costs than patients who did not undergo surgery, regardless of their randomisation. Table 38 summarises 
the incremental results of the PP analysis. Similar to the ITT analysis, the surgical policy is likely to be 
cost-effective at conventional (NICE) thresholds for cost-effectiveness. The incremental costs are higher and 
the incremental QALYs lower for the PP analysis (for surgery compared with medical management) than 
for the ITT analysis if no adjustment is made for baseline imbalances in EQ-5D. Therefore, the ICER is also 
greater (surgery is less cost-effective than suggested by the ITT analysis). Once total QALYs are adjusted 
for baseline EQ-5D, however, the incremental mean QALYs increase substantially and the ICER is reduced. 
Nevertheless, the adjusted ICER in the ITT analysis is lower than that in the PP analysis by around £2000.
Scenario sensitivity analysis: all general practitioner and all hospital costs for 
complete case
The results of the scenario analyses strengthen the case for the surgical policy (Table 39). For scenario 1, 
replacing reflux-related GP costs by all GP costs, the ICER increased slightly in relation to the base case. 
Nevertheless, the ICER remains well below conventional thresholds and the probability of surgery being 
cost-effective is > 0.83, for both adjusted and unadjusted analyses. In scenario 2, replacing reflux-related 
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hospital costs by all hospital costs, medical management was ‘dominated’ by the surgical policy because of 
this intervention being associated with greater benefits in terms of QALYs and lower costs. For this scenario 
the probability of surgery being cost-effective was > 0.93.
Sensitivity analysis for the multiple imputation model: departure from missing 
at random assumption
The multiple imputation procedure assumes that the individuals who completed and returned all 
questionnaires are similar to the individuals who did not, conditional on their observed characteristics 
(MAR assumption).69,79 However, this may not be the case: patients who did not return a questionnaire 
may have experienced worse HRQoL and accrued higher health service costs, or vice versa. Sensitivity 
analysis on the multiple imputation model tested how sensitive the cost-effectiveness results are to the 
MAR assumption. Figure 21 represents the change in NMB adjusted for baseline EQ-5D as costs and QALYs 
are varied in patients with missing data. The origin, marked as ‘base case’, refers to the incremental results 
from the multiple imputed data set (ICER = £7028 per additional QALY). The right quadrant plots NMB 
after increasing the total costs in steps of 10% for patients for whom there was missing data, for both 
treatment groups and for surgery-allocated patients. The left quadrant plots NMB after decreasing total 
QALYs in similar fashion. Positive values for NMB indicate that surgery is cost-effective; negative values 
indicate that surgery is not cost-effective for a threshold of £20,000 per additional QALY.
The cost-effectiveness of surgery is relatively insensitive to any increase in costs; the NMB changes little 
if costs are increased for patients with missing data in both treatment groups and if costs are increased 
just for surgery-allocated patients with missing data. A similar result is observed for the reduction in total 
QALYs for all patients with missing data. In contrast, the cost-effectiveness of surgery is highly sensitive 
if it is assumed that surgery-allocated patients with missing data experience lower HRQoL than patients 
with complete data. A 10% decrease in QALYs for patients randomised to surgery with missing data 
results in NMB decreasing to negative values. This scenario shows that missing data can have an impact 
on the results under certain conditions. It is impossible to empirically confirm or refute the scenario from 
FIGURE 20 Net monetary benefit (incremental QALYs × £20,000 per QALY – incremental costs) over the duration of the 
REFLUX trial for the multiple imputation and complete-case data sets (QALYs adjusted by baseline EQ-5D).
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the data in the trial, but it could be considered an extreme case. It seems improbable in practice that 
surgical patients with poor quality of life are less likely to respond to follow-up questionnaires than similar 
participants undergoing medical management.
Conclusion
The results of the within-trial economic analysis suggest that laparoscopic fundoplication is the more 
cost-effective option for the management of the sorts of patients suffering from GORD who were eligible 
for the REFLUX trial. The ICER for the ITT approach in the complete case was between £5468 and £8410 
per additional QALY, and for the multiple imputed data set was between £7028 and £7792 per additional 
QALY, depending on whether QALYs are unadjusted or adjusted for baseline. Adjusted results are likely 
to be more reflective of the improvement in HRQoL associated with surgery. The probability of surgery 
being cost-effective was > 0.80 for all analyses. The results are robust to the scenario analyses testing 
assumptions regarding resource-use and missing data mechanism apart from when surgery-allocated 
patients with missing data were assumed to experience lower HRQoL than other patients. In all scenarios 
the ICERs were similar to the base case ICERs and well below NICE cost-effectiveness thresholds.
TABLE 38 Incremental analysis for the PP analysis at 5 years of follow-up for the complete-case data set
Adjustment for 
baseline EQ-5D
Incremental 
mean costs 
(95% CI) (£) 
Incremental 
mean QALYs 
(95% CI) ICER (£)
Probability 
cost-effective 
at £20,000 per 
QALYa
Probability 
cost-effective 
at £30,000 per 
QALYa
Unadjusted QALYs 2323.77 
(1799.90 to 
2847.65)
0.1782 (–0.1316 
to 0.4879)
13,043.90 0.672 0.747
Adjusted QALYs 2323.77 
(1799.90 to 
2847.65)
0.3200 (0.0837 
to 0.5562)
7262.85 0.957 0.983
a Probability of intervention being cost-effective was calculated with semiparametric bootstrapping.
TABLE 39 Incremental analysis for the scenario sensitivity analysis at 5 years of follow-up for the complete-case 
data set
Sensitivity 
analysis
Adjustment 
for baseline 
EQ-5D?
Incremental 
mean costs 
(95% CI) (£) 
Incremental 
mean QALYs 
(95% CI) ICER (£)
Probability 
cost-effective 
at £20,000 
per QALYa
Probability 
cost-effective 
at £30,000 
per QALYa
Scenario 1: all 
GP costs
No – 
unadjusted 
QALYs
1685.60 
(1103.97 to 
2267.23)
0.2125 
(–0.0748 to 
0.4998)
7932.23 0.826 0.863
Yes – adjusted 
QALYs
1685.60 
(1103.97 to 
2267.23)
0.3191 
(0.1061 to 
0.5321)
5282.36 0.987 0.994
Scenario 2: all 
hospital costs
No – 
unadjusted 
QALYs
–262.72 
(–860.08 to 
334.65)
0.2125 
(–0.0748 to 
0.4998)
Medical 
management 
dominated
0.930 0.928
Yes – adjusted 
QALYs
–£262.72 
(–860.08 to 
334.65)
0.3191 
(0.1061 to 
0.5321)
Medical 
management 
dominated
0.999 0.999
a Probability of intervention being cost-effective calculated with semiparametric bootstrapping.
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Validation of within-trial (5-year) analysis and exploration of 
the need for a long-term model
Introduction
The within-trial analysis found that surgery was cost-effective over a 5-year time horizon. A sufficient 
condition for surgery to be unambiguously cost-effective over a longer term is that, in each year after 
5 years, HRQoL is lower and costs are the same or increasing faster in the medical group than in the 
surgical group. The results from both the multiple imputation and the complete-case analysis suggest 
that surgery is likely to be a cost-effective alternative over the longer term. Based on the ITT analyses 
undertaken so far, it is unlikely that mean HRQoL in patients who had surgery will become lower than 
that in patients on medical management after 5 years, and it is also very unlikely that mean annual costs 
incurred by surgery patients will exceed those incurred by medical management patients. If these results 
are robust, then there is no need to develop an economic model to extrapolate the 5-year results over a 
longer time horizon. Surgery would simply become more cost-effective over time.
This section develops a statistical model to investigate whether or not the results obtained in the within-
trial economic analysis are robust to alternative assumptions and methods, and uses the results to consider 
whether or not the evidence supports this sufficient condition over the longer term.
FIGURE 21 Net monetary benefit (incremental QALYs adjusted for baseline EQ-5D × £20,000 per QALY – incremental 
costs) over variation in total costs and total QALYs in the multiple imputed data set.
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Methods
Overview
The aim of this analysis was to estimate the difference in costs and the difference in HRQoL (measured 
with the EQ-5D) between the surgical and medical management randomised groups and describe how 
this difference evolves over time. A simple way of doing this would be to estimate the difference in costs 
and outcomes at each time point independently. The results of this analysis were shown in Table 34 (for 
costs) and Table 35 (for EQ-5D). These showed that costs were greater in the surgical group in the first 
year but greater in the medical group thereafter. EQ-5D tended to be higher in the surgical group in years 
4 and 5 but the CIs crossed zero. There are two main limitations of this simple analysis:
1. The outcomes at each time point are unlikely to be independent. If the outcomes at one time point are 
correlated with those at other time points this analysis may lead to biased estimates of standard errors.
2. The analysis does not take account of missing data. If missing data are not MCAR then this analysis 
may lead to biased estimates of the mean of the coefficients.
The multiple imputation accounts for the correlation of responses from the same individuals and for the 
missing data (see Table 36). However, the validity of this analysis depends on the correct specification of 
the equations used to impute the missing data. Moreover, other regression-based methods are available 
for handling missing data in longitudinal studies, principally mixed models, and results may be sensitive to 
the methods used. This section uses a mixed model to handle the missing data and compares predicted 
outcomes with those using multiple imputation.
Mixed models
A mixed model is a regression-based method for handling continuous data that is measured at more than 
one time point during follow-up. It allows estimation of treatment effects under the assumption that the 
data are MAR, that is, dropout may depend on intermediate values. Analysing each time period separately 
assumes that dropouts are MCAR, a stronger assumption. A mixed model uses all of the observed data. 
Individuals who dropped out after providing intermediate data contribute to the estimation of the final 
outcomes. This analysis has the same aims as multiple imputation but uses a different method and with 
different assumptions. Therefore, it can also be viewed as a sensitivity analysis to test the robustness of the 
multiple imputation.
The mixed model can be written as:
Where for an individual i,
Yi = a +bRi + Xi + ei, ei ~ MVN(0,Σ)
Ri = randomised group
Yi = vector of all outcomes (at times 1. . .T)
Xi = vector of covariates
The variance–covariance matrix Σ is unstructured, that is, no prior assumptions are made about the values 
of the correlations. Separate models are fitted for costs and for EQ-5D. Baseline values of the EQ-5D 
are included as an ‘outcome’ (i.e. at t = 1). Dummies representing time points 1 to T were included as 
covariates Xi. Treatment effects are included as time*randomised group interactions although no treatment 
effect at baseline is allowed. No other covariates are included in the model.
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Results
Costs
Figure 22 shows the difference in costs (excluding initial surgery) in years 1–5. Mean costs are greater in 
the medical management arm of the trial after the first year and the CIs only just cross zero. These results 
are very similar to those of Table 34.
European Quality of Life-5 Dimensions
Figure 23 shows the difference in EQ-5D at 3 months and in years 1–5. Mean HRQoL tends to be greater 
in the surgical group during the trial, although the CIs cross zero in some periods. These results are very 
similar to those of Table 35.
Conclusion
The results of the mixed model (taking account of correlations and missing data) are very similar to those 
of the complete-case analyses (which assumed that data at different time points were independent) and 
the multiple imputation (see Table 36). All of these analyses show that follow-up costs are significantly 
greater in the medical management arm of the trial (because of greater reflux-related hospital admissions, 
GP visits and use of medication). The analyses also show that surgery tends to be more effective, in terms 
of HRQoL, than medical management over the 5-year follow-up. Although this treatment difference 
appears to weaken over time, there is no reason to expect that surgery will become less effective with 
a longer follow-up. Consequently, the evidence suggests that the cost-effectiveness of laparoscopic 
fundoplication will not diminish if measured over a longer follow-up time. Nevertheless, there is 
uncertainty surrounding these conclusions because of the large proportion of missing data.
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FIGURE 22 Difference in costs (£) excluding initial surgery (mean, 95% CI).
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FIGURE 23 Difference in EQ-5D, adjusted for baseline (mean, 95% CI).
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Discussion
The results of the cost-effectiveness analysis strongly suggest that a policy of offering laparoscopic 
fundoplication to people with GORD who require long-term PPI treatment for symptom control is more 
cost-effective than continuing to manage them with PPIs (with selective use of surgery if symptoms are 
poorly controlled), assuming that the cost-effectiveness thresholds used by NICE (£20,000–30,000 per 
QALY) are appropriate for the NHS. Surgery represents a greater initial investment and lower medium-term 
costs, whereas costs associated with medical management remain relatively constant or slightly increase 
over time. The difference in HRQoL achieved with surgery is sustained over 5 years, although the results 
indicate that mean EQ-5D scores for surgery and medical management tended to converge (as discussed 
in Chapter 3, in part this reflects later surgery in patients randomised to medical management). The 
ICER favours surgery when incremental QALYs are both adjusted and unadjusted for baseline EQ-5D. 
Nevertheless, adjusted incremental QALYs are likely to be a more reliable estimate of treatment effect as 
they account for differences in baseline utility. Patients randomised to medical management reported 
higher baseline utility than patients randomised to surgery. Failure to adjust for these baseline differences 
could result in a biased ICER, as discussed elsewhere.62 The results from the multiple imputed data set are 
likely to be more accurate than the results from the complete-case analysis because of the large number 
of patients with incomplete data (> 50%). Therefore, multiple imputation was chosen for the base case. 
Nevertheless, the results are similar across the data sets and laparoscopic surgery is the more cost-effective 
intervention for both.
There is little uncertainty regarding the cost-effectiveness results once adjustment for EQ-5D at baseline is 
performed. The probability of surgery being cost-effective ranged between 0.932 and 0.999 for the base 
case and across the scenarios tested. Furthermore, it is clear from the results of the scenario analysis that 
the base-case results are robust to alternative costing assumptions. The PP analysis is used to test whether 
or not the ITT analysis is potentially misleading because of the dilution of treatment effect (some patients 
randomised to surgery did not have surgery and some patients randomised to medical management 
actually had surgery). The PP analysis has the advantage of mimicking clinical practice and could be 
thought to be more relevant to decision-makers. However, the PP analysis is not without its limitations. 
First, and as with any PP analysis, it is sensitive to selection bias because of breaking randomisation. 
Second, the PP analysis may still underestimate the effect of surgery because patients having surgery 
between 2 and 5 years are counted as medical management. Third, the PP analysis is actually a subset 
of the ITT groups, which further reduces the data set. For these reasons, the ITT results are likely to be 
more reliable. It is important to characterise any uncertainty in the analysis as failure to do so can result 
in inaccurate estimates of cost-effectiveness, particularly when costs and benefits are highly skewed.82 
In addition, any analyses of uncertainty can help to illustrate where caution should be exercised when 
interpreting the results of a cost-effectiveness analysis. The results of the sensitivity analyses suggest that 
the uncertainty is likely to be driven by HRQoL. If QALYs for randomised surgery patients with missing data 
are reduced, surgery may no longer be cost-effective.
For the within-trial analysis no assumptions are needed about the longer-term effectiveness and 
costs associated with surgery and medical management. However, the within-trial analysis has some 
disadvantages. First, it does not account for any differences in costs and QALYs that may be expected 
over the longer term (> 5 years), which could be due to differences in recurrence/relapse, medication use, 
NHS service utilisation or HRQoL. Second, it uses data only from the REFLUX trial and does not consider 
other sources of evidence. Third, only a limited range of sensitivity analyses was possible. Finally, the 
large proportion of missing observations required an assumption regarding the mechanism of missing 
data, which may have some impact on the cost-effectiveness estimates. The exploration of the need for 
a longer-term model aimed to address the first limitation of the within-trial analysis. A mixed model was 
used to examine the trend in the difference in costs and the difference in QALYs between treatment groups 
over time.
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No evidence was found to suggest that the cost-effectiveness of surgery diminishes over a longer follow-up 
time. Both multiple imputation and mixed models are commonly used methods to handle missing data. 
Multiple imputation was used in the previous section because, by imputing missing data, it naturally 
allows the estimation of the total cost and total QALYs for each patient in the trial. Furthermore, it can 
handle correlation between several outcomes (in this case costs and QALYs) as well as correlation between 
outcomes over time. Mixed models do not explicitly impute missing data but adjust the estimates of the 
differences between treatment groups at each discrete follow-up time to take account of the missing 
data. The approach therefore offers an alternative method to multiple imputation to examine trends in the 
difference in costs and the difference in QALYs between treatment groups over time. Because the analyses 
using multiple imputation and mixed models agree, we can have more confidence that the results are valid 
and that surgery is the most cost-effective intervention.
A number of other studies have quantified the cost-effectiveness of laparoscopic fundoplication and 
medical management. Not all of these, however, use a common metric (such as QALYs) to measure 
benefits. Of those studies quantifying the benefits associated with the two treatments using QALYs, 
the ICER for surgery ranged from £180 to £49,000. There are a number of key differences between the 
methodologies used in the studies, which limit the extent to which comparisons can be made between 
results. Importantly, not all of the studies are based on within-trial analysis; in fact, only two are: those 
by Grant et al.1 and Goeree et al.46 The remainder use modelling techniques to either extrapolate short-
term trial results over the longer term or pool available evidence to generate estimates of costs and 
outcomes. Comparing the results from Grant et al.1 with those from Goeree et al.46 we can see that 
there are quite significant differences in the estimates of cost per QALY, from £19,000 in Grant et al.1 
to £49,000 in Goeree et al.46 This difference is primarily driven by the difference in QALYs. In Goeree et 
al.46 the EQ-5D score is actually lower in the surgical group than in the medical management group (this 
is unadjusted for baseline imbalances) whereas the HUI3 score is higher for the surgical group than the 
medical management group. The reason for the difference between the EQ-5D and the HUI3 scores is 
not discussed in the paper. The cost differences in the two studies were similar. Comparing the results 
from Goeree et al.46 with those from the updated trial analysis we see even starker contrast between the 
ICERs produced (£7028 vs £49,000). Again, this is driven by the differences in EQ-5D scores observed 
throughout the trial period. The EQ-5D scores in the REFLUX 5-year analysis are consistently higher in the 
surgery group than in the medical management group, although there is a tendency for convergence 
towards the end of the follow-up period. Further research is required to look at why the trials produce 
such different results using the EQ-5D.
Other considerations
The generalisability of these findings to the GORD population in the UK is difficult to ascertain because the 
proportion of GORD patients meeting the entry criteria for this trial is uncertain. The surgeons participating 
in the trial may be more proficient in the procedure than those in actual practice. Furthermore, capacity 
constraints may limit the offer of the surgery policy to all potentially eligible patients.
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Chapter 6 Conclusions
In the report of the first phase of the REFLUX trial1 we concluded that, among the sorts of patients recruited to the trial, laparoscopic fundoplication ‘significantly increases general and reflux related QoL 
measures, at least up to 12 months after surgery’. There was, however, considerable uncertainty about 
cost-effectiveness, largely because the follow-up period was so short. Varying plausible assumptions about 
the longer-term effects of surgery, particularly in terms of QALYs gained and costs of medication, led to 
markedly differing results. This was the basis for this second phase of the trial, in which follow-up has 
been extended out to a time equivalent to 5 years after surgery.
The trial has a pragmatic design and compared two policies for managing GORD, rather than directly 
comparing surgery with PPI therapy. This is the basis for the primary analyses being based on the 
ITT principle as this directly compares the policies. The first policy can be characterised as relatively 
early surgery for most eligible patients but with the option to take medication if considered helpful, 
irrespective of whether or not surgery had been performed. The second policy can be described as 
medical management as appropriate with ‘delayed’ surgery in selected cases. Hence, we have not made 
an assumption that those taking medication after surgery are ‘failures’. In our view, although surgery 
may have improved symptoms, the addition of PPIs may give further improvement and hence should be 
considered to be a component of both policies.
In contrast to the other large randomised trial (the LOTUS trial,48 discussed in Chapter 4), whose primary 
outcome was ‘treatment failure’, we chose patient-reported outcome measures as our primary and main 
secondary outcome measures. The advantage is that they provide a ‘common currency’ across the two 
trial policies and do not depend on clinical judgements (as ‘treatment failures’ do). There is, however, 
a concern that completion of the patient-reported outcome questionnaires may be influenced by the 
nature of the management received. We had a reminder of this in the early stages of our trial. The DMC 
noticed an imbalance in baseline scores of the first few patients randomised, but not in other descriptive 
characteristics. It seemed that this might have been due to completion of the form after the allocation was 
known (although it could still have been due to chance); once it was made a requirement that the form 
had to be filled in before the allocation was known, however, this discrepancy disappeared. We believe 
that a strength of the long-tem follow-up as reported here is that, as the time from the differentiating 
event (surgery or no surgery) gets increasingly long, the possibility of such reporting bias becomes remote. 
Protection was also provided by the partially randomised patient preference design: the randomised 
component was limited to patients who were uncertain which treatment to choose while those who had 
strong views were enrolled into the preference groups.
We designed the trial with the aim of making the management policies as similar as possible to normal 
NHS care. So, for example, a large number of centres were involved (both teaching and non-teaching 
hospitals); recruitment was based on gastroenterologist–upper gastrointestinal surgeon partnerships; 
surgeons chose the type of fundoplication and other aspects of the procedure; after optimisation of 
medical management in secondary care, all subsequent medical care was in general practice; there was 
no requirement for extra tests or hospital visits; and simple entry criteria identified people with chronic 
troublesome GORD symptoms that required anti-reflux medication for reasonable control suitable for 
either policy (average age 46 years). The results should, therefore, be easily generalisable to standard 
NHS care.
The one area in which we think the trial did not ‘mimic’ usual care is in the relatively low proportion of 
those allocated surgery who actually had surgery (62%; see Table 10). There are reasons for thinking that 
the unusual circumstances of a randomised trial comparing medical management with surgery were partly 
responsible for the large proportion who did not have surgery. We think the rate (84%) in the preference 
group is likely to be more indicative of ‘normal’ acceptance rates. For this reason we undertook secondary 
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adjusted treatment received analyses aimed to compensate for this. These analyses are likely to give a 
better estimate of differential effects in usual care, but because they depart from the randomised groups 
and hence may be prone to bias they should be treated with appropriate caution. We also explored 
this issue through post hoc analyses stratified by whether or not those allocated surgery actually had 
fundoplication. This showed (see Figure 18) that those who had surgery had lower baseline REFLUX scores 
(worse symptoms) than those who did not have an operation, but that, following surgery, their scores 
were consistently higher that those who did not have surgery.
Despite our best attempts to retain the cohort of participants there has been some attrition over the 
course of the follow-up period. The response rate of 69% at 5 years can be considered satisfactory in a 
study of this type and is similar to the rate in the LOTUS trial (67%).48 The rate in the REFLUX trial reflects 
the decision among some participants to withdraw, but with high levels of return among those remaining. 
Responders did differ from non-responders but we used analysis techniques to make the most of the 
available data (repeated measures and imputation), and the responders in the two randomised groups 
were generally reassuringly similar in respect of baseline characteristics.
The new results provide clear evidence of a sustained greater improvement in GORD-related QoL in the 
group randomised to surgery. The results also suggest sustained benefit in respect of generic health-related 
measures of QoL, although the differences attenuate over time and are not statistically significant at 
5 years. In these respects the REFLUX trial is in line with the results of the other three randomised trials 
that have compared laparoscopic surgery with medical management. The worse the symptoms at entry 
(the lower the score at baseline), the greater are the benefits of surgery.
By 5 years, 24 (13%) of the participants randomly allocated to medical management had undergone 
anti-reflux surgery. Exploratory analyses (see Figure 19) showed that, as a group, these 24 had low REFLUX 
questionnaire scores (worse symptoms) at trial entry, which subsequently improved markedly after surgery. 
Hence, this group is at least a contributory factor to the narrowing of differences between the randomised 
groups over time (see, in particular, Figures 3 and 17) and a reason for thinking that the ITT-based analyses 
comparing the two management policies are likely to underestimate the effects of surgery.
The follow-up has clarified the rates of longer-term use of PPI medication in both policies. In the 
randomised medical group, 87% were taking medication at 1 year, falling gradually to 82% at 5 years (see 
Figure 2). The equivalent figures in the randomised surgery group were 36% at 1 year (15% among those 
who had surgery) and 41% (26%) at 5 years. This was in response to a question that, to avoid problems 
with recall, asked just about the preceding 2 weeks (rather than the full year), and we have assumed that 
the 2 weeks are typical of the previous year. We know, however, that medication use is sometimes dynamic 
– that patients stop and start. This is apparent in Table 13, for example: among those in the medical group 
who were not taking medication at the end of the first year, 13 (68%) of the 19 respondents reported that 
they were taking PPIs at 5 years.
Short-term complications of surgery were described in more detail in the first report of this trial. However, 
the REFLUX trial is consistent with the other three trials in this respect, with small numbers having 
associated visceral injuries, postoperative problems and dilatation of the wrap. The longer-term follow-up 
has now clarified the likelihood of further surgery following a fundoplication. Overall, 4% (n = 16) of the 
total 364 in the study who had fundoplication had a subsequent reflux-related operation, of whom two 
had a further (i.e. third) operation. Reoperation was most often conversion to a different type of wrap 
or a reconstruction of the same wrap. There were only two cases of reversal of the fundoplication and 
neither was in the randomised comparison. In total, 3% (n = 12) of those who had fundoplication required 
surgical treatment for a complication directly related to the original surgery, including oesophageal 
dilatation (n = 4) and repair of incisional hernia (n = 3). As described in Chapter 4, although it is not 
possible to extract exactly comparable data, these results are broadly in line with those of the other trials.
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Where the REFLUX trial results do differ from the results of the other trials, especially the LOTUS trial, is 
in the likelihood and extent of adverse symptoms associated with fundoplication. Dysphagia, flatulence 
and bloating, and inability to vomit despite wanting to have all been reported to be problematical after 
fundoplication. However, in the REFLUX trial, the patterns of difficulty swallowing, flatulence and wanting 
to vomit but being physically unable to do so were similar in the two randomised groups (see Table 15), 
with no statistically significant differences.
The economic analysis of the 5-year data from the REFLUX trial had two phases. First, a within-trial 5-year 
cost-effectiveness analysis was undertaken; this was followed by an exploration of the need to develop a 
longer-term model. Differences in mean costs and mean QALYs at 5 years were used to derive an estimate 
of relative cost-effectiveness. The base-case approach used multiple imputation (principally because of 
the extent of missing data), an ITT analysis and adjustment for baseline QALYs. As described in Chapter 5, 
complete-case and PP analyses were also undertaken, as were a range of structural, scenario and 
probabilistic sensitivity analyses. Costs were estimated from a health-care perspective and consideration 
was limited to randomised trial participants. Costs for each participant were calculated by multiplying 
their use of health-care resources by associated unit costs and were discounted at an annual rate of 3.5%. 
HRQoL was calculated from serial EQ-5D measurements. The mean (SD) costs in the first year were £2501 
(£1698) in the surgical group compared with £560 (£1007) in the medical group; in each subsequent 
year the mean costs were around £175 higher in the medical group. The estimated incremental mean 
cost of the surgical policy was £1518 (95% CI £1006 to £2029) with incremental mean QALYs of 0.2160 
(95% CI 0.0205 to 0.4115), giving an ICER of £7028. The probability of the surgical policy being the 
more cost-effective was 0.93 at a threshold of £20,000 per QALY and 0.96 at a threshold of £30,000 
per QALY. The complete-case analysis gave similar results and the conclusions were robust to plausible 
changes in assumptions, the only exception being when surgery-allocated patients with missing data were 
assumed to experience lower HRQoL than other patients. A regression-based mixed-model approach was 
then used to explore the robustness of the findings and to gauge the likelihood that the current strong 
evidence for cost-effectiveness might be reversed over subsequent years. The regression-based model gave 
very similar results to the base-case imputation approach. Given the trends in both costs and benefits, it 
was concluded that it was highly unlikely that the cost-effectiveness of surgery would be reversed when 
extrapolated beyond 5 years.
Thus, this second phase of the REFLUX trial has accomplished what it set out to do. After 5 years’ 
follow-up, a policy of relatively early laparoscopic fundoplication among patients for whom reasonable 
control of GORD symptoms requires long-term medication and for whom both surgery and medical 
management are suitable continues to provide better relief of GORD symptoms with associated better QoL. 
Although surgery carries risks, complications were rare. And despite being initially more costly, a surgical 
policy was found to be highly likely to be cost-effective for such patients at conventional threshold costs 
per QALY.
Implications for health care
Extending the use of laparoscopic fundoplication to people whose GORD symptoms require long-term 
medication for reasonable control and who would be suitable for surgery would provide health gain that 
extends over a number of years. The longer-term data reported here indicate that this is highly likely to be 
a cost-effective use of resources. The more troublesome the symptoms, the greater the potential benefit 
from surgery.
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Recommendations for research
The practical implications for health services of any extension of the use of laparoscopic fundoplication 
depend on how many patients might seek such surgery as a consequence. Most patients taking anti-reflux 
medication are managed in general practice. Currently, it is uncertain how many people require long-term 
medication for reasonable control of their GORD symptoms, how many of these would be suitable for 
surgery and how many would seek it; hence, it is not clear what the most efficient provision of future care 
might be. We therefore recommend further research to address these issues and explore the practical and 
resource implications of alternative policies for laparoscopic fundoplication, which include extending its 
use within the NHS to the sorts of patients enrolled in the REFLUX trial.
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Appendix 1 Annual questionnaire
 
 
  
 
 
(for completion by co-ordinating 
 centre in Aberdeen) 
 
 
 
 
 
 
 
ANNUAL FOLLOW-UP QUESTIONNAIRE 
 
 
 
A questionnaire for people participating in the REFLUX trial,  
which aims to find out whether taking medication or having an operation  
is the best form of treatment for gastro-oesophageal reflux disease 
 
 
 
 
 
CONFIDENTIAL 
 
 
This study is funded by the NHS Research and Development Health Technology Assessment 
Programme 
Participant Study No       
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PLEASE READ ALL THE INSTRUCTIONS BEFORE COMPLETING THE 
QUESTIONNAIRE 
 
Thank you for agreeing to take part in the study.  The responses you give in this 
questionnaire will help us find out if the treatments you get are helpful for your condition. 
 
The information you provide will be completely confidential.  
 
 
 
HOW TO FILL IN THE QUESTIONNAIRE 
 
For each section please put a cross in the appropriate box like this: 
 
	  
Do you drive a car?	   	   	   Yes	   	   	   	  
	   	   	   	   	   	  
	   	   	   	   	   No	  
	  
 
 
If you make any errors while completing this questionnaire, shade out the incorrect box completely and put a 
cross in the correct box like this: 
 
 
Do you drive a car? 	   	   Yes	   	   	   	  
	   	   	   	   	   	  
	   	   	   	   	   No	  
 
 
The intended answer above is No.   
	  
PLEASE USE A BLUE OR BLACK PEN TO FILL IN YOUR ANSWERS 
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REFLUX QUESTIONNAIRE 
 
For the questions in section A - F, please put a cross in the box which best describes how often your 
symptoms have occurred and the effect they have had on your quality of life. 
 
 
SECTION A - HEARTBURN 
 
 
A1. In the last two weeks, how often have you experienced heartburn (a burning sensation which 
moves up from your chest to your throat)? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Everyday 
 
A2. In the last two weeks, how often have you experienced any discomfort or pain in your chest? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
  Everyday 
 
A3. In the last two weeks, how much has the heartburn or discomfort/pain in your chest affected 
your quality of life? 
 Not at all 
 A little 
 Moderately 
 A lot                                                                                                                                         
 Extremely 
 
	   Participant Study No 
        
              
      (for completion by co-ordinating  
                centre in Aberdeen) 
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SECTION B - ACID REFLUX 
 
 
 
B1. In the last two weeks, how often have you experienced acid reflux and/or had an acid taste in 
 your mouth? 
 
           Not at all 
                  Once a week 
 Two or three times a week 
 Most days 
 Everyday 
  
B2. In the last two weeks, how often have you been sick (vomited)? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Everyday 
  
 B3.      In the last two weeks, how often have you regurgitated (brought up) quantities of liquid                                               
 or solids into your mouth? 
 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Everyday 
 
B4. In the last two weeks, how often have you experienced a feeling of nausea (without actually 
 being sick or regurgitating)? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Everyday 
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B5. In the last two weeks, how often have you wanted to be sick but physically been unable to? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Everyday 
  
 
B6. In the last two weeks, how much have these acid reflux symptoms affected your quality of 
life? 
 
 Not at all 
 A little 
 Moderately 
 A lot 
 Extremely  
 
SECTION C – WIND 
 
 
 
C1. In the last two weeks, how often have you experienced a lot of wind from the lower bowel? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Everyday  
 
C2. In the last two weeks, how often have you experienced a lot of burping/belching? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Everyday  
  
 
	   Participant Study No 
        
              
      (for completion by co-ordinating  
                centre in Aberdeen) 
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C3. In the last two weeks, how often have you experienced bloatedness and/or a feeling of 
trapped wind, in your stomach? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Everyday 
C4. In the last two weeks, how often have you experienced loud gurgling noises from your 
 stomach? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Everyday 
  
 
C5. In the last two weeks, how much have these wind problems affected your quality of life? 
 
 Not at all 
 A little 
 Moderately 
 A lot 
 Extremely  
 
 
 
SECTION D - EATING AND SWALLOWING 
 
 
 
D1. In the last two weeks, how often have you experienced difficulty swallowing food or have you 
actually choked on food? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Everyday 
 
	   Participant Study No 
        
              
     (for completion by co-ordinating  
                centre in Aberdeen) 
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D2. In the last two weeks, how often have your eating habits been restricted because of your 
condition?  Examples might be eating more slowly, having smaller portions or eating 
different foods. 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Everyday 
  
 
D3. In the last two weeks, how much have these problems with eating affected your quality of 
life?   
 
 Not at all 
 A little 
 Moderately 
 A lot 
 Extremely  
 
SECTION E – BOWEL MOVEMENTS 
 
  
E1. In the last two weeks, how often have you experienced diarrhoea and/or loose               
stools? 
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Everyday 
  
E2. In the last two weeks, how often have you experienced constipation and/or hard stools? 
 
 Not at all   
 Once a week 
 Two or three times a week 
 Most days 
 Everyday 
  
	   Participant Study No 
        
              
      (for completion by co-ordinating  
                centre in Aberdeen) 
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E3.  In the last two weeks, how often have you had a feeling of an urgent need to have a bowel 
movement?       
 
 Not at all 
 Once a week 
 Two or three times a week 
 Most days 
 Everyday 
  
 
E4. In the last two weeks, how often have you had a feeling of not emptying your bowels? 
 
 
 Not at all
 Once a week 
 Two or three times a week 
 Most days 
 Everyday 
  
 
E5.  In the last two weeks, how much have these bowel problems affected your quality of life? 
 
 Not at all 
 A little 
 Moderately 
 A lot 
 Extremely 
 
SECTION F – SLEEP 
 
 
 
F1. In the last two weeks, how often have you experienced difficulty in lying down to sleep? 
 
           Not at all  
             Once a week 
Two or three times a week 
 Most nights 
 Every night 
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F2. In the last two weeks, how often have you experienced difficulty getting to sleep because of 
your reflux symptoms? 
 
               Not at all 
                  Once a week 
 Two or three times a week 
 Most nights 
 Every night 
 
F3.    In the last two weeks, how often have you been woken up because of your reflux symptoms? 
 
 
 Not at all   
 Once a week 
 Two or three times a week 
 Most nights 
 Every night 
  
 
F4. In the last two weeks, how much have these sleep related problems affected your quality of 
life?                
 
   
 Not at all 
 A little 
 Moderately 
 A lot 
 Extremely 
 
 
 
 
 
 
 
	   Participant Study No 
        
              
     (for completion by co-ordinating  
                centre in Aberdeen) 
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SECTION G – WORK, PHYSICAL AND SOCIAL ACTIVITIES 
 
 
For the following section, please put a cross in the box which best applies to you. 
 
 
G1. In the last two weeks, have your reflux symptoms affected you at work (paid or voluntary)? 
 
 Not applicable (I do not do paid or voluntary work)  
 No, my symptoms do not affect me 
 Yes, my symptoms have affected me but I still work 
 Yes, I have worked less often because of my symptoms 
 Yes, I have not worked in the last two weeks because of my symptoms  
                                                                                             I no longer work because of my symptoms	  
 
 
 
G2. In the last two weeks, have your reflux symptoms affected your ability to perform less 
strenuous activities (such as going for a gentle walk, shopping or housework)? 
 
 
 Not applicable (I do not perform these activities, though this is not due to my reflux symptoms) 
  
                No, my symptoms do not affect me 
  
            Yes, my symptoms have affected me but I still perform these activities as often as ever 
  Yes, I perform these activities less often because of my symptoms  
 Yes, I have not performed these activities in the last two weeks  
                                       I no longer perform these activities at all because of my symptoms 
 
 
 
G3. In the last two weeks, have your reflux symptoms affected your ability to perform strenuous 
activities (such as brisk walking or swimming)? 
 
 
 Not applicable (I do not perform these activities, though this is not due to my reflux symptoms) 
 
                                                                                                      No, my symptoms do not affect me 
 
              Yes, my symptoms have affected me but I still perform these activities as often as ever  
                                                 Yes, I perform these activities less often because of my symptoms   
                                                     Yes, I have not performed these activities in the last two weeks   
                                          I no longer perform these activities at all because of my symptoms 
 
	   Participant Study No 
        
              
      (for completion by co-ordinating  
                centre in Aberdeen) 
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G4. In the last two weeks, have you found that your reflux symptoms have affected any of your 
social activities (such as going out for meals, going out for drinks or socializing with other 
people)?   
 
            Not applicable (I do not perform these activities, though this is not due to my reflux symptoms) 
 
                                                                                              No, my symptoms do not affect me 
 Yes, my symptoms have affected me but I still perform these activities as often as ever 
 Yes, I perform these activities less often because of my symptoms 
 Yes, I have not performed these activities in the last two weeks 
    I no longer perform these activities at all because of my symptoms  
 
 
G5. In the last two weeks, how much has the effect of your reflux symptoms on your work, 
physical or social activities affected your quality of life?   
 
 Not at all 
 A little 
 Moderately 
 A lot 
 Extremely 
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SECTION H – DESCRIBING YOUR OWN HEALTH TODAY 
 
 
By placing a cross in one box in each group below, please indicate which statements best describe 
your own health state today 
 
 
Mobility I have no problems in walking about 
                                                                                      I have some problems in walking about 
                               I am confined to bed 
 
 
Self-care                                                                               I have no problems with self-care 
   I have some problems washing or dressing myself 
                                 I am unable to wash or dress myself 
 
 
Usual Activities I have no problems with performing my usual activities 
(e.g. work, study, 
housework, family or  I have some problems with performing my usual activities 
leisure activities) 
                      I am unable to perform my usual activities 
             
          
Pain/Discomfort I have no pain or discomfort 
                          I have moderate pain or discomfort 
                                    I have extreme pain or discomfort 
 
 
Anxiety/Depression I am not anxious or depressed 
                     I am moderately anxious or depressed 
                       I am extremely anxious or depressed 
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SECTION H -  DESCRIBING YOUR OWN HEALTH TODAY 
 
 
 
Please indicate on this scale     
how good or bad your own health  
state is today. 
 
The best health state you can 
imagine is marked 100 and the 
worst health state you can imagine 
is marked 0. 
  
Please draw a line from the box below 
to the point on the scale that best 
indicates how good or bad your health 
           state is today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Your own 
health state 
today 
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SECTION I – GENERAL HEALTH 
 
Please fill in all the questions again by putting a cross in the relevant box of the answer that applies 
to you. 
 
These questions ask for your views about your health and how you feel about life in general.  Do not 
spend too much time in answering as your immediate response is likely to be the most accurate. 
 
1. In general, would you say your health is: 
  
 Excellent    Very good   Good Fair Poor  
  
 
 
 
2. Compared to one year ago, how would you rate your health in general now?  
 
         Much better Somewhat better About the               Somewhat  Much worse 
       now than one now than one same as one worse now than now than one 
     year ago      year ago year ago    one year ago   year ago 
 
 
 
 
3. The following questions are about activities you might do during a typical day.  Does                          
           your health now limit you in these activities?  If so, how much? 
 
                                                                                       Yes  Yes       No, not
    limited      limited    limited 
    a lot        a little        at all 
   
 a) Vigorous activities, such as running, lifting heavy objects, 
 participating in strenuous sport 
 
 b) Moderate activities, such as moving a table, pushing   
      a vacuum cleaner, bowling or playing golf 
 c) Lifting or carrying groceries 
 d) Climbing several flights of stairs  
      e) Climbing one flight of stairs 
       f) Bending, kneeling or stooping 
      g) Walking more than one mile 
      h) Walking several hundred yards 
       i) Walking one hundred yards 
j) Bathing or dressing yourself 
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4.  During the past 4 weeks, how much of the time have you had any of the following problems with 
your work or other regular daily activities as a result of your physical health? 
 
    All of       Most of     Some of    A little of  None of  
  the time    the time     the time   the time  the time 
   
a) Cut down on the amount of time you spent 
on work or other activities 
 
b) Accomplished less than you would like 
  
c) Were limited in the kind of work or other 
activities 
 
d) Had difficulty performing the work or other 
activities (for example, it took extra effort) 
 
 
 
 
 
5. During the past 4 weeks, how much of the time have you had any of the following problems with 
your work or other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)? 
 
    All of Most of   Some of    A little of  None of  
  the time the time   the time the time  the time 
   
a) Cut down on the amount of time you spent 
on work or other activities 
 
b) Accomplished less than you would like 
 
c) Did work or other activities less  
carefully than usual  
 
  
 
 
 
6.    During the past 4 weeks, to what extent has your physical health or emotional problems 
 interfered with your normal social activities with the family, friends, neighbours, or groups? 
 
             Not at all           Slightly Moderately  Quite a bit         Extremely 
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7. How much bodily pain have you had during the past 4 weeks? 
  
               None  Very mild  Mild      Moderate   Severe   Very severe 
  
 
 
 
 
8. During the past 4 weeks, how much did pain interfere with your normal work (including 
both outside the home and housework)? 
  
             Not at all  A little bit  Moderately Quite a bit            Extremely    
  
 
 
 
 
9. These questions are about how you feel and how things have been with you during the past 
4 weeks.  For each question, please give the one answer that comes closest to the way you 
have been feeling.  How much of the time during the past 4 weeks… 
 
 
    All of Most of    Some of A little of   None of  
  the time the time    the time   the time   the time 
   
a) Did you feel full of life?   
 
b) Have you been very nervous? 
 
c) Have you felt so down in the dumps that   
 nothing could cheer you up? 
 
 
d) Have you felt calm and peaceful? 
 
e) Did you have a lot of energy? 
 
f) Have you felt downhearted and depressed?  
  
  
    g) Did you feel worn out?   
   
h) Have you been happy? 
 
i) Did you feel tired? 
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10. During the past 4 weeks, how much of the time has your physical health or emotional     
 problems interfered with your social activities? 
  
  All of the   Most of the  Some of the      A little of the None of the 
     time        time        time       time       time 
  
 
 
 
 
11. How TRUE or FALSE is each of the following statements for you? 
 
  Definitely    Mostly  Don’t     Mostly    Definitely
       true       true  know  false      false 
   
a)  I seem to get sick a little easier than other 
   people 
 
b)    I am as healthy as anybody I know 
  
c)  I expect my health to get worse 
 
d) My health is excellent 
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SECTION J - HEALTH CARE RELATED QUESTIONS 
 
 
In the following questions, we are trying to find out about some of the costs you incurred over the 
last 12 MONTHS as a result of your health problems. 
 
If you are not sure or cannot remember exact details, please give the best answer you can. 
 
 
1. CURRENT EMPLOYMENT   
 
Please tick the box, which best describes your current employment status. 
 
                               Full time employment                                                         Housework  
 
                              Part time employment                                                     Seeking work  
 
                                                    Student                                                                  Other  
 
                                                     Retired    
 
 
 
2.   TIME AWAY FROM WORK, DUE TO ILLNESS 
  
If you are in paid employment, how many days off work have you had in the past  
12 MONTHS because of health problems? 
 
 
 
3.  VISITS TO NHS HEALTH CARE FACILITIES  
 
a) How many times in the past 12 MONTHS have you personally visited your GP?  Do not include 
visits made on behalf of others, or if you are a woman attending routine visits because of your 
pregnancy.   
 
  Total number    Visits because of your reflux 
                of visits    symptoms 
    
 
b) How many times in the past 12 MONTHS have you personally had a visit from your GP?  
 
  Total number   Visits because of your reflux    
  of visits    symptoms 
 
  
      Days in total    Days because of reflux symptoms 
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Please give details of the visits that you have had TO or FROM your GP in the spaces below 
(continue on a separate sheet if necessary). 
 
 
Visit 1       
       
Date of visit Month   Year 2 0         
     Reason for visit   
 
 
 
 
    
 
 
      
Visit 2       
Date of visit Month   Year 2 0         
              Reason for visit  
 
 
 
 
    
 
 
      
Visit 3       
       Date of visit Month   Year 2 0         
       Reason for visit  
 
 
 
 
    
 
 
      
Visit 4       
       Date of visit Month   Year 2 0         
       Reason for visit  
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c) How many times in the past 12 MONTHS have you personally had to attend the outpatients or 
casualty department of a hospital? 
 
 
 
Total number     Visits because of your reflux symptoms    
of visits 
 
d) How many times in the past 12 MONTHS have you personally been admitted to a hospital as a 
day case (do not stay overnight)? 
 
 
	  
Total number of     Admissions because of  
 day case admissions    your reflux symptoms 
 
 
Please give details of the day case admissions you have had and approximate date, in the spaces below 
(continue on a separate sheet if necessary).  
 
Admission 1   
    Date of admission Day   Month   Year 2 0    
    Reason for day case admission  
 
 
 
 
       
Admission 2       
       Date of admission Day   Month   Year 2 0    
       Reason for day case admission  
 
 
 
 
       
Admission 3      
       Date of admission Day   Month   Year 2 0    
       Reason for day case admission  
 
 
 
 
       
Admission 4       
       Date of admission Day   Month   Year 2 0    
       Reason for day case admission  
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e) How many times in the past 12 MONTHS have you personally been admitted to a hospital for 
treatment as an inpatient (overnight or longer)? 
 
 
 
	  Total number of     Admissions because of  
 inpatient admissions    your reflux symptoms 
	  	  
Please give details of the inpatient stays you have had, in the spaces below. 
(continue on a separate sheet if necessary) 
 
Admission 1     
Date of admission Day   Month   Year 2 0    
 Number of nights      
       Reason for admission and 
details of any procedures 
 
 
 
 
 
       
Admission 2      
Date of admission Day   Month   Year 2 0    
 Number of nights      
       Reason for admission and 
details of any procedures 
 
 
 
 
 
       
Admission 3      
Date of admission Day   Month   Year 2 0    
 Number of nights      
       Reason for admission and 
details of any procedures 
 
 
 
 
 
       
Admission 4      
Date of admission Day   Month   Year 2 0    
 Number of nights      
       Reason for admission and 
details of any procedures 
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4.   PRESCRIBED MEDICATION FOR REFLUX 
 
 
 Are you currently being PRESCRIBED medication for reflux symptoms? 
 
   YES NO    If NO, please go to question 5 on 
               page 29 
    
  
 
If YES, please put a cross in the box against the current dose you are being prescribed 
and write in the number of tablets you have taken in the last two weeks.   
 
(Please note the dose can be found on the side of your tablet bottle or packet) 
 
 
 
              Number of tablets  
                           taken in the last  
                   Dose (mg)                            2 weeks  
 
Omeprazole (Losec) 10mg 20mg         40mg 
 
Lansoprazole (Zoton) 15mg 30mg 
 
Pantoprazole (Protium) 20mg 40mg       
 
Rabeprazole (Pariet) 10mg 20mg 
 
Esomeprazole (Nexium) 20mg 40mg 
 
Ranitidine (Zantac) 150mg            300mg 
 
Famotidine (Pepcid)   20mg  40mg 
 
Nizatidine (Axid) 150mg              300mg 
 
Cimetidine (Tagamet) 400mg              800mg 
  
Domperidone (Motilium)                10mg               20mg 
  
Metoclopramide (Maxolon)                 10mg  20mg 
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If you are prescribed any other medication (tablets or liquid) for your reflux symptoms that 
are not listed above, please list below the name(s) of the medicine(s) and include the 
number of times you have taken it in the last two weeks.  
   
          Number of times 
Names of medication    taken in last 2 weeks        
 
e.g. Gaviscon 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.  NON PRESCRIBED MEDICATION FOR REFLUX 
 
Please list below the names of any NON PRESCRIBED (over the counter) medication 
(tablets/liquid) you take for your REFLUX symptoms and include the number of times you 
have taken it in the last two weeks. 
 
            Number of times 
Names of medication       taken in last 2 weeks  
 
e.g. Rennies 
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IF YOU HAVE ANY OTHER COMMENTS about your gastro-oesophageal reflux 
symptoms, your reflux treatment or this study, please write them below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
THANK YOU FOR YOUR HELP IN COMPLETING 
THIS QUESTIONNAIRE 
 
 
 
 
 
 
 
	  
Once you have completed the form, please return it in the pre-paid envelope provided 
or to the following address: 
 
 
REFLUX Trial Office 
Health Services Research Unit  
 Polwarth Building 
Foresterhill 
 Aberdeen AB25 2ZD 
Tel: 01224 XXXXXX 
Fax: 01224 XXXXXX 
  E-mail: reflux@hsru.abdn.ac.uk 
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Appendix 2 Intra- and postoperative surgical 
outcomes
TABLE 40 Intra- and post-operative surgical outcomes
Surgical outcome
Surgical participants, n (%)
Randomised (n = 111) Preference (n = 218)
Conversion 2 (1.8) 0 (0.0)
Liver injury 1 (0.9) 1 (0.5)
Splenic injury 0 (0.0) 1 (0.5)
Pleural injury 1 (0.9) 2 (0.9)
Oesophageal injury 0 (0.0) 0 (0.0)
Other visceral injury 0 (0.0) 0 (0.0)
Haemorrhage 1 (0.9) 1 (0.5)
Pneumothorax 0 (0.0) 2 (0.9)
Blood transfusion 0 (0.0) 1 (0.5)a
Other postoperative event 3 (2.7) 5 (2.3)
ICU admission 0 (0.0) 0 (0.0)
HDU admission 1 (0.9) 2 (0.9)
Reoperation within 12 months 0 (0.0) 3 (1.4)
Stricture dilatation or food disimpaction required within 
12 months
1 (0.9) 2 (0.9)
Discharged status
Home 107 (96.4) 213 (97.7)
Other 4 (3.6) 5 (2.3)
Length of stay (days), median (IQR) 2 (2–3) 2 (2–3)
HDU, high-dependency unit; ICU, intensive-care unit; IQR, interquartile range.
a Participant was transfused with three units.
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Appendix 3 Tables showing medication use in 
preceding fortnight at each time point of follow-up
TABLE 41 Follow-up at the time point equivalent to 3 months after surgery: medications
Medication
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT PP ITT PP ITT PP ITT PP
Number randomised/allocated 178 111 179 169 261 218 192 189
Number of responders 150 109 158 150 230 203 182 178
PPIs, n (%)a
Any PPI 47  
(31.3)
8  
(7.3)
140  
(88.6)
133  
(88.7)
41  
(17.8)
13  
(6.4)
167  
(91.8)
152  
(84.9)
Omeprazole 16  
(10.7)
5  
(4.6)
45  
(28.5)
45  
(30.0)
15  
(6.5)
3  
(1.5)
57  
(31.3)
57  
(31.8)
Lansoprazole 19  
(12.7)
3  
(2.8)
55  
(34.8)
54  
(36.0)
13  
(5.7)
7  
(3.5)
67  
(36.8)
64  
(35.8)
Pantoprazole 1 (0.7) 0 (0.0) 9 (5.7) 8 (5.3) 3 (1.3) 2 (1.0) 14 (7.7) 14 (7.8)
Rabeprazole 4 (2.7) 1 (0.9) 9 (5.7) 9 (6.0) 3 (1.3) 0 (0.0) 13 (7.1) 13 (7.3)
Esomeprazole 7  
(4.7)
1  
(0.9)
22  
(13.9)
21  
(14.0)
7  
(3.0)
3  
(1.5)
21  
(11.5)
21  
(11.7)
H2RAs, n (%)
a
Any H2RA 1 (0.7) 0 (0.0) 12 (7.6) 10 (6.7) 4 (1.7) 2 (1.0) 14 (7.7) 13 (7.3)
Ranitidine 0 (0.0) 0 (0.0) 8 (5.1) 8 (5.3) 2 (0.9) 1 (0.5) 10 (5.5) 9 (5.0)
Famotidine 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.6)
Cimetidine 1 (0.7) 0 (0.0) 1 (0.6) 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Nizatidine 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.6)
Over-the-counter H2RA 0 (0.0) 0 (0.0) 4 (2.5) 4 (2.7) 2 (0.9) 1 (0.5) 3 (1.7) 3 (1.7)
Prokinetics, n (%)a
Any prokinetic 7 (4.7) 3 (2.8) 6 (3.8) 5 (3.3) 7 (3.0) 6 (3.0) 5 (2.7) 4 (2.2)
Domperidone 3 (2.0) 1 (0.9) 6 (3.8) 5 (3.3) 3 (1.3) 2 (1.0) 4 (2.2) 3 (1.7)
Metoclopramide 4 (2.7) 2 (1.8) 0 (0.0) 0 (0.0) 4 (1.7) 4 (2.0) 1 (0.5) 1 (0.6)
Any reflux-related drug, n (%)a 50  
(33.3)
10  
(9.2)
146  
(92.4)
139  
(92.7)
45  
(19.6)
17  
(8.4)
176  
(96.7)
161  
(89.9)
Other prescribed drugs, nb
Alginates 0 0 4 4 0 0 2 2
Antispasmodics (e.g. 
dicycloverine)
0 0 1 1 2 2 0 0
Chelates (e.g. sucralfate) 0 0 0 0 0 0 0 0
continued
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Medication
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT PP ITT PP ITT PP ITT PP
Other ulcer-healing drugs 0 0 0 0 0 0 0 0
Mucogel 0 0 0 0 0 0 1 1
Asilone 0 0 0 0 0 0 0 0
Non-gastrointestinal 1 1 0 0 2 1 1 1
Anti-motility 0 0 0 0 1 1 0 0
a Percentage is for responders completing the relevant section of the questionnaire.
b More than one prescription per person possible.
TABLE 41 Follow-up at the time point equivalent to 3 months after surgery: medications (continued)
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TABLE 42 Follow-up at the time point equivalent to 12 months after surgery: medications
Medication
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT PP ITT PP ITT PP ITT PP
Number randomised/allocated 178 111 179 169 261 218 192 189
Number of responders 154 104 164 155 230 202 177 174
PPIs, n (%)a
Any PPI 56  
(36.4)
13  
(12.5)
142  
(86.6)
139  
(89.7)
42  
(18.3)
19  
(9.4)
156  
(88.1)
154  
(88.5)
Omeprazole 19  
(12.3)
6  
(5.8)
47  
(28.7)
45  
(29.0)
14  
(6.1)
4  
(2.0)
61  
(34.5)
60  
(34.5)
Lansoprazole 21  
(13.6)
2  
(1.9)
51  
(31.1)
50  
(32.3)
17  
(7.4)
12  
(5.9)
56  
(31.6)
5  
(31.6)
Pantoprazole 2 (1.3) 1 (1.0) 9 (5.5) 9 (5.8) 3 (1.3) 1 (0.5) 16 (9.0) 16 (9.2)
Rabeprazole 3 (1.9) 1 (1.0) 12 (7.3) 12 (7.7) 2 (0.9) 0 (0.0) 9 (5.1) 9 (5.2)
Esomeprazole 11  
(7.1)
3  
(2.9)
25  
(15.2)
25  
(16.1)
8  
(3.5)
3  
(1.5)
15  
(8.5)
15  
(8.6)
H2RAs, n (%)
a
Any H2RA 4 (2.6) 3 (2.9) 9 (5.5) 9 (5.8) 5 (2.2) 2 (1.0) 13 (7.3) 13 (7.5)
Ranitidine 3 (1.9) 2 (1.9) 7 (4.3) 7 (4.5) 2 (0.9) 0 (0.0) 8 (4.5) 8 (4.6)
Famotidine 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.6)
Cimetidine 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Nizatidine 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Over-the-counter H2RA 1 (0.6) 1 (1.0) 2 (1.2) 2 (1.3) 3 (1.3) 2 (1.0) 5 (2.8) 5 (2.9)
Prokinetics, n (%)a
Any prokinetic 6 (3.9) 2 (1.9) 4 (2.4) 4 (2.6) 5 (2.2) 4 (2.0) 6 (3.4) 5 (2.9)
Domperidone 4 (2.6) 1 (1.0) 4 (2.4) 4 (2.6) 1 (0.4) 0 (0.0) 5 (2.8) 4 (2.3)
Metoclopramide 2 (1.3) 1 (1.0) 0 (0.0) 0 (0.0) 4 (1.7) 4 (2.0) 1 (0.6) 1 (0.6)
Any reflux-related drug, n (%)a 58  
(37.7)
15  
(14.4)
148  
(90.2)
144  
(92.9)
46  
(20.0)
22  
(10.8)
165  
(93.2)
163  
(93.7)
Other prescribed drugs, nb
Alginates 3 0 4 4 1 0 5 5
Antispasmodics (e.g. 
dicycloverine)
1 1 4 4 1 1 1 1
Chelates (e.g. sucralfate) 0 0 0 0 0 0 0 0
Other ulcer- healing drugs 0 0 0 0 0 0 0 0
Mucogel 0 0 1 1 0 0 0 0
Asilone 0 0 0 0 0 0 0 0
Non-gastrointestinal 2 2 6 5 4 4 3 3
Anti-motility 0 0 0 0 0 0 0 0
a Percentage is for responders completing the relevant section of the questionnaire.
b More than one prescription per person possible.
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TABLE 43 Follow-up at the time point equivalent to 2 years after surgery: medications
Medication
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT PP ITT PP ITT PP ITT PP
Number randomised/allocated 178 111 179 169 261 218 192 189
Number of responders 128 86 142 136 203 182 156 153
PPIs, n (%)a
Any PPI 47  
(36.7)
13  
(15.1)
121  
(85.2)
119  
(87.5)
43  
(21.2)
29  
(15.9)
129  
(82.7)
128  
(83.7)
Omeprazole 17 (13.3) 4 (4.7) 43 (30.3) 42 (30.9) 11 (5.4) 8 (4.4) 48 (30.8) 47 (30.7)
Lansoprazole 17 (13.3) 3 (3.5) 39 (27.5) 39 (28.7) 15 (7.4) 13 (7.1) 42 (26.9) 42 (27.5)
Pantoprazole 1 (0.8) 1 (1.2) 6 (4.2) 5 (3.7) 2 (1.0) 1 (0.5) 12 (7.7) 12 (7.8)
Rabeprazole 4 (3.1) 1 (1.2) 12 (8.5) 12 (8.8) 3 (1.5) 0 (0.0) 6 (3.8) 6 (3.9)
Esomeprazole 8 (6.3) 4 (4.7) 20 (14.1) 20 (14.7) 9 (4.4) 5 (2.7) 14 (9.0) 14 (9.2)
H2RAs, n (%)
a
Any H2RA 2 (1.6) 1 (1.2) 5 (3.5) 5 (3.7) 1 (0.5) 0 (0.0) 13 (8.3) 13 (8.5)
Ranitidine 2 (1.6) 1 (1.2) 4 (2.8) 4 (2.9) 1 (0.5) 0 (0.0) 12 (7.7) 12 (7.8)
Famotidine 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.7) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.7)
Cimetidine 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Over-the-counter H2RA 1 (0.8) 0 (0.0) 2 (1.4) 2 (1.5) 2 (1.0) 2 (1.1) 2 (1.3) 2 (1.3)
Prokinetics, n (%)a
Any prokinetic 5 (3.9) 4 (4.7) 7 (4.9) 6 (4.4) 5 (2.5) 3 (1.6) 4 (2.6) 4 (2.6)
Domperidone 5 (3.9) 4 (4.7) 3 (2.1) 3 (2.2) 2 (1.0) 0 (0.0) 3 (1.9) 3 (2.0)
Metoclopramide 0 (0.0) 0 (0.0) 4 (2.8) 3 (2.2) 3 (1.5) 3 (1.6) 1 (0.6) 1 (0.7)
Any reflux-related drug, n (%)a 48  
(37.5)
14  
(16.3)
124  
(87.3)
122  
(89.7)
46  
(22.7)
30  
(16.5)
140  
(89.7)
139  
(90.8)
Other prescribed drugs, nb
Alginates 5 2 4 4 5 3 6 6
Antispasmodics (e.g. 
dicycloverine)
1 1 0 0 0 0 1 1
Chelates (e.g. sucralfate) 0 0 0 0 1 1 0 0
Other ulcer-healing drugs 0 0 0 0 0 0 1 1
Mucogel 1 1 0 0 0 0 0 0
Asilone 0 0 0 0 0 0 0 0
Non-gastrointestinal 1 0 0 0 3 3 5 5
Anti-nausea 0 0 1 1 1 1 0 0
Anti-motility 0 0 0 0 0 0 0 0
Over the counter – not 
prescribed
6 0 8 7 2 1 6 6
a Percentage is for responders completing the relevant section of the questionnaire.
b More than one prescription per person possible.
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TABLE 44 Follow-up at the time point equivalent to 3 years after surgery: medications
Medication
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT PP ITT PP ITT PP ITT PP
Number randomised/allocated 178 111 179 169 261 218 192 189
Number of responders 132 92 134 133 196 175 159 156
PPIs, n (%)a
Any PPI 50  
(37.9)
18  
(19.6)
112  
(83.6)
112  
(84.2)
47  
(24.0)
32  
(18.3)
129  
(81.1)
128  
(82.1)
Omeprazole 19 (14.4) 8 (8.7) 43 (32.1) 43 (32.3) 16 (8.2) 9 (5.1) 51 (32.1) 50 (32.1)
Lansoprazole 13 (9.8) 1 (1.1) 37 (27.6) 37 (27.8) 20 (10.2) 16 (9.1) 45 (28.3) 45 (28.8)
Pantoprazole 3 (2.3) 3 (3.3) 4 (3.0) 4 (3.0) 3 (1.5) 3 (1.7) 10 (6.3) 10 (6.4)
Rabeprazole 5 (3.8) 2 (2.2) 8 (6.0) 8 (6.0) 1 (0.5) 0 (0.0) 6 (3.8) 6 (3.8)
Esomeprazole 8 (6.1) 5 (5.4) 20 (14.9) 20 (15.0) 6 (3.1) 4 (2.3) 12 (7.5) 12 (7.7)
H2RAs, n (%)
a
Any H2RA 2 (1.5) 1 (1.1) 2 (1.5) 2 (1.5) 2 (1.0) 0 (0.0) 10 (6.3) 10 (6.4)
Ranitidine 2 (1.5) 1 (1.1) 2 (1.5) 2 (1.5) 2 (1.0) 0 (0.0) 9 (5.7) 9 (5.8)
Famotidine 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.6) 1 (0.6)
Over-the-counter H2RA 1 (0.8) 0 (0.0) 2 (1.5) 2 (1.5) 6 (3.1) 2 (1.1) 4 (2.5) 2 (1.3)
Prokinetics, n (%)a
Any prokinetic 3 (2.3) 2 (2.2) 6 (4.5) 6 (4.5) 5 (2.6) 2 (1.1) 4 (2.5) 4 (2.6)
Domperidone 2 (1.5) 2 (2.2) 4 (3.0) 4 (3.0) 2 (1.0) 0 (0.0) 3 (1.9) 3 (1.9)
Metoclopramide 1 (0.8) 0 (0.0) 2 (1.5) 2 (1.5) 3 (1.5) 2 (1.1) 1 (0.6) 1 (0.6)
Any reflux-related drug, n (%)a 51  
(38.6)
18  
(19.6)
113  
(84.3)
113  
(85.0)
47  
(24.0)
32  
(18.3)
135  
(84.9)
134  
(85.9)
Other prescribed drugs, nb
Alginates 9 4 12 12 10 3 12 6
Antispasmodics (e.g. 
dicycloverine) 
1 1 1 1 0 0 1 1
Chelates (e.g. sucralfate) 0 0 0 0 1 1 0 0
Other ulcer-healing drugs 0 0 0 0 0 0 1 1
Mucogel 0 0 0 0 1 0 0 0
Asilone 0 0 0 0 0 0 0 0
Non-gastrointestinal 2 2 6 6 1 3 1 5
Anti-nausea 0 0 0 0 0 0 0 0
Anti-motility 0 0 0 0 1 1 0 0
Over the counter – not 
prescribed
0 0 1 1 2 1 2 6
a Percentage is for responders completing the relevant section of the questionnaire.
b More than one prescription per person possible.
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TABLE 45 Follow-up at the time point equivalent to 4 years after surgery: medications
Medication
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT PP ITT PP ITT PP ITT PP
Number randomised/allocated 178 111 179 169 261 218 192 189
Number of responders 126 88 129 127 168 152 142 139
PPIs, n (%)a
Any PPI 52  
(41.3)
21  
(23.9)
104  
(80.6)
104  
(81.9)
42  
(25.0)
30  
(19.7)
118  
(83.1)
117  
(84.2)
Omeprazole 21 (16.7) 6 (6.8) 40 (31.0) 40 (31.5) 17 (10.1) 13 (8.6) 44 (31.0) 43 (30.9)
Lansoprazole 15 (11.9) 6 (6.8) 34 (26.4) 34 (26.8) 16 (9.5) 13 (8.6) 48 (33.8) 48 (34.5)
Pantoprazole 1 (0.8) 1 (1.1) 4 (3.1) 4 (3.1) 1 (0.6) 0 (0.0) 6 (4.2) 6 (4.3)
Rabeprazole 5 (4.0) 2 (2.3) 6 (4.7) 6 (4.7) 2 (1.2) 0 (0.0) 4 (2.8) 4 (2.9)
Esomeprazole 8 (6.3) 6 (6.8) 16 (12.4) 16 (12.6) 3 (1.8) 2 (1.3) 12 (8.5) 12 (8.6)
H2RAs, n (%)
a
Any H2Ra 0 (0.0) 0 (0.0) 1 (0.8) 1 (0.8) 4 (2.4) 1 (0.7) 6 (4.2) 6 (4.3)
Ranitidine 0 (0.0) 0 (0.0) 1 (0.8) 1 (0.8) 4 (2.4) 1 (0.7) 5 (3.5) 5 (3.6)
Famotidine 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.7) 1 (0.7)
Over-the-counter H2RA 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.8) 2 (1.3) 2 (1.4) 2 (1.4)
Prokinetics, n (%)a
Any prokinetic 6 (4.8) 4 (4.5) 8 (6.2) 7 (5.5) 5 (3.0) 3 (2.0) 7 (4.9) 7 (5.0)
Domperidone 5 (4.0) 3 (3.4) 5 (3.9) 4 (3.1) 3 (1.8) 1 (0.7) 6 (4.2) 6 (4.3)
Metoclopramide 1 (0.8) 1 (1.1) 3 (2.3) 2 (1.6) 2 (1.2) 2 (1.3) 1 (0.7) 1 (0.7)
Any reflux-related drug, n (%)a 51  
(40.5)
21  
(23.9)
106  
(82.2)
105  
(82.7)
43  
(25.6)
31  
(20.4)
125  
(88.0)
124  
(89.2)
Other prescribed drugs, nb
Alginates 12 4 11 11 12 9 13 13
Antispasmodics (e.g. 
dicycloverine)
2 2 2 1 0 0 0 0
Chelates (e.g. sucralfate) 0 0 0 0 0 0 0 0
Other ulcer-healing drugs 0 0 0 0 0 0 0 0
Mucogel 0 0 0 0 0 0 0 0
Asilone 1 1 1 1 0 0 1 1
Non-gastrointestinal 4 4 3 1 1 0 0 0
Anti-nausea 0 0 1 1 1 1 0 0
Anti-motility 0 0 0 1 1 1 0 0
Over the counter – not 
prescribed
0 0 0 0 3 2 0 0
a Percentage is for responders completing the relevant section of the questionnaire.
b More than one prescription per person possible.
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TABLE 46 Follow-up at the time point equivalent to 5 years after surgery: medications
Medication
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT PP ITT PP ITT PP ITT PP
Number randomised/allocated 178 111 179 169 261 218 192 189
Number of responders 127 90 119 116 176 158 136 133
PPIs, n (%)a
Any PPI 55  
(43.3)
23  
(25.6)
98  
(82.4)
97  
(83.6)
48  
(27.3)
36  
(22.8)
116  
(85.3)
113  
(85.0)
Omeprazole 24 (18.9) 10 (11.1) 44 (37.0) 43 (37.1) 22 (12.5) 15 (9.5) 48 (35.3) 46 (34.6)
Lansoprazole 16 (12.6) 5 (5.6) 31 (26.1) 31 (26.7) 18 (10.2) 15 (9.5) 45 (33.1) 45 (33.8)
Pantoprazole 1 (0.8) 1 (1.1) 2 (1.7) 2 (1.7) 0 (0.0) 0 (0.0) 7 (5.1) 7 (5.3)
Rabeprazole 3 (2.4) 2 (2.2) 4 (3.4) 4 (3.4) 0 (0.0) 0 (0.0) 2 (1.5) 2 (1.5)
Esomeprazole 9 (7.1) 6 (6.7) 17 (14.3) 17 (14.7) 7 (4.0) 6 (3.8) 12 (8.8) 11 (8.3)
H2RAs, n (%)
a
Any H2RA 0 (0.0) 0 (0.0) 2 (1.7) 2 (1.7) 3 (1.7) 2 (1.3) 6 (4.4) 6 (4.5)
Ranitidine 0 (0.0) 0 (0.0) 1 (0.8) 1 (0.9) 3 (1.7) 2 (1.3) 5 (3.7) 5 (3.8)
Famotidine 0 (0.0) 0 (0.0) 1 (0.8) 1 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Over-the-counter H2RA 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 4 (2.3) 1 (0.6) 4 (2.9) 4 (3.0)
Prokinetics, n (%)a
Any prokinetic 6 (4.7) 5 (5.6) 5 (4.2) 4 (3.4) 8 (4.5) 6 (3.8) 5 (3.7) 4 (3.0)
Domperidone 5 (3.9) 4 (4.4) 4 (3.4) 3 (2.6) 4 (2.3) 2 (1.3) 4 (2.9) 3 (2.3)
Metoclopramide 1 (0.8) 1 (1.1) 2 (1.7) 1 (0.9) 3 (1.7) 3 (1.9) 1 (0.7) 1 (0.8)
Any reflux-related drug, n (%)a 56  
(44.1)
24  
(26.7)
98  
(82.4)
97  
(83.6)
49  
(27.8)
37  
(23.4)
121  
(89.0)
118  
(88.7)
Other prescribed drugs, nb
Alginates 11 3 11 11 12 9 15 15
Antispasmodics (e.g. 
dicycloverine)
1 1 0 0 1 0 1 1
Chelates (e.g. sucralfate) 0 0 0 0 0 0 0 0
Other ulcer-healing drugs 0 0 0 0 0 0 0 0
Mucogel 0 0 0 0 0 0 0 0
Asilone 1 1 0 0 0 0 0 0
Non-gastrointestinal 1 1 3 1 1 0 1 1
Anti-nausea 0 0 0 0 1 0 0 0
Anti-motility 0 0 0 0 1 1 0 0
Over the counter – not 
prescribed
0 0 0 0 2 0 0 0
a Percentage is for responders completing the relevant section of the questionnaire.
b More than one prescription per person possible.
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Appendix 4 Tables showing health status 
measures at each time point of follow-up
TABLE 47 Follow-up at the time point equivalent to 3 months after surgery: health status
Health status measure
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT PP ITT PP ITT PP ITT PP
Number randomised/
allocated
178 111 179 169 261 218 192 189
Number of responders 149 97 157 141 229 186 182 168
REFLUX QoL, mean (SD)a 83.9 
(19.4)
85.9 
(19.0)
70.6 
(24.6)
70.8 
(24.4)
80.4 
(21.6)
82.5 
(20.3)
80.2 
(18.2)
80.6 
(17.7)
REFLUX symptom score, mean (SD)a
General discomfort 
symptom score
84.8 
(17.3)
89.4 
(14.0)
66.9 
(26.2)
66.5 
(26.0)
84.1 
(19.6)
87.2 
(16.6)
75.7 
(19.6)
76.0 
(19.5)
Wind and frequency 
symptom score
58.1 
(19.7)
55.9 
(19.7)
53.7 
(22.6)
54.4 
(22.5)
52.2 
(21.1)
52.6 
(20.7)
60.7 
(22.2)
60.9 
(22.3)
Nausea and vomiting 
symptom score
91.5 
(15.7)
93.1 
(15.7)
82.1 
(20.7)
82.3 
(20.2)
90.2 
(15.2)
91.6 
(13.7)
89.5 
(12.9)
90.0 
(11.9)
Activity limitation 
symptom score
88.2 
(17.0)
89.9 
(16.7)
81.6 
(19.6)
81.9 
(19.0)
88.4 
(18.0)
89.7 
(17.5)
87.9 
(13.2)
88.0 
(13.3)
Constipation and 
swallowing symptom 
score
79.2 
(20.0)
78.7 
(20.7)
75.8 
(20.9)
77.0 
(19.8)
77.1 
(21.2)
76.9 
(21.3)
84.2 
(16.9)
84.6 
(16.5)
SF-36 scores, mean (SD)a
Norm-based physical 
functioning
49.2 
(10.0)
49.3 
(10.4)
46.5 
(11.5)
46.6 
(11.6)
49.9 
(9.7)
50.4 
(9.4)
47.6 
(10.3)
47.5 
(10.4)
Norm-based role physical 47.7 
(11.8)
47.4 
(12.1)
44.8 
(12.1)
45.0 
(12.1)
48.1 
(11.3)
48.7 
(10.7)
47.1 
(10.4)
47.1 
(10.4)
Norm-based bodily pain 48.5 
(10.3)
48.8 
(10.8)
45.3 
(11.4)
45.3 
(11.3)
48.4 
(11.3)
49.0 
(11.2)
46.5 
(10.2)
46.5 
(10.3)
Norm-based general 
health
46.3 
(11.0)
47.4 
(11.0)
40.7 
(11.2)
40.7 
(11.2)
47.2 
(11.3)
48.2 
(11.1)
42.5 
(10.5)
42.6 
(10.4)
Norm-based vitality 47.1 
(11.9)
48.0 
(12.1)
43.9 
(12.4)
44.3 
(12.2)
48.0 
(11.9)
48.4 
(11.9)
44.7 
(11.4)
44.8 
(11.4)
Norm-based social 
functioning
47.2 
(11.5)
47.5 
(12.1)
43.6 
(12.7)
43.8 
(12.6)
46.8 
(12.3)
47.6 
(12.0)
46.9 
(10.5)
46.9 
(10.5)
Norm-based role 
emotional
48.3 
(12.3)
48.4 
(12.5)
43.9 
(14.2)
44.1 
(14.2)
47.0 
(12.6)
48.9 
(11.7)
47.0 
(11.4)
46.9 
(11.4)
Norm-based mental 
health
48.7 
(12.0)
49.7 
(11.9)
44.5 
(12.2)
44.7 
(11.9)
48.3 
(12.2)
49.2 
(11.8)
47.1 
(10.6)
47.1 
(10.7)
EQ-5D, mean (SD)a 0.788 
(0.233)
0.806 
(0.239)
0.689 
(0.301)
0.696 
(0.299)
0.806 
(0.245)
0.817 
(0.240)
0.763 
(0.231)
0.765 
(0.229)
a Mean (SD) based on responders completing relevant section of the questionnaire.
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TABLE 48 Follow-up at the time point equivalent to 12 months after surgery: health status
Health status measure
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT PP ITT PP ITT PP ITT PP
Number randomised/allocated 178 111 179 169 261 218 192 189
Number of responders 154 98 165 149 232 192 181 169
REFLUX QoL, mean (SD)a 84.6 
(17.9)
88.3 
(15.6)
73.4 
(23.3)
73.1 
(23.7)
83.3 
(20.7)
86.0 
(17.9)
79.2 
(19.2)
79.4 
(19.0)
REFLUX symptom score, mean (SD)a
General discomfort symptom 
score
84.7 
(17.5)
90.2 
(14.0)
67.4 
(25.8)
66.7 
(25.8)
85.0 
(19.4)
87.7 
(16.5)
73.9 
(20.7)
74.0 
(20.8)
Wind and frequency symptom 
score
56.7 
(21.0)
56.9 
(21.7)
52.6 
(23.3)
52.7 
(23.5)
56.9 
(22.5)
57.5 
(22.1)
61.4 
(21.9)
61.5 
(22.0)
Nausea and vomiting 
symptom score
91.9 
(14.4)
94.7 
(11.8)
84.0 
(18.6)
83.3 
(18.8)
91.1 
(16.5)
93.3 
(13.8)
88.6 
(15.4)
88.9 
(14.4)
Activity limitation symptom 
score
90.7 
(12.8)
93.3 
(11.5)
82.2 
(19.2)
81.6 
(19.4)
90.8 
(16.8)
92.4 
(14.8)
87.3 
(14.7)
87.4 
(14.8)
Constipation and swallowing 
symptom score
79.3 
(19.1)
80.2 
(19.6)
74.5 
(22.8)
75.2 
(22.3)
78.5 
(20.2)
79.1 
(19.7)
83.6 
(17.6)
83.8 
(17.4)
SF-36 scores, mean (SD)a
Norm-based physical 
functioning
48.9 
(10.3)
49.6 
(10.3)
47.2 
(11.0)
47.2 
(10.9)
49.7 
(10.8)
50.3 
(10.5)
47.4 
(10.5)
47.4 
(10.6)
Norm-based role physical 46.7 
(11.4)
47.4 
(11.3)
45.8 
(11.8)
46.0 
(11.7)
49.0 
(11.2)
49.6 
(10.5)
46.8 
(10.7)
46.8 
(10.7)
Norm-based bodily pain 47.7 
(10.4)
48.5 
(10.7)
44.5 
(10.9)
44.5 
(10.9)
49.1 
(11.3)
49.9 
(11.1)
47.4 
(9.9)
47.4 
(10.0)
Norm-based general health 45.2 
(11.1)
46.2 
(11.8)
40.7 
(11.2)
40.5 
(11.1)
46.4 
(10.8)
47.2 
(10.6)
42.3 
(10.1)
42.3 
(10.1)
Norm-based vitality 46.9 
(11.5)
47.6 
(11.6)
44.2 
(11.9)
44.4 
(11.7)
47.3 
(12.0)
48.0 
(11.7)
45.1 
(10.3)
45.2 
(10.3)
Norm-based social 
functioning
46.9 
(11.6)
47.8 
(11.7)
45.2 
(12.2)
45.4 
(12.1)
46.9 
(12.5)
47.8 
(12.1)
46.6 
(10.6)
46.6 
(10.6)
Norm-based role emotional 46.4 
(13.5)
47.2 
(12.9)
44.2 
(14.4)
44.4 
(14.2)
47.3 
(13.3)
48.1 
(12.7)
46.2 
(12.0)
46.1 
(12.0)
Norm-based mental health 47.2 
(11.7)
48.5 
(11.6)
46.4 
(12.1)
46.5 
(12.2)
46.9 
(12.0)
47.4 
(12.0)
46.5 
(10.9)
46.6 
(10.9)
EQ-5D, mean (SD)a 0.754 
(0.247)
0.777 
(0.232)
0.709 
(0.272)
0.710 
(0.270)
0.791 
(0.263)
0.803 
(0.252)
0.741 
(0.240)
0.743 
(0.238)
 a Mean (SD) based on responders completing relevant section of the questionnaire.
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TABLE 49 Follow-up at the time point equivalent to 2 years after surgery: health status
Health status measure
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT PP ITT PP ITT PP ITT PP
Number randomised/allocated 178 111 179 169 261 218 192 189
Number of responders 128 86 142 136 203 182 156 153
REFLUX QoL, mean (SD)a 85.5 
(17.3)
89.2 
(15.1)
76.9 
(22.8)
77.0 
(22.9)
85.3 
(19.0)
87.1 
(17.5)
80.4 
(19.1) 
80.5 
(19.1)
REFLUX symptom score, mean (SD)a
General discomfort symptom 
score
83.1 
(18.5)
88.2 
(15.0)
71.8 
(25.4)
71.5 
(25.4)
85.7 
(19.9)
88.2 
(17.1)
75.2 
(19.5)
75.1 
(19.6)
Wind and frequency symptom 
score
57.1 
(20.0)
57.1 
(20.0)
54.9 
(24.1)
55.4 
(24.4)
56.1 
(23.2)
56.9 
(22.5)
61.1 
(21.6)
61.3 
(21.5)
Nausea and vomiting 
symptom score
92.4 
(13.1)
94.3 
(11.6)
86.3 
(18.1)
86.3 
(18.4)
91.9 
(14.6)
93.0 
(13.1)
89.3 
(14.0)
89.5 
(13.4)
Activity limitation symptom 
score
91.2 
(12.1)
93.7 
(10.5)
83.3 
(20.6)
83.6 
(20.2)
92.4 
(14.7)
93.3 
(13.5)
86.8 
(15.6)
86.9 
(15.6)
Constipation and swallowing 
symptom score
80.5 
(19.5)
81.3 
(20.2)
77.6 
(22.5)
77.5 
(22.9)
80.1 
(21.0)
80.7 
(20.7)
81.5 
(17.6)
81.6 
(17.7)
SF-36 scores, mean (SD)a
Norm-based physical 
functioning
48.4 
(9.8)
48.9 
(9.7)
46.7 
(11.3)
47.0 
(11.0)
49.0 
(11.0)
49.6 
(10.2)
46.2 
(11.7)
46.2 
(11.7)
Norm-based role physical 48.6 
(10.6)
49.2 
(10.0)
45.8 
(12.2)
46.0 
(12.0)
49.3 
(10.8)
49.9 
(10.1)
46.1 
(11.1)
45.9 
(11.2)
Norm-based bodily pain 47.6 
(9.3)
48.1 
(8.8)
44.8 
(10.7)
45.1 
(10.6)
47.7 
(10.0)
48.2 
(9.6)
45.7 
(9.1)
45.9 
(9.1)
Norm-based general health 44.6 
(11.1)
45.2 
(11.9)
41.3 
(11.4)
41.3 
(11.3)
46.5 
(10.7)
46.9 
(10.4)
41.6 
(10.4)
41.7 
(10.3)
Norm-based vitality 46.6 
(10.7)
46.9 
(10.9)
43.4 
(11.6)
43.4 
(11.3)
47.1 
(11.6)
47.5 
(11.4)
44.4 
(10.6)
44.4 
(10.5)
Norm-based social 
functioning
47.4 
(11.4)
48.1 
(11.2)
45.3 
(12.0)
45.5 
(11.7)
47.7 
(12.1)
48.1 
(11.8)
46.2 
(11.6)
46.2 
(11.6)
Norm-based role emotional 48.4 
(11.8)
49.0 
(11.6)
45.5 
(14.1)
45.8 
(13.8)
48.9 
(11.8)
49.8 
(10.7)
45.5 
(12.4)
45.3 
(12.4)
Norm-based mental health 47.9 
(11.5)
47.9 
(12.0)
45.6 
(11.7)
45.9 
(11.6)
48.0 
(12.0)
48.8 
(11.5)
45.6 
(10.8)
45.5 
(10.8)
EQ-5D, mean (SD)a 0.762 
(0.272)
0.790 
(0.244)
0.717 
(0.313)
0.721 
(0.308)
0.796 
(0.257)
0.816 
(0.233)
0.736 
(0.235)
0.735 
(0.237)
a Mean (SD) based on responders completing relevant section of the questionnaire.
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TABLE 50 Follow-up at the time point equivalent to 3 years after surgery: health status
Health status measure
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT PP ITT PP ITT PP ITT PP
Number randomised/allocated 178 111 179 169 261 218 192 189
Number of responders 132 92 134 133 196 175 159 156
REFLUX QoL, mean (SD)a 87.0 
(15.0)
88.0 
(15.3)
79.9 
(20.1)
79.7 
(20.1)
85.6 
(18.2)
87.3 
(17.2)
81.9 
(16.4)
81.9 
(16.5)
REFLUX symptom score, mean (SD)a
General discomfort symptom 
score
85.4 
(17.4)
88.4 
(17.1)
74.8 
(23.1)
74.6 
(23.1)
85.7 
(19.6)
87.3 
(18.6)
77.4 
(18.7)
77.2 
(18.7)
Wind and frequency symptom 
score
59.5 
(22.9)
57.9 
(23.6)
56.1 
(25.5)
55.8 
(25.4)
55.3 
(22.5)
55.9 
(22.4)
62.0 
(22.8)
62.1 
(22.7)
Nausea and vomiting 
symptom score
94.0 
(10.2)
95.4 
(9.0)
89.2 
(16.2)
89.1 
(16.2)
92.1 
(14.8)
93.0 
(14.3)
90.3 
(13.4)
90.4 
(13.3)
Activity limitation symptom 
score
91.6 
(13.2)
93.0 
(13.3)
87.6 
(16.7)
87.5 
(16.7)
92.7 
(12.1)
93.6 
(11.6)
88.9 
(12.9)
88.9 
(13.0)
Constipation and swallowing 
symptom score
82.1 
(16.8)
81.1 
(17.0)
79.6 
(20.1)
79.4 
(20.1)
78.4 
(21.7)
78.7 
(21.4)
83.1 
(17.4)
83.3 
(17.4)
SF-36 scores, mean (SD)a
Norm-based physical 
functioning
49.1 
(10.2)
49.8 
(9.9)
47.8 
(11.3)
47.8 
(11.3)
49.3 
(10.6)
49.6 
(10.4)
46.9 
(11.2)
46.9 
(11.3)
Norm-based role physical 48.1 
(10.9)
48.1 
(11.1)
47.0 
(11.4)
46.9 
(11.4)
48.5 
(11.3)
48.9 
(10.9)
46.7 
(11.4)
46.5 
(11.4)
Norm-based bodily pain 47.4 
(9.7)
46.3 
(9.8)
46.3 
(10.3)
46.3 
(10.3)
48.1 
(10.2)
48.6 
(10.0)
46.4 
(9.1)
46.3 
(9.1)
Norm-based general health 45.3 
(10.0)
45.8 
(10.1)
42.4 
(11.8)
42.3 
(11.8)
46.2 
(11.2)
46.6 
(11.1)
41.8 
(10.2)
41.8 
(10.2)
Norm-based vitality 46.0 
(11.5)
46.8 
(11.2)
44.7 
(12.7)
44.6 
(12.7)
47.1 
(11.7)
47.7 
(11.6)
44.5 
(10.3)
44.5 
(10.3)
Norm-based social 
functioning
48.5 
(10.4)
48.7 
(10.6)
46.2 
(11.9)
46.1 
(11.9)
47.6 
(12.4)
47.9 
(12.3)
47.0 
(11.3)
46.9 
(11.3)
Norm-based role emotional 49.6 
(9.9)
49.2 
(10.4)
45.9 
(13.3)
45.8 
(13.4)
48.0 
(12.9)
48.2 
(12.8)
47.0 
(11.8)
46.8 
(11.8)
Norm-based mental health 49.5 
(10.8)
49.7 
(11.0)
46.1 
(12.0)
46.0 
(12.0)
47.9 
(12.0)
48.4 
(11.8)
46.6 
(10.6)
46.5 
(10.6)
EQ-5D, mean (SD)a 0.803 
(0.231)
0.790 
(0.252)
0.747 
(0.262)
0.745 
(0.262)
0.803 
(0.249)
0.805 
(0.251)
0.763 
(0.231)
0.761 
(0.232)
a Mean (SD) based on responders completing relevant section of the questionnaire.
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TABLE 51 Follow-up at the time point equivalent to 4 years after surgery: health status
Health status measure
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT PP ITT PP ITT PP ITT PP
Number randomised/allocated 178 111 179 169 261 218 192 189
Number of responders 126 88 129 127 168 152 142 139
REFLUX QoL, mean (SD)a 85.2 
(18.2)
87.7 
(17.7)
81.1 
(20.7)
81.9 
(19.4)
86.2 
(16.8)
86.9 
(16.3)
83.7 
(17.2)
83.7 
(17.2)
REFLUX symptom score, mean (SD)a
General discomfort symptom 
score
83.1 
(20.8)
87.0 
(20.2)
77.4 
(21.9)
77.5 
(21.8)
85.7 
(19.4)
87.5 
(17.4)
79.2 
(19.7)
79.0 
(19.8)
Wind and frequency symptom 
score
58.1 
(22.1)
57.0 
(23.1)
53.6 
(23.9)
53.2 
(23.7)
55.3 
(23.0)
55.7 
(22.8)
62.4 
(23.4)
62.5 
(23.5)
Nausea and vomiting 
symptom score
91.0 
(16.7)
93.6 
(14.9)
89.2 
(16.4)
89.4 
(16.1)
92.9 
(12.7)
94.0 
(11.3)
91.4 
(11.7)
91.6 
(11.4)
Activity limitation symptom 
score
91.8 
(13.1)
93.6 
(12.4)
87.5 
(17.2)
88.1 
(15.3)
92.1 
(13.7)
92.9 
(12.6)
90.4 
(12.9)
90.4 
(12.9)
Constipation and swallowing 
symptom score
80.4 
(19.4)
79.7 
(20.0)
79.6 
(20.9)
79.8 
(20.6)
79.0 
(21.9)
79.5 
(20.9)
82.8 
(18.1)
82.9 
(18.1)
SF-36 scores, mean (SD)a
Norm-based physical 
functioning
47.9 
(10.1)
48.5 
(10.4)
47.5 
(11.7)
47.7 
(11.4)
49.5 
(10.6)
50.0 
(10.1)
47.2 
(10.4)
47.1 
(10.5)
Norm-based role physical 47.5 
(11.9)
47.1 
(12.4)
46.7 
(12.2)
46.8 
(12.0)
49.4 
(10.6)
49.8 
(10.2)
47.6 
(10.3)
47.5 
(10.4)
Norm-based bodily pain 46.1 
(10.4)
46.4 
(11.0)
46.3 
(10.2)
46.4 
(10.0)
47.8 
(10.1)
48.1 
(10.1)
47.9 
(9.0)
47.9 
(9.0)
Norm-based general health 44.6 
(10.4)
45.5 
(11.0)
42.2 
(11.4)
42.4 
(11.2)
46.5 
(11.2)
47.0 
(10.9)
42.2 
(11.4)
42.1 
(11.5)
Norm-based vitality 44.8 
(10.7)
44.8 
(10.9)
45.6 
(11.7)
45.6 
(11.4)
47.4 
(11.6)
48.1 
(11.5)
45.1 
(11.0)
45.1 
(11.0)
Norm-based social 
functioning
45.6 
(12.7)
45.8 
(12.9)
46.1 
(11.9)
46.3 
(11.6)
48.3 
(11.1)
48.9 
(10.6)
46.7 
(11.3)
46.8 
(11.4)
Norm-based role emotional 48.1 
(12.4)
48.7 
(12.4)
46.5 
(14.1)
46.7 
(13.8)
48.9 
(11.7)
49.4 
(11.3)
47.2 
(11.5)
47.3 
(11.5)
Norm-based mental health 47.5 
(11.8)
49.1 
(11.2)
47.0 
(12.0)
47.2 
(11.6)
48.7 
(11.5)
49.1 
(11.3)
47.3 
(11.2)
47.4 
(11.2)
EQ-5D, mean (SD)a 0.771 
(0.244)
0.778 
(0.264)
0.754 
(0.272)
0.760 
(0.258)
0.806 
(0.254)
0.825 
(0.229)
0.773 
(0.213)
0.773 
(0.215)
a Mean (SD) based on responders completing relevant section of the questionnaire.
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TABLE 52 Follow-up at the time point equivalent to 5 years after surgery: health status
Health status measure
Randomised participants Preference participants
Surgical Medical Surgical Medical
ITT PP ITT PP ITT PP ITT PP
Number randomised/allocated 178 111 179 169 261 218 192 189
Number of responders 127 90 119 116 176 158 136 133
REFLUX QoL, mean (SD)a 86.7 
(13.8)
89.8 
(11.7)
80.7 
(20.3)
80.6 
(20.4)
85.3 
(17.3)
86.2 
(17.1)
84.8 
(15.2)
85.0 
(15.3)
REFLUX symptom score, mean (SD)a
General discomfort symptom 
score
85.0 
(17.5)
89.6 
(14.2)
75.3 
(22.6)
75.0 
(22.7)
85.7 
(19.0)
86.7 
(18.6)
78.8 
(19.2)
78.8 
(19.3)
Wind and frequency symptom 
score
58.8 
(21.8)
58.7 
(22.5)
56.4 
(22.7)
55.8 
(22.5)
54.0 
(23.5)
53.9 
(23.3)
65.3 
(22.2)
65.7 
(22.0)
Nausea and vomiting 
symptom score
92.5 
(12.7)
94.9 
(10.1)
89.6 
(15.1)
89.9 
(14.5)
93.2 
(11.8)
93.8 
(10.8)
92.1 
(11.3)
92.4 
(10.9)
Activity limitation symptom 
score
93.2 
(11.4)
95.3 
(9.5)
87.7 
(18.5)
88.3 
(16.6)
92.6 
(13.6)
93.4 
(13.2)
91.2 
(11.9)
91.3 
(11.9)
Constipation and swallowing 
symptom score
81.2 
(18.7)
81.0 
(18.9)
78.3 
(20.4)
78.8 
(19.8)
80.3 
(19.9)
80.5 
(19.8)
84.3 
(17.9)
84.5 
(18.0)
SF-36 scores, mean (SD)a
Norm-based physical 
functioning
48.4 
(9.6)
48.3 
(9.9)
48.2 
(11.1)
48.4 
(11.0)
49.3 
(10.6)
49.8 
(10.2)
47.0 
(12.0)
46.9 
(12.1)
Norm-based role physical 47.3 
(11.9)
47.3 
(12.4)
47.7 
(11.8)
47.9 
(11.6)
49.7 
(10.1)
50.1 
(9.9)
47.9 
(10.0)
47.8 
(10.0)
Norm-based bodily pain 46.3 
(10.3)
47.3 
(11.1)
46.2 
(10.9)
46.6 
(10.7)
47.9 
(10.5)
48.0 
(10.5)
48.0 
(8.8)
47.9 
(8.9)
Norm-based general health 44.1 
(10.3)
44.9 
(10.6)
43.2 
(11.5)
43.4 
(11.4)
47.0 
(10.8)
47.2 
(10.6)
43.3 
(9.2)
43.2 
(9.3)
Norm-based vitality 45.3 
(11.2)
46.0 
(11.5)
46.4 
(12.0)
46.5 
(12.0)
47.7 
(11.9)
47.8 
(11.9)
45.2 
(10.9)
45.2 
(11.0)
Norm-based social 
functioning
47.4 
(11.7)
48.0 
(12.1)
47.0 
(12.0)
47.3 
(11.7)
48.4 
(11.4)
48.7 
(11.3)
48.2 
(10.4)
48.1 
(10.4)
Norm-based role emotional 48.6 
(11.8)
49.0 
(11.7)
47.5 
(12.6)
47.7 
(12.2)
49.8 
(10.0)
50.1 
(9.7)
48.2 
(10.6)
48.1 
(10.6)
Norm-based mental health 47.7 
(11.9)
48.8 
(11.8)
48.9 
(11.5)
49.2 
(11.2)
49.4 
(11.6)
49.4 
(11.6)
47.5 
(10.3)
47.4 
(10.3)
EQ-5D, mean (SD)a 0.774 
(0.259)
0.777 
(0.281)
0.761 
(0.282)
0.770 
(0.269)
0.800 
(0.253)
0.807 
(0.249)
0.794 
(0.206)
0.793 
(0.208)
a Mean (SD) based on responders completing relevant section of the questionnaire.
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Appendix 5 Characteristics of the four randomised 
controlled trials of laparoscopic fundoplication 
compared with medical management
Anvari et al. trial44–46
Methods Randomisation: computerised sequence generation
Allocation concealment: apparently yes, although blocking used to ensure 1 : 1 randomisation 
(‘blocking factor determined by data centre’)
Blinding: not possible; outcome assessment: at office visit (questionnaires before medical 
assessment) at 6 and 12 months, by telephone at 3 and 9 months
Follow-up: 3, 6, 9 and 12 months and 3 years
Setting: single centre in Canada (four experienced surgeons)
Inclusion criteria: chronic symptoms of GORD requiring long-term therapy; dependent on PPIs for 
at least 12 months; adults aged 18–70 years; GORD symptom score of < 18 and a score of > 70 on 
visual analogue scale (VAS) (0–100) of symptom control at screening; % acid reflux > 4% at baseline
Exclusion criteria: pregnancy, malignancy, aperistaltic esophagus, severe comorbidity and previous 
GORD surgery
Participants Sample size: 216 (a priori)
Randomised: 104; medical: 52 [50 received medication (96%)], surgical: 52 [51 received surgery 
(98%)]
Age, mean: medical 42.1 years; surgical 42.9 years
Sex (M/F): medical 26/26; surgical 29/23
Interventions Medical: optimised PPI as per detailed symptom management algorithm
Surgical: laparoscopic Nissen fundoplication. Comprised construction of 2.5- to 3-cm 360° wrap. 
Short gastric vessels divided routinely to achieve floppy wrap
Outcomes Primary outcome: GERSS – includes heartburn, regurgitation, bloating, dysphagia and epigastric/
retrosternal pain. Total scale score 0–60. Well controlled defined as score < 18
Secondary outcomes: oesophageal function: endoscopy, manometry and 24-hour pH; QoL: SF-36 
(0–100), EQ-5D (0–1) and VAS 0–100 for patient satisfaction with symptom control. A score of 70 
was considered the threshold for symptom control on the VAS
Type of trial design On explanatory end of explanatory–pragmatic continuum
Clinical leadership Upper gastrointestinal surgeon
Risk of bias 
Allocation 
concealment?
Probably concealed – explanation of randomisation and concealment given in methods, although 
blocking could have jeopardised this
Free of selective 
reporting?
One concern: heartburn-free days promoted to primary outcome at 3 years
Sequence 
generation?
Computerised sequence generation but blocked and size of block not stated
Incomplete 
outcome data 
addressed?
Some evidence to suggest differential loss to follow-up at 3 years: 8/52 vs 3/52; no responder 
analysis
Notes Trial funded by the Canadian Institute of Health Research and Ontario Ministry of Health
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LOTUS trial47–50
Methods Randomisation: randomisation in blocks of four
Allocation concealment: unclear
Blinding: not possible; outcome assessment: primary outcome (treatment failure) dependent on 
clinical decision-making, which was not blinded
Follow-up: 6 months and 1, 3 and 5 years
Setting: 39 centres across 11 European countries
Inclusion criteria: oesophagitis grade no more than Los Angeles grade B; GORD symptoms no more 
than mild; response to PPI in run-in phase
Exclusion criteria: previous oesophageal, gastric or duodenal surgery; primary oesophageal 
disorders; inflammatory bowel disorders; any gastrointestinal absorption abnormality; other significant 
concomitant disease
Participants Sample size: 550 – not clear if stated a priori
Randomised: 554; medical: 266, surgical: 288 [248 received surgery (86%)] – specialist surgery
Age, mean (SD): medical 45.4 (11.5) years; surgical 44.8 (10.9) years
Sex (M/F): medical 199/67; surgical 199/89
Interventions Medical: esomeprazole 20 mg once daily, which could be increased stepwise
Surgical: laparoscopic anti-reflux surgery. Used crural repair and short floppy total fundoplication in 
standardised approach
Outcomes Primary outcome: time to treatment failure
Secondary outcomes: symptoms related to GORD (heartburn, acid regurgitation and dysphagia 
severity); other gastrointestinal symptoms (flatulence, diarrhoea, epigastric pain, bloating) from GSRS; 
endoscopy; QoL using QOLRAD; perioperative and postoperative mortality (< 30 days); dysphagia 
requiring further treatment; serious adverse events; rate of conversion to open surgery 
Type of trial 
design
Principally explanatory with some pragmatic features (calls itself ‘exploratory’)
Clinical leadership Upper gastrointestinal surgeon
Risk of bias
Allocation 
concealment?
Unclear; randomisation in blocks of four, otherwise not reported
Free of 
selective 
reporting?
No evidence of selective reporting, although QOLRAD data only reported in supplementary table at 
5 years
Sequence 
generation?
Unclear; randomisation in blocks of four
Incomplete 
outcome data 
addressed?
Not fully: follow-up at 3 years: 204/288 vs 208/266; at 5 years: 180/288 (62.5%) vs 192/266 (72.2%). 
No data on 14% allocated surgery who did not have an operation
Notes Trial funded by AstraZeneca R&D, with three authors employed by AstraZeneca
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Mahon et al. trial51–53
Methods Randomisation: ‘computerised randomisation’ – no details
Allocation concealment: unclear, not reported
Blinding: not possible
Follow-up: 3 months and 1 year; separate follow-up of participants from one centre at 7 years
Setting: two UK centres (two experienced surgeons)
Inclusion criteria: GORD for at least 6 months, dependent on PPIs for at least 3 months and aged 
> 16 to < 70 years
Exclusion criteria: significant oesophageal dysmotility and morbid obesity (BMI > 35 kg/m2) 
Participants Sample size: a priori apparently 215 although basis not clear
Randomised: 217; medical: 108, surgical: 109 (apparently all received surgery)
Age, median (range): medical 47 (35–57) years; surgical 48 (39–56) years
Sex (M : F ratio): medical 1 : 2.6; surgical 1 : 1.9
Interventions Medical: one of four different PPI regimens, aiming to abolish symptoms
Surgical: laparoscopic Nissen fundoplication. Used crural repair and short floppy wrap of 3 cm; 
division of short gastric vessels as deemed necessary
Outcomes PGWI, GSRS, dysphagia, DeMeester score, operation time, length of stay, conversion to open 
surgery, reoperation rate, mortality rate, lower oesophageal sphincter pressure, postoperative 
complications, % time pH < 4, cost, patient satisfaction only at 7 years (scale 1–3)
Type of trial design At explanatory end of explanatory–pragmatic continuum
Clinical leadership Upper gastrointestinal surgeon
Risk of bias 
Allocation 
concealment? 
Unclear, not reported
Free of selective 
reporting? 
Unclear, primary outcome not clearly prespecified
Sequence 
generation?
‘Computerised randomisation’ 
Incomplete 
outcome data 
addressed?
Among 108 in medical group, well-being scores were available for 108 at baseline and 96 at one 
year; equivalent figures among 109 in surgical group were 104 and 99, respectively
Notes Trial partially funded by Jansen Pharmaceutics; economic evaluation funded by Ethicon Endo-
Surgery. All participants in medical group offered surgery at 1 year: 54/92 (59%) underwent surgery
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REFLUX trial1–3
Methods Randomisation: computer-generated sequence
Allocation concealment: yes
Blinding: not possible; outcome assessment by patient-completed postal questionnaires
Follow-up: 3 months and annually for 5 years 
Setting: 21 UK centres
Inclusion criteria: GORD symptoms for > 12 months requiring PPI; evidence of GORD 
(endoscopy and/or pH monitoring)
Exclusion criteria: BMI > 40 kg/m2; Barrett’s esophagus > 3 cm; paraoesophageal hernia; 
oesophageal stricture
Participants Sample size: 600 (sample size recalculated from 600 to 392 after advice from DMC)
Randomised: 357; medical: 179, surgical: 178 [111 received surgery (62%)] – by, or 
supervised by, experienced surgeon
Age, mean (SD): medical 45.9 (11.9) years; surgical 46.7 (10.3) years
Sex (M/F): medical 120/59; surgical 116/62
Interventions Medical: best medical management after review. Lansoprazole was predominant PPI at study 
entry; omeprazole and lansoprazole most commonly reported at follow-up
Surgical: laparoscopic surgery. Type of fundoplication was left to discretion of surgeon and 
all surgical techniques considered as a single policy
Outcomes Primary outcome: REFLUX questionnaire score (heartburn, acid reflux, wind, eating and 
swallowing, bowel movements, sleep, work, physical and social activity)
Secondary outcomes: QoL: EQ-5D and SF-36; serious morbidity; mortality; patient costs; 
NHS costs 
Type of trial design Pragmatic on explanatory–pragmatic continuum. Also included parallel, non-randomised 
preference groups
Clinical leadership Upper gastrointestinal surgeon and gastroenterologist partnerships
Risk of bias 
Allocation 
concealment?
Allocation conducted by trials unit independent of all clinical teams 
Free of selective 
reporting?
ITT and PP analysis presented as prespecified
Sequence generation? Computerised randomisation 
Incomplete outcome 
data addressed?
Adjusted treatment received and PP analyses reported in addition to ITT. Follow-up at 
12 months: 154/178 (87%) vs 164/179 (92%)
Notes Trial funded by NIHR HTA programme
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Appendix 6 Search strategies for economic 
evaluation review
Gastro-oesophageal reflux disease search terms used in a recent Cochrane Review and adapted for use in the systematic review described in Chapter 5.57
Economic evaluation search
The Cochrane Library (includes NHS Economic Evaluation Database)
http://onlinelibrary.wiley.com/o/cochrane/cochrane_search_fs.html
Searched: 19 April 2011.
#1 MeSH descriptor Gastroesophageal Reflux explode all trees (1356)
#2 (gastroesophageal near/3 reflux):ti,ab,kw (1764)
#3 (gastro near/3 oesophageal near/3 reflux):ti,ab,kw (657)
#4 (gastro near/3 esophageal near/3 reflux):ti,ab,kw (657)
#5 (gord):ti,ab,kw (103)
#6 (gerd):ti,ab,kw (413)
#7 MeSH descriptor Duodenogastric Reflux explode all trees (50)
#8 (duodenogastric near/3 reflux):ti,ab,kw (58)
#9 MeSH descriptor Bile Reflux explode all trees (22)
#10 (bile near/3 reflux):ti,ab,kw (78)
#11 (acid near/3 reflux):ti,ab,kw (281)
#12 MeSH descriptor Dyspepsia explode all trees (864)
#13 (dyspep*):ti,ab,kw (2165)
#14 (belch* or burp*):ti,ab,kw 100
#15 MeSH descriptor Eructation explode all trees (18)
#16 (eructation):ti,ab,kw (52)
#17 MeSH descriptor Heartburn explode all trees (255)
#18 (heartburn or indigestion):ti,ab,kw (985)
#19 MeSH descriptor Esophagitis explode all trees (583)
#20 (esophagitis or oesophagitis):ti,ab,kw (1273)
#21 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR 
#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20), from 2005 to 2011 (1367)
1367 results made up of:
 z Economic evaluations (NHS EED): 85
 z Cochrane reviews (CDSR): 54
 z Other systematic reviews (DARE): 59
 z Technology assessments (HTA): 13
 z Clinical trials (Cochrane Central Register of Controlled Trials, CENTRAL): 1147
 z Methods studies (Cochrane Methodology Register): 9.
A total of 10 of the CDSR records were pre 2005 and so they were deleted. In addition to the 85 NHS 
EED records, all CDSR, DARE and HTA records were also saved to EndNote library reflux.enl (marked CDSR, 
DARE, HTA or NHS EED in the Custom 4 field) in case they are useful (Thomson Reuters, CA, USA).
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Quality-of-life searches
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations 
Ovid MEDLINE(R) and Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations – 1948 to present.
Searched: 20 April 2011 via OVID interface.
1. exp gastroesophageal reflux/ (18,908)
2. (gastroesophageal adj3 reflux).tw. (11,313)
3. (gastro adj3 oesophageal adj3 reflux).tw. (3146)
4. (gastro adj3 esophageal adj3 reflux).tw. (898)
5. gord.tw. (562)
6. gerd.tw. (4147)
7. exp duodenogastric reflux/ (1511)
8. (duodenogastric adj3 reflux).tw. (813)
9. exp bile reflux/ (649)
10. (bile adj3 reflux).tw. (895)
11. (acid adj3 reflux).tw. (2044)
12. exp dyspepsia/ (6549)
13. dyspep$.tw. (9171)
14. (belch$ or burp$).tw. (771)
15. exp eructation/ (257)
16. eructation.tw. (173)
17. exp heartburn/ (1395)
18. (heartburn or indigestion).tw. (3760)
19. exp esophagitis/ (8478)
20. (esophagitis or oesophagitis).tw. (10,081)
21. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 
20 (44,775)
22. exp life tables/ (10,574)
23. “quality of life”/ (89,134)
24. health status/ (47,125)
25. exp health status indicators/ (150,921)
26. (utilit$ approach$ or health gain or hui or hui2 or hui 2 or hui3 or hui 3).ti,ab. (1099)
27. (health measurement$ scale$ or health measurement$ questionnaire$).ti,ab. (31)
28. (standard gamble$ or categor$ scal$ or linear scal$ or linear analog$ or visual scal$ or magnitude 
estimat$).ti,ab. (3759)
29. (time trade off$ or rosser$ classif$ or rosser$ matrix or rosser$ distress$ or hrqol).ti,ab. (5160)
30. (index of wellbeing or quality of wellbeing or qwb).ti,ab. (150)
31. (rating scale$ or multiattribute$ health ind$ or multi attribute$ health ind$).ti,ab. (26,439)
32. (health utilit$ index or health utilit$ indices).ti,ab. (484)
33. (multiattribute$ theor$ or multi attribute$ theor$ or multiattribute$ analys$ or multi attribute$ 
analys$).ti,ab. (9)
34. (health utilit$ scale$ or classification of illness state$ or 15d or 15 d or 15 dimension).ti,ab. (2878)
35. (health state$ utilit$ or 12d or 12 d or 12 dimension).ti,ab. (2009)
36. well year$.ti,ab. (20)
37. (multiattribute$ utilit$ or multi attribute$ utilit$).ti,ab. (152)
38. health utilit$ scale$.ti,ab. (7)
39. (qol or 5d or 5-d or 5 dimension or quality of life or eq-5d or eq5d or eq 5d or euroqol).ti,ab. 
(114,629)
40. (qualy or qaly or qualys or qalys or quality adjusted life year$).ti,ab. (4631)
41. life year$ gain$.ti,ab. (1289)
42. willingness to pay.ti,ab. (1517)
43. (hye or hyes or health$ year$ equivalent$).ti,ab. (58)
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44. (person trade off$ or person tradeoff$ or time tradeoff$ or time trade off$).ti,ab. (776)
45. theory utilit$.ti,ab. (7)
46. life table$.ti,ab. (6627)
47. health state$.ti,ab. (2838)
48. (sf36 or sf 36).ti,ab. (9654)
49. (short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six 
or short form thirtysix or short form thirty six).ti,ab. (4429)
50. (6d or 6-d or 6 dimension).ti,ab. (4590)
51. or/22-50 (366,981)
52. 21 and 51 (3337)
53. limit 52 to yr=”2005 - 2011” (1726)
A total of 1726 results saved to EndNote library reflux.enl (marked MEDLINE in the Custom 4 field).
EMBASE
EMBASE – 1996 to week 15 2011.
Searched: 20 April 2011 via OVID interface.
1. exp gastroesophageal reflux/ (24,724)
2. (gastroesophageal adj3 reflux).tw. (10,538)
3. (gastro adj3 oesophageal adj3 reflux).tw. (2717)
4. (gastro adj3 esophageal adj3 reflux).tw. (867)
5. gord.tw. (670)
6. gerd.tw. (5466)
7. exp duodenogastric reflux/ (993)
8. (duodenogastric adj3 reflux).tw. (292)
9. exp bile reflux/ (509)
10. (bile adj3 reflux).tw. (505)
11. (acid adj3 reflux).tw. (1939)
12. exp dyspepsia/ (15,437)
13. dyspep$.tw. (7897)
14. (belch$ or burp$).tw. (706)
15. exp eructation/ (315)
16. eructation.tw. (100)
17. exp heartburn/ (5566)
18. (heartburn or indigestion).tw. (3660)
19. exp esophagitis/ (12,163)
20. esophagitis.tw. (6246)
21. oesophagitis.tw. (1696)
22. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 
20 or 21 (51,561)
23. life tables/ (1840)
24. exp “quality of life”/ (158,965)
25. health status/ (53,662)
26. health survey/ (104,329)
27. (utilit$ approach$ or health gain or hui or hui2 or hui 2 or hui3 or hui 3).ti,ab. (1100)
28. (health measurement$ scale$ or health measurement$ questionnaire$).ti,ab. (35)
29. (standard gamble$ or categor$ scal$ or linear scal$ or linear analog$ or visual scal$ or magnitude 
estimat$).ti,ab. (2771)
30. (time trade off$ or rosser$ classif$ or rosser$ matrix or rosser$ distress$ or hrqol).ti,ab. (6267)
31. (index of wellbeing or quality of wellbeing or qwb).ti,ab. (139)
32. (rating scale$ or multiattribute$ health ind$ or multi attribute$ health ind$).ti,ab. (25,950)
33. (health utilit$ index or health utilit$ indices).ti,ab. (550)
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34. (multiattribute$ theor$ or multi attribute$ theor$ or multiattribute$ analys$ or multi attribute$ 
analys$).ti,ab. (9)
35. (health utilit$ scale$ or classification of illness state$ or 15d or 15 d or 15 dimension).ti,ab. (2773)
36. (health state$ utilit$ or 12d or 12 d or 12 dimension).ti,ab. (1630)
37. well year$.ti,ab. (7)
38. (multiattribute$ utilit$ or multi attribute$ utilit$).ti,ab. (132)
39. health utilit$ scale$.ti,ab. (5)
40. (qol or 5d or 5-d or 5 dimension or quality of life or eq-5d or eq5d or eq 5d or euroqol).ti,ab. 
(131,090)
41. (qualy or qaly or qualys or qalys or quality adjusted life year$).ti,ab. (5406)
42. life year$ gain$.ti,ab. (1495)
43. willingness to pay.ti,ab. (1724)
44. (hye or hyes or health$ year$ equivalent$).ti,ab. (40)
45. (person trade off$ or person tradeoff$ or time tradeoff$ or time trade off$).ti,ab. (785)
46. theory utilit$.ti,ab. (7)
47. life table$.ti,ab. (3428)
48. health state$.ti,ab. (2931)
49. (sf36 or sf 36).ti,ab. (12,136)
50. (short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six 
or short form thirtysix or short form thirty six).ti,ab. (5063)
51. (6d or 6-d or 6 dimension).ti,ab. (3389)
52. or/23-51 (364,882)
53. 22 and 52 (4601)
54. limit 53 to yr=”2005 - 2011” (2906)
A total of 2906 results saved to EndNote library reflux.enl (marked EMBASE in the Custom 4 field).
Results of literature search
EndNote library records were deduplicated as far as possible.
Source Results Results after deduplication
NHS EED 85 85
CDSR 44 44
DARE 59 56
HTA 13 12
MEDLINE 1726 1640
EMBASE 2906 1825
Total 4833 3662
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Appendix 7 Within-trial cost-effectiveness 
analysis: health-related quality-of-life and cost-
effectiveness results
TABLE 53 Within-trial cost-effectiveness analysis: health-related quality-of-life and cost-effectiveness results
Study Grant et al. 20081 Goeree et al. 201146
Trial REFLUX (multicentre UK) Anvari (single centre in Canada)
Follow-up Within-trial cost-effectiveness analysis 
over 1 year
Within-trial cost-effectiveness analysis over 3 years
Number of patients 318a 104 
Perspective UK NHS Societal perspective
Price year 2006 UK pounds 2009 Canadian dollars (2010 tested in sensitivity 
analysis)
HRQoL instrument EQ-5D HUI (primary instrument); SF-6D and EQ-5D (tested in 
sensitivity analysis)
QoL improved over time across all utility instruments; 
however, the QALYs gained estimated with EQ-5D 
were less than half of those estimated with HUI3 and 
SF-6D
Difference in mean 
QALYs
0.066 (95% CI 0.026 to 0.107) 0.109 (SD 0.784)
Difference in mean 
costs
£1280 (£1054 to £1468) C$3205 (SD C$16,828)
ICER £19,000 per QALY gained C$29,400 per QALY gained (utilities from HUI3); 
C$76,310 per QALY gained (utilities from EQ-5D)
Probability of surgery 
being cost-effective
When k = £20,000, probability = 46%; 
when k = £30,000, probability = 86%
Laparoscopic Nissen fundoplication has the highest 
probability of being the most cost-effective treatment 
when k is > C$30,000
a The REFLUX economic analysis included both ITT and PP analysis. Results presented in this table are based on the ITT 
analysis.
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Appendix 8 Validation of the multiple imputation
TABLE 54 Predictors of missingness at the 95% confidence level
Follow-up
Predictors of missingness (p < 0.05)
Pseudo-R2Variable Coefficient
Year 1 EQ-5D at baseline 2.2842 0.0673
EQ-5D at 3 months –3.7987
Year 2 EQ-5D at baseline 1.4209 0.0230
Year 3 EQ-5D at baseline –3.4594 0.1681
EQ-5D at 3 months 2.7446
EQ-5D at year 2 2.0889
Year 4 –a –a 0.0288
Year 5 EQ-5D at baseline –7.4267 0.1358
EQ-5D at year 3 3.1675
a For year 4, no coefficient was statistically significant at the 95% confidence level. Pseudo-R2 obtained with 
constant only.
Note: Only coefficients for the variables significant at the 95% confidence level are shown, despite all models tested 
including a similar set of variables: demographics (age, sex, BMI), ITT allocation, PP status, costs for the previous years 
and EQ-5D scores for the previous follow-up points.
The existence of predictors for missingness at the 95% confidence level indicates that data may not be 
MCAR and therefore that the multiple imputed data set is more reliable than the complete case.
Figures 24 and 25 compare the distribution of total costs and total QALYs, respectively, across the first 10 
imputed data sets and the original data (imputation number 0). The distribution is similar, providing some 
assurance that the multiple imputation strategy was successful.
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FIGURE 24 Distribution of total costs across the first 10 imputed data sets and for the original data set (imputation 
number 0).
FIGURE 25 Distribution of total QALYs across the first 10 imputed data sets and for the original data set (imputation 
number 0). 
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Appendix 9 Costs and health-related quality of 
life for allocation according to per protocol at 1 year: 
structural sensitivity analysis
TABLE 55 Total mean costs and total mean QALYs for the medical management and surgery groups according to ITT 
and PP at 1 year for the complete case
Treatment 
allocated (ITT)
PP at 1 year
Medical 
management Surgery Total
Total costs Medical 
management
£1201.61 £3718.18 £1316.00
Total QALYs 3.5665 2.6076 3.5229
Number of patients 84 4 88
Total costs Surgery £989.06 £3525.38 £2981.89
Total QALYs 3.7016 3.7447 3.7354
Number of patients 18 66 84
Total costs Total £1164.10 £3536.40 £2129.57
Total QALYs 3.5904 3.6797 3.6268
Number of patients 102 70 172
Note: cells highlighted by shading refer to PP at 1 year groups considered for the incremental analysis.
TABLE 56 Health-related quality of life (EQ-5D) according to PP analysis
Completed questionnaires 
returned at each time point
Follow-up
Mean (SD) EQ-5D
Difference in mean 
EQ-5D (surgery – medical 
management) (95% CI)b,c
Surgery 
(n = 178a)
Medical 
management 
(n = 179a) Surgery
Medical 
management
108 162 Baseline 0.7184 (0.2394) 0.7266 (0.2553) –0.0082 (–0.0691 to 0.0528)
108 143 3 months 0.8059 (0.2393) 0.6910 (0.3068) 0.1148 (0.0446 to 0.1851)
102 153 Year 1 0.7773 (0.2323) 0.7064 (0.2703) 0.0709 (0.0065 to 0.1353)
83 129 Year 2 0.7903 (0.2442) 0.7170 (0.3133) 0.0733 (–0.0068 to 0.1532)
89 127 Year 3 0.7897 (0.2521) 0.7563 (0.2492) 0.0336 (–0.0356 to 0.1018)
88 122 Year 4 0.7785 (0.2636) 0.7550 (0.2678) 0.0236 (–0.0498 to 0.0969)
87 110 Year 5 0.7771 (0.2812) 0.7654 (0.2782) 0.0117 (–0.0674 to 0.0908)
a n refers to number of patients originally randomised to each trial arm.
b CIs estimated using OLS regression.
c Unadjusted for baseline EQ-5D.
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TABLE 57 Costs associated with resource use for PP analysis
Returned questionnaires in each 
year
Mean (SD) resource-use cost (£) 
according to PP at 1 year 
Incremental mean 
cost (surgery – medical 
management) (95% CIa) (£) Surgery
Medical 
management Year Surgery
Medical 
management
104 154 1b 3241.78 (1263.80) 361.28 (668.12) 2880.50 (2634.08 to 3126.91)
86 133 2 82.57 (373.46) 159.80 (366.76) –77.23 (–177.98 to 23.51)
92 128 3 79.80 (349.15) 289.27 (913.00) –209.47 (–406.78 to –12.15)
88 124 4 96.49 (368.53) 314.70 (1362.96) –218.21 (–512.14 to 75.72)
90 112 5 43.17 (133.98) 233.60 (645.33) –190.43 (–326.93 to –53.93)
Cost category
Surgery in year 1 2780.73 (1756.83) 0c 2780.73 (2704.69 to 2856.76)
Reflux-related hospital night admissions 403.07 (1305.30) 315.49 (833.69) 87.58 (–242.21 to 417.37)
Reflux-related hospital day admissions 159.78 (423.32) 231.64 (608.67) –71.86 (–236.56 to 92.84)
Reflux-related GP visits 130.93 (940.68) 193.31 (465.70) –62.37 (–176.00 to 51.26)
Medication 87.69 (217.69) 383.01 (525.63) –295.32 (–424.17 to –166.47)
a CIs estimated using OLS regression.
b Refers to the patients who returned the final year 1 questionnaire.
c By definition, none of the medical management patients in PP underwent surgery.
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THE PLACE OF MINIMAL ACCESS SURGERY AMONGST PEOPLE 
WITH GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) 
A UK COLLABORATIVE STUDY 
 
(Known as the REFLUX Trial) 
 
 
 
 
 
AIM To identify the optimal place within the NHS for minimal access surgery 
amongst people with GORD, whose symptoms would otherwise be 
managed with long-term medical therapy. 
 
DESIGN 
 
Multicentre, pragmatic randomised trial (with parallel non-randomised 
preference groups). 
 
PATIENT 
ELIGIBILTY 
• Documented evidence of GORD (endoscopy and/or manometry/24h 
pH monitoring) 
• Symptoms for more than 12 months and currently requiring 
maintenance proton pump inhibitor (PPI) therapy for reasonable 
symptom control 
• Received care from a participating clinician 
• Suitable for either policy (ASA grade I or II) 
• Recruiting doctor uncertain which management policy is better 
• Give informed consent to either random allocation of management or 
follow-up after preferred management 
 
RECRUITMENT Based on surgeon-physician ‘partnership’ in at least 15 centres. 
 
INTERVENTIONS A laparoscopic surgery based policy compared with a continued medical 
management policy. 
 
OUTCOME 
MEASUREMENT 
Primary – Disease specific outcome and NHS costs 
Secondary – Patient costs and Health-related quality of life (EQ5D, SF36) 
 
ORGANISATION • All whole-hearted contributors part of the GORD Trialist Group 
(with group authorship of main reports) 
• Conduct overseen by Steering Group 
• Trial Office in Aberdeen responsible for day-to-day non-clinical co-
ordination 
• Sessional research nurses in each clinical centre 
• Health economic evaluation and outcome measure assessment jointly 
led from York and Aberdeen 
 
FUNDING NHS R&D Health Technology Assessment Programme 
 
PROTOCOL SUMMARY  
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1. OUTLINE OF THE TRIAL 
Aim 
The aim is to identify the optimal place within the NHS of minimal access surgery 
amongst people with gastro-oesophageal reflux disease (GORD).  Its focus is people 
whose symptoms would otherwise be managed with long-term medical therapy.  The 
background and justification are summarised in Appendix I. 
 
Objectives 
• To evaluate the clinical effectiveness, cost-effectiveness, and safety of a policy of 
relatively early laparoscopic surgery compared with continued medical management 
amongst people with GORD judged suitable for both policies. 
• To explore factors which may influence the relative performance of the two policies, 
such as patient preference, surgeon experience, pre-enrolment symptoms and signs, 
underlying pathology, type of operative procedure used or choice of therapy, and 
time since surgery. 
• To explore the impact that various policies for using laparoscopic surgery would 
have on the NHS and society in respect of the costs or savings that they would imply 
for (a) those providing surgical care (in secondary care settings), (b) those providing 
long-term medical management (usually in primary care settings), and (c) those with 
GORD. 
 
Design 
The study will have two complementary components: 
A A randomised trial (with parallel non-randomised preference groups) comparing 
a laparoscopic surgery based policy with a continued medical management 
policy to assess their relative clinical effectiveness. 
B An economic evaluation of laparoscopic surgery for GORD to compare the cost-
effectiveness of the two management policies, to identify the most efficient 
provision of future care, and to describe the resource impact that various policies 
for fundoplication would have on the NHS. 
The rationale for the study design is described in Appendix II. 
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2. THE RANDOMISED TRIAL (WITH PARALLEL PREFERENCE GROUPS) 
Centre eligibility  
Clinical centres will be based on local partnerships between surgeons with experience of 
laparoscopic fundoplication and the gastroenterologists, with whom they share the 
secondary care of patients with GORD.  Centres will be eligible if they include:  
1. a surgeon who has performed at least 50 laparoscopic fundoplication operations 
2. one or more gastroenterologists who agree to collaborate with the surgeon in the 
trial. 
 
Patient eligibility 
Inclusion criteria 
1. Documented evidence of GORD (based on endoscopy and/or manometry/24hr pH 
monitoring) 
2. Symptoms for more than 12 months and currently requiring maintenance proton 
pump inhibitor (PPI) therapy for reasonable symptom control (Patients who are 
intolerant to PPIs and therefore require Histamine Receptor Antagonists (H2RAs) 
therapy to control their symptoms will also be included) 
3. Care provided by a participating clinician 
4. Suitable for either policy (including ASA grade I or II) 
5. Recruiting doctor uncertain which management policy is better 
6. Informed consent either to random allocation of management or to follow-up after 
preferred management 
 
Exclusion criteria 
1. Morbidly obese (BMI >40 kg/m2) 
2. Barrett’s oesophagus of more than 3 cm or have evidence of dysplasia 
3. Paraoesophageal hernia 
4. Oesophageal stricture 
 
Although there is no formal age limit, it will be younger patients with GORD who will 
be eligible, who are expected to be aged between 18 and 65 years .   
NIHR Journals Library www.journalslibrary.nihr.ac.uk
AppENDIx 10
156
   
 6 
 
Health technology policies being compared 
Laparoscopic surgery policy:  
Most of those allocated to this policy will have surgery.  Deferring or declining will 
remain an option, however, even after trial entry, particularly amongst those recruited 
by a gastroenterologist and referred to a surgeon for consideration of surgery within the 
trial.  Participants who have not had manometry/pH studies will undergo these tests 
before surgery to exclude achalasia. 
 
The surgery will be performed either by a surgeon who has undertaken more than 50 
laparoscopic fundoplications or by a less experienced surgeon working under the 
supervision of an experienced surgeon.  It is recommended that crural repair be routine 
and non-absorbable, synthetic sutures (not silk) be used for the repair.  The type of 
fundoplication used will be left to the discretion of an experienced surgeon.  For the 
purposes of the main comparisons, the different surgical techniques for laparoscopic 
fundoplication will be considered as parts of a single policy.  The study design will, 
however, allow indirect comparisons between techniques. 
 
It is expected that local policies for thromboembolism prophylaxis will include a suitable 
anticoagulant (such as heparin or tinzaparin) plus surgical stockings or pneumatic 
compression. 
 
Medical therapy policy:  
Most of those allocated to the medical therapy policy will continue ‘best medical 
management’ (appropriate PPI), as recommended by the clinician responsible for care.  
Management should conform to the principles of the Genval Workshop Report (see 
Appendix III).  While all the recommendations of this workshop cannot be summarised 
here, they include stepping down antisecretory medication in most patients to the lowest 
dose that maintains acceptable symptom control.  Patients who have had severe 
oesophagitis should not be managed on the basis of symptoms alone, however.  While it 
is expected that most trial participants allocated medical management will continue to be 
managed in this way, surgery should be considered if a clear indication for it 
subsequently develops. 
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Outcome measurements 
Primary: 
a ‘Disease-specific’ outcome to include the need for changes in treatment, reflux 
and other gastro-intestinal symptoms, and the side effects and complications of 
both therapies.   
b NHS costs including treatments, investigations, consultations and other contacts 
with the health service. 
Secondary: 
c Health-related quality of life – EQ5D and SF36. 
d Patient costs including loss of earnings, reduction in activities, and the cost of 
prescriptions and travel to health care. 
Other: 
e Other serious morbidity, such as operative complications 
f Mortality 
 
The instrument for collecting this information are in Appendix IV.  The ways in which 
these data will be displayed in the final report are illustrated in Appendix V. 
 
Sample size and statistical analysis 
A sample size of 600 will identify a difference between the two randomised groups of 
less than 0.25 of the standard deviation of the disease-specific instrument, EQ5D or SF36  
with 80% power using a significance level of 5%.  Based on the same arguments, about 
300 people will be recruited to each arm of the preference study.  
 
The cost savings of a surgical policy will largely depend on the number of patients 
managed surgically who no longer require PPI treatment.  A trial with 300 surgically 
managed patients will estimate this proportion to within about 5% with 95% statistical 
confidence. 
 
A single principal analysis is planned within the current time frame when all 
participants have been followed-up for at least 12 months after surgery (or an equivalent 
time if managed medically).  Standard statistical techniques will be used with analysis 
by intention to treat and 95% confidence intervals.  Secondary analyses will explore 
differential effects within pre-stated sub-groups, characterised by initial symptom 
severity and surgeon’s preferred operative procedure; 99% confidence intervals will be 
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generated for such analyses to reflect their exploratory nature.  The issue of continued 
surgeon ‘learning’ will also be investigated using curve fitting techniques.   
 
 
3. THE ECONOMIC EVALUATION 
The economic evaluation is described in detail in Appendix VI.  It will have three 
components: a within-trial cost-effectiveness study; a detailed assessment of the 
preferences of patients with GORD; and an outside-trial cost-effectiveness analysis based 
on decision modelling.  
 
 
4. PRACTICAL ARRANGEMENTS 
Each clinical centre will be supported by a part-time research nurse. 
 
Identification of potential participants 
Potential participants will be identified in three ways: 
• Retrospective case-note review 
• Prospective identification of current case 
• Referral from general practice 
These are summarised in Figure 1.  The actual approach used will vary between centres, 
but case note review is likely to be the principal method. 
 
As a general rule, potentially eligible participants will be booked for an outpatient 
appointment.  They will be sent a brief letter, together with a copy of the information 
leaflets in advance, letting them know that the trial is likely to be discussed with them 
(Appendix VII).  At the appointment, the clinician will review the person’s symptoms 
and current treatment regimen, and assess eligibility for the trial following the 
completion of a Patient Assessment Form (Appendix VIII).  If eligibility is confirmed, the 
person will be invited to see the research nurse who will describe the study and discuss 
any issues that arise. This is summarised in Figure 2.  The nurse will also give a 
supplementary information leaflet that describes the operation in more detail (Appendix 
IX).  Information will also be sent to the general practitioner (GP) in case the participant 
consults them to discuss the trial (Appendix X); a specific clinic letter will follow from 
the consultant. 
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Figure 1.  Flowchart describing sources for patient identification
Case Notes
(Retrospective)
Outpatient Review
Clinic/Appointment
Endoscopy/pH clinic
(Prospective)
GP local co-operatives
/primary care groups
Clinician identifies
potentially eligible
patient at
endoscopy/pH
clinic
Research nurse (RN)
to identify potentially
eligible patients from
endoscopy list /case
notes
Potentially eligible
patients filtered into
outpatient review
clinic
Letter sent to local co-
operatives/primary care groups
GP refers potentially
eligible patient to
collaborating clinician
RN & Outpatient clinic to
issue appointment cards,
letters & patient
information leaflets
Clinician/RN to
filter potentially
eligible patients
into outpatient
review clinic
Clinician to assess GP
referral letter
Potentially eligible
patients to be filtered
into outpatient
review clinic
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Figure 2.  Flowchart describing patient recruitment
GP subcommittees/
Primary Care Groups
Endoscopy/pH clinic
Prospective
Mini outpatient
review clinic
Clinician to review patient
& assess eligibility using the
patient assessment form (PAF)
Eligible Not eligible
Nurse to discuss study with patient
Recruitment Procedures
YES to RCT at
clinic
Undecided to RCT at clinic No to RCT at
clinic
Complete randomised(r)
consent form &
participant entry form
(PEF)
Patient offered more time to consider
(48hrs)
Patient sent home with trial information
leaflet, consent form & baseline
questionnaire
Patient followed up to confirm
decision
Yes to RCT No
Patient asked to sign the
consent form & return with
the baseline questionnaire
RN to complete PEF
Patient offered
preference
option
No
Yes to
preference
Log & shred
PAF
Patient offered
preference option
YesNo
Log &
shred PAF
Complete
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Consent to participate  
The randomised trial: 
Some potential participants will make a decision about participation at this appointment.  
Those who wish to participate in the randomised trial will be asked to sign a consent 
form (Appendix XI).  On this, they will confirm that they have been given the 
information they require and that the study has been explained to them.  They will also 
confirm that they understand that they will be sent questionnaires from the Trial Office 
at participant-specific time intervals after joining the study.  (This will be at a time 
equivalent to around three months and 12 months after surgery.)  They will also be told 
that it is anticipated that further follow-up will be performed periodically thereafter for 
some years. 
 
The preference study: 
A person who does not want to take part in the randomised trial because of a strong 
preference for one type of treatment management will be asked to take part in the 
preference arm of the study.  Those who wish to participate in the preference study will 
be given a preference information leaflet and asked to sign a consent form (Appendix 
XII).  In addition to the details collected on the randomised consent form, they will 
confirm their preferred treatment allocation.   
 
Any person who is uncertain will be given at least 48 hours to consider participation.  A 
research nurse will then phone them to find out their decision and make arrangements 
as appropriate for them to sign a randomised trial or a preference study consent form.  
 
One copy of the consent form will be given to the participant, another will be filed in the 
patient’s hospital case notes, and the third will be posted to the Trial Office.   
 
 
Information to be collected at trial entry 
Once a participant has agreed to join the trial, the research nurse will record basic 
identifying and descriptive information on a standard form (Appendix XIII).  This 
information will be sent to the Trial Office. 
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The participant will take home a baseline questionnaire to complete, and will be asked to 
return it in a pre-paid envelope to the Trial Office. 
 
Study registration (and treatment allocation when randomised) 
The entry procedure will distinguish between those who have agreed to randomisation 
and those who have agreed to participate in the preference part of the study.   
 
The treatment allocation for participants consenting to the randomised arm of the trial 
will be computer-generated in the Trial Office.  The allocation will be stratified by centre, 
with balance in respect of other key prognostic variables – age (18-50 y or 51-65 y), sex 
(M or F), and BMI (≤28 or >29 kg/m2) - by a process of minimisation.  
 
A letter will be sent from the Trial Office to each participant (Appendix XIV), their GP 
(Appendix XV) and the local research nurse, confirming the treatment allocation and 
whether they are taking part in the randomised- or preference-arm of the trial.  A letter 
will also be sent to the respective collaborating surgeon or gastroenterologist with 
respect to the treatment the participant is allocated. 
 
Clinical management 
Clinical management will be left to the discretion of the clinician responsible for care.  A 
summary of the different clinical management pathways is illustrated in Figure 3. 
 
Participants who are allocated to the surgical arm, will be invited to a consultation with 
the collaborating surgeon.  (Participants who have not already had manometry/pH 
studies will be booked to undergo these tests prior to this consultation.)  During this 
consultation, the surgeon will confirm that there is no contra-indication to surgery and 
discuss the operation in more detail with the participant, before arranging a date for the 
operation.  The intra-operative details will be recorded by the surgeon on specially 
designed study forms (Appendix XVI). 
 
All other in-hospital data collection will be the responsibility of the local study nurse.   
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Figure 3.  Flowchart showing clinical management post recruitment
Trial Office checks all paperwork and matches up
coded BQ’s with PEF
Trial Office enters information into database &
allocates treatment
Randomised Preference
SurgeryMedication Surgery Medication
Participant referred for manometry /pH
(if they have not already had these tests)
Trial Office sends letter RN to give to
surgeon confirming participants allocation
Participant referred to surgeon
for pre surgical consultation
Trial Office sends letter confirming treatment allocation to participant, GP & RN
Participant undergoes
laparoscopic surgical procedure
Trial Office sends participant 1st follow up questionnaire
(equivalent to 3 months after surgery)
Trial Office sends participant 2nd follow up questionnaire
(equivalent to 12 months after surgery)
Research Nurse (RN) sends completed
paperwork (patient assessment form (PAF)/
consent form/ participant entry form (PEF)
to Trial Office
Participant returns baseline
questionnaire (BQ) to Trial Office
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Follow-up in the trial 
Follow-up by postal questionnaire will be performed twice, at participant-specific time 
intervals after joining the study.  (This will be at a time equivalent to around three and 
12 months after surgery).  When necessary, clarification of clinical management will be 
sought through the research nurses (while they are in post) and then subsequently 
through the recruiting doctor or general practitioner.  While it is anticipated that further 
follow-up will be performed periodically thereafter for some years (dependent on 
funding being available at that time) these subsequent assessments are not part of this 
protocol. 
 
Data collection after trial entry 
All data will be sent to the Trial Office in Aberdeen for processing.  Staff in Aberdeen 
will work closely with the research nurses to secure as complete and accurate data as 
possible.  A random 10% sample of data will be double-entered to check accuracy.  
Extensive range and consistency checks will further enhance the quality of the data. 
 
Organisation 
Local organisation 
The trial is designed to limit the extra work for collaborating clinicians to tasks that only 
they can do.  Research nurses will facilitate the trial locally, and the central organisation 
will take responsibility for data management and participant follow-up. 
 
Clinical collaborators (gastroenterologist and/or surgeon) will: 
1. establish the trial locally (e.g. identifying a ‘partnering’ clinician or surgeon if not 
already agreed; facilitating local research ethics committee approval; identifying and 
appointing a local research nurse; and ensuring that all clinical staff involved in the 
care of patients with GORD are informed about the trial)  
2. take responsibility for clinical aspects of the trial locally (e.g. if any particular 
concerns emerge) 
3. notify the Trial Office of any unexpected clinical events that might be related to trial 
participation 
4. provide support and supervision for all aspects of the work of the local research 
nurse 
5. represent the centre at REFLUX trial collaborators’ meetings 
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Research nurses will: 
1. keep local staff informed about the trial and its progress 
2. keep regular contact with the local gastroenterologist(s) and surgeon 
3. maintain regular contact with the Trial Office 
4. identify potential participants and log whether or not they are recruited to the trial 
(including the preference groups) - with reasons for non-participation 
5. arrange for the initial letter of invitation and information leaflet to be sent to 
potential participants prior to an out-patient assessment.  
6. assist the participating clinicians (e.g. at assessment clinics) to give additional 
information and seek consent to study entry 
7. ensure that the baseline data describing participants are collected and sent back to 
the Trial Office 
8. facilitate later follow-up by, for example, helping with local tracing 
9. provide support for participants in other ways if there are difficulties 
10. represent the centre at trial nurse meetings and collaborators’ meetings 
 
 
5. TRIAL CO-ORDINATION 
Trial Offices 
The main Trial Office is within the Health Services Research Unit in Aberdeen and gives 
day-to-day support to the clinical centres.  This Office is responsible for all central co-
ordination of the trial, including centre and research nurse support, study entry and 
randomisation, postal follow-up, data processing and statistical analysis.  
 
The economic evaluation and the outcome development work is based in the Centre for 
Health Economics and the Department of Health Sciences and Clinical Evaluation, 
respectively, both within the University of York. 
 
The Steering Group 
The trial is co-ordinated by a Steering Group (listed in Appendix XVII).  The Steering 
Group, in consultation with the Collaborative Group (see below), will take responsibility 
for any major decisions, such as the need to close recruitment early to one or more parts 
of the study or to change the protocol for any reason. 
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The Collaborative Group 
The Collaborative Group is made up of the surgeons, gastroenterologists and research 
nurses contributing to the trial, members of the Steering Group, and representatives 
from the Trial Offices.  
 
The Data Monitoring Committee 
A data monitoring committee will be established.  It will be independent of the trial 
organisers.  During the period of recruitment to the trial, interim analyses will be 
supplied, in strict confidence, to the data monitoring committee, together with any other 
analyses that the committee may request.  This may include analyses of data from other 
comparable trials.  In the light of these interim analyses, the data monitoring committee 
will advise the Steering Group if, in its view, the trial has provided both (a) proof 
beyond reasonable doubt1 that for all or some types of patients one intervention is 
clearly indicated in terms of clinical- and cost-effectiveness, and (b) evidence that might 
reasonably be expected to influence materially the care of people with GORD by 
clinicians who know the results of this and comparable trials.  The Steering Group can 
then decide to consult the Collaborative Group about whether or not to modify intake 
into the trial or to report results early.  Unless this happens, however, the Steering 
Group, the Collaborative Group and Trial Offices (except those who supply the 
confidential analyses) will remain ignorant of the interim results considered by the 
committee. 
 
The frequency of interim analyses will depend on the judgement of the chairman of the 
committee, in consultation with the Steering Group. 
 
6. FINANCE 
The trial is supported by a grant from the Health Technology Assessment Programme of 
the NHS Executive Research and Development Programme. 
                                                      
Note: 
1 Appropriate criteria for proof beyond reasonable doubt cannot be specified precisely.  A 
difference of at least three standard deviations in the interim analysis of a major endpoint may be 
needed to justify halting, or modifying, such a study prematurely.  If this criteria were to be 
adopted, it would have the practical advantage that the exact number of interim analyses would 
be of little importance, and so no fixed schedule is proposed (Peto R et al Br J Cancer 1976; 34: 584-
612). 
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7. A STUDY OF FACTORS IMPACTING ON PATIENTS DECISION TO PARTICIPATE  
      IN THE REFLUX TRIAL (APPENDIX XVIII)  
During the recruitment phase of the trial, it is anticipated that a CSO research fellow will 
undertake supplementary site visits to explore the patients’ perspective in relation to 
trial recruitment. A small number of centres will be purposively selected using 
qualitative methods (non-participation observation and in-depth interviews). It is 
proposed that the selected centres will reflect varying recruitment rates. 
 
It is expected that, subject to clinician and patient consent, the research fellow would sit-
in and observe reflux clinics where patients are approached to join the study.  The 
researcher would aim to supplement the observational work by interviewing some of 
the patients (again, subject to consent) about their experience of trial recruitment and 
factors impacting on their decision to join the trial or not. 
 
It is hoped this small but very useful complementary study nested in the REFLUX trial, 
will help identify factors impacting on patient recruitment and enable us to look at ways 
of addressing these issues to facilitate improved future trial recruitment. 
 
8. PUBLICATION 
The success of the trial depends entirely on the whole-hearted collaboration of a large 
number of people.  For this reason, chief credit for the trial will be given, not to the 
committees or central organisers, but to all those who have whole-heartedly collaborated 
in the trial.  The trial’s publication policy is described in detail in Appendix XIX.  The 
results of the trial will be reported first to the trial collaborators.  The main report will be 
drafted by the Steering Group, and circulated to all the clinical collaborators for 
comment.  The final version will be agreed by the Steering Group before submission for 
publication, on behalf of the collaboration.  To safeguard the integrity of the study, 
reports of sub-studies will not be submitted for publication without prior discussion 
with the Steering Group.  Once the main report has been published, a lay summary will 
be sent to participants who have indicated that they would like to receive one. 
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